<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006647.pub4" GROUP_ID="CHILDCA" ID="816106110215470302" MERGED_FROM="" MODIFIED="2014-09-04 13:06:29 +0100" MODIFIED_BY="Jos Noorman" REVIEW_NO="010" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-09-04 13:06:29 +0100" MODIFIED_BY="Jos Noorman">
<TITLE MODIFIED="2008-06-17 13:57:33 +0200" MODIFIED_BY="Elvira van Dalen">Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer</TITLE>
<CONTACT MODIFIED="2014-09-04 13:06:29 +0100" MODIFIED_BY="Jos Noorman"><PERSON ID="13729" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elvira</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>van Dalen</LAST_NAME><EMAIL_1>e.c.vandalen@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660 (room TKsO-247)</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5665697</PHONE_1><FAX_1>+ 31 20 5669021</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-09-04 13:06:29 +0100" MODIFIED_BY="Jos Noorman"><PERSON ID="13729" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elvira</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>van Dalen</LAST_NAME><EMAIL_1>e.c.vandalen@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660 (room TKsO-247)</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5665697</PHONE_1><FAX_1>+ 31 20 5669021</FAX_1></ADDRESS></PERSON><PERSON ID="4FC2D70C82E26AA201D66C39D572E5E9" ROLE="AUTHOR"><FIRST_NAME>Martine</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Raphaël</LAST_NAME><EMAIL_1>m.f.raphael-2@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatric Hematology and Oncology</DEPARTMENT><ORGANISATION>Wilhelmina Children's Hospital, University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 70 3674545</PHONE_1><FAX_1>+ 31 70 3670868</FAX_1></ADDRESS></PERSON><PERSON ID="B012C2C282E26AA200D5E26BD510BA90" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Huib N</FIRST_NAME><LAST_NAME>Caron</LAST_NAME><EMAIL_1>h.n.caron@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660 (room F8-239)</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5665656</PHONE_1><FAX_1>+31 20 6912231</FAX_1></ADDRESS></PERSON><PERSON ID="13704" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Leontien</FIRST_NAME><MIDDLE_INITIALS>CM</MIDDLE_INITIALS><LAST_NAME>Kremer</LAST_NAME><EMAIL_1>l.c.kremer@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5667132</PHONE_1><FAX_1>+31 20 5669690</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-06-17 16:16:36 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="1" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="7" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-09-04 11:28:03 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-09-04 11:28:03 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Summary of most important changes in the update:</P>
<P>The search for eligible studies was updated to July 2013.</P>
<P>One new randomised controlled trial (RCT) addressing children with acute myeloid leukemia was included (this type of tumour was not addressed in the earlier versions of this review).</P>
<P>For the risk of bias assessment we used the most recent recommendations of the Childhood Cancer Group. All RCTs (including those already included in earlier versions of the review) were scored using the new risk of bias criteria.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-08-12 10:24:55 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>The search for eligible studies was updated to July 2013.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-03-13 15:59:05 +0100" MODIFIED_BY="Jos Noorman">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-03-13 15:59:05 +0100" MODIFIED_BY="Jos Noorman">
<DATE DAY="30" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Summary of most important changes in the update:</P>
<P>The search for eligible studies was updated to March 2010.</P>
<P>One new randomized controlled trial addressing children with hepatoblastoma was included (this type of tumour was not addressed in the original version of the review).</P>
<P>Furthermore, long-term follow-up data of the RCT addressing children with Wilms' tumour were included in the update. For overall survival the results changed from a significant difference in favour of treatment with anthracyclines into no significant difference between the treatment groups.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-03-13 15:59:05 +0100" MODIFIED_BY="Jos Noorman">
<DATE DAY="30" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>The search for eligible studies was updated to March 2010.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Foundation of Paediatric Cancer Research (SKK)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Stichting Kinderen Kankervrij (KiKa)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-09-04 12:03:29 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-09-04 11:34:43 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-09-04 11:31:37 +0200" MODIFIED_BY="[Empty name]">Treatment with or without anthracycline chemotherapy for childhood cancer</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-04 11:34:43 +0200" MODIFIED_BY="[Empty name]">
<P>Anthracyclines are used in the treatment of different types of childhood cancer. Unfortunately, one of the most important adverse effects of anthracyclines is damage to the heart. This can become manifest not only during treatment but also years after the end of treatment. A well-informed decision on the use of anthracyclines in the treatment of different types of childhood cancer should be based on the available evidence on both the antitumour effects of anthracyclines and the risk of damage to the heart.</P>
<P>This systematic review focused on randomised studies evaluating the antitumour effects of anthracycline therapy. The authors found that at the moment no high quality evidence is available which shows that the use of anthracyclines has an increased antitumour effect in acute lymphoblastic leukaemia (ALL) as compared to treatment without anthracyclines, but there was some suggestion that this might be the case. Further high quality studies are needed to provide a definitive conclusion. For Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non-Hodgkin lymphoma, hepatoblastoma and acute myeloid leukaemia (AML) the review authors found only limited data and were unable to draw conclusions. Also, there were no data for other childhood cancers. More high quality research is needed. At the moment there are five ongoing or unpublished randomised studies evaluating the use of anthracyclines in the following types of childhood cancer, hepatoblastoma, ALL (two studies), rhabdomyosarcoma, and Wilms' tumour.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-09-04 11:31:34 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-08-12 10:25:22 +0200" MODIFIED_BY="[Empty name]">
<P>One of the most important adverse effects of anthracyclines is cardiotoxicity. A well-informed decision on the use of anthracyclines in the treatment of childhood cancers should be based on evidence regarding both antitumour efficacy and cardiotoxicity. This review is the second update of a previously published Cochrane review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-06-17 16:05:06 +0200" MODIFIED_BY="[Empty name]">
<P>To compare antitumour efficacy (survival and tumour response) and cardiotoxicity of treatment including or not including anthracyclines in children with childhood cancer. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-09-04 11:28:25 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2013, Issue 6), MEDLINE (1966 to July 2013) and EMBASE (1980 to July 2013). In addition, we searched reference lists of relevant articles and conference proceedings, the International Society for Paediatric Oncology (SIOP) (from 2002 to 2012) and American Society of Clinical Oncology (ASCO) (from 2002 to 2013). We have searched for ongoing trials in the ISRCTN register and the National Institute of Health register (both screened August 2013) (<A HREF="http://www.controlled-trials.com/">http://www.controlled-trials.com</A>).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-06-17 16:05:50 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing treatment of any type of childhood cancer with and without anthracyclines and reporting outcomes concerning antitumour efficacy or cardiotoxicity.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-04 11:28:38 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently performed the study selection, risk of bias assessment and data extraction. Analyses were performed according to the guidelines of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-04 11:31:07 +0200" MODIFIED_BY="[Empty name]">
<P>We identified RCTs for seven types of tumour, acute lymphoblastic leukaemia (ALL) (three trials; 912 children), Wilms' tumour (one trial; 316 children), rhabdomyosarcoma and undifferentiated sarcoma (one trial; 413 children), Ewing's sarcoma (one trial; 94 children), non-Hodgkin lymphoma (one trial; 284 children), hepatoblastoma (one trial; 255 children) and acute myeloid leukaemia (AML) (one trial; 394 children). All studies had methodological limitations. For ALL no evidence of a significant difference in antitumour efficacy was identified in the meta-analyses, but in most individual studies there was a suggestion of better antitumour efficacy in patients treated with anthracyclines. For both Wilms' tumour and Ewing's sarcoma a significant difference in event-free and overall survival in favour of treatment with anthracyclines was identified, although for Wilms' tumour the significant difference in overall survival disappeared with long-term follow-up. For rhabdomyosarcoma and undifferentiated sarcoma, non-Hodgkin lymphoma and hepatoblastoma no difference in antitumour efficacy between the treatment groups was identified. The same was true for AML, with the exception of overall survival in a post hoc analysis in a subgroup of patients with relapsed core binding factor (CBF)-AML in which patients treated with anthracyclines did better. Clinical cardiotoxicity was evaluated in four RCTs; no significant difference between the treatment groups was identified, but in all individual studies there was a suggestion of a lower rate of clinical cardiotoxicity in patients who did not receive anthracyclines. None of the studies evaluated asymptomatic cardiac dysfunction. No RCTs were identified for other childhood cancers.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-09-04 11:31:34 +0200" MODIFIED_BY="[Empty name]">
<P>At the moment no evidence from RCTs is available which underscores the use of anthracyclines in ALL. However, 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. For Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non-Hodgkin lymphoma, hepatoblastoma and AML only one RCT was available for each type and, therefore, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours. For other childhood cancers no RCTs were identified and therefore no conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-09-04 12:03:00 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-09-04 11:40:11 +0200" MODIFIED_BY="[Empty name]">
<P>Anthracyclines, like doxorubicin, daunorubicin and epirubicin, have gained widespread use in the treatment of numerous childhood cancers, both solid tumours and haematological malignancies. Nearly 60% of children diagnosed with a malignancy receive anthracyclines as part of their treatment.</P>
<P>Unfortunately, one of the most important side effects of anthracyclines is cardiotoxicity (that is damage to the heart), which has been known since their introduction (<LINK REF="REF-Lefrak-1973" TYPE="REFERENCE">Lefrak 1973</LINK>). The damage can become manifest in patients as either clinical heart failure (<LINK REF="REF-Von-Hoff-1979" TYPE="REFERENCE">Von Hoff 1979</LINK>) or asymptomatic cardiac dysfunction (<LINK REF="REF-Lipshultz-2005" TYPE="REFERENCE">Lipshultz 2005</LINK>). Asymptomatic cardiac dysfunction includes various cardiac abnormalities diagnosed with different diagnostic methods, like echocardiography, nuclear angiography, cardiac biopsy or cardiac markers, in asymptomatic patients. Anthracycline-induced cardiotoxicity is a widely prevalent problem in children; the incidence of clinical heart failure has been reported to be as high as 16% 0.9 to 4.8 years after treatment (<LINK REF="REF-Kremer-2002a" TYPE="REFERENCE">Kremer 2002a</LINK>) and the prevalence of asymptomatic cardiac dysfunction has been reported to be more than 57% at a median of 6.4 years after treatment (<LINK REF="REF-Kremer-2002b" TYPE="REFERENCE">Kremer 2002b</LINK>). The risk of anthracycline-induced cardiotoxicity is dose-dependent. In a cohort study of 830 children a cumulative anthracycline dose of 300 mg/m² or more produced an eight-fold higher risk of clinical heart failure as compared to lower doses (less than 300 mg/m²) (<LINK REF="REF-Van-Dalen-2006" TYPE="REFERENCE">Van Dalen 2006</LINK>). The consequences of anthracycline-induced cardiotoxicity are extensive. It can lead to long-term side effects, causing severe morbidity and reduced quality of life. The cardiotoxicity involves long-term treatment and thus high medical costs and it causes premature death. The excess mortality due to cardiac disease is eight-fold higher than expected for long-term survivors of childhood cancer compared to the normal population (<LINK REF="REF-Mertens-2001" TYPE="REFERENCE">Mertens 2001</LINK>).</P>
<P>If anthracycline therapy does not have an added value with regard to tumour response and survival compared to treatment without anthracyclines, it should not be used in treatment protocols for childhood cancer. As a result, anthracycline-induced cardiotoxicity would not be an issue. Although ample evidence supports the antileukaemic activity of anthracyclines administered as a single drug, data supporting anthracycline use in modern multi-drug combinations, which now constitute the mainstay of current acute lymphoblastic leukaemia (ALL) treatments, are lacking. It is unclear if the use of anthracyclines improves the outcome (<LINK REF="REF-Messinger-1999" TYPE="REFERENCE">Messinger 1999</LINK>). Also, in a randomised controlled trial (RCT) in children with advanced stage non-lymphoblastic non-Hodgkin's lymphoma, the addition of daunorubicin to treatment with COMP (intrathecal arabinofuranosyl cytidine (ARA-C), cyclophosphamide, vincristine, methotrexate and prednisone) did not improve the prognosis; children treated with daunorubicin had an event-free survival of 57%, whereas in children treated without daunorubicin the event-free survival was 55% (no significant difference) (<LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>).</P>
<P>This is the second update of the first systematic review evaluating the state of the evidence on the use of anthracyclines in the treatment of childhood cancer.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-10-30 14:40:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary objective:</B>
<BR/>
</P>
<UL>
<LI>to compare survival in children with any type of malignancy receiving anthracyclines as part of their treatment with survival in children not receiving anthracyclines as part of their treatment.</LI>
</UL>
<P>
<B>Secondary objectives:</B>
<BR/>
</P>
<UL>
<LI>to compare tumour response in both treatment groups;</LI>
<LI>to compare cardiotoxicity in both treatment groups.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-04 11:45:59 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-09-04 11:43:25 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-10-30 14:39:16 +0100" MODIFIED_BY="[Empty name]">
<P>RCTs comparing treatment of childhood cancer with and without anthracyclines.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-30 14:41:56 +0100" MODIFIED_BY="[Empty name]">
<P>Children (aged 0 to 18 years at diagnosis) with any type of malignancy at any stage. RCTs including both children and adults were only eligible for inclusion in this review if the majority of participants were children and the maximal age of the participants did not exceed 30 years.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-09-04 11:40:39 +0200" MODIFIED_BY="[Empty name]">
<P>Treatment with and without anthracyclines. Therapy other than anthracyclines (that is chemotherapy, cardioprotective interventions, radiotherapy or surgery, or a combination) should have been the same in both treatment groups. Timing of different aspects of the treatment may have differed between the study groups, but the cumulative doses of therapy other than anthracyclines should not have differed more than 25% between the study groups. Furthermore, prior treatment should have been comparable in both treatment groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-09-04 11:43:25 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-09-04 11:40:41 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Survival (overall survival and event-free survival as defined by the authors of the original study)</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-09-04 11:43:25 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tumour response (as defined by the authors of the original study)</LI>
<LI>Anthracycline-induced cardiotoxicity (i.e. clinical heart failure (as defined by the authors of the original study) or asymptomatic cardiac dysfunction (defined as either histological abnormalities according to the Billingham score (<LINK REF="REF-Billingham-1978" TYPE="REFERENCE">Billingham 1978</LINK>) on myocardial biopsies or abnormalities in cardiac function measured by echocardiography or radionuclide ventriculography))</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-09-04 11:42:13 +0200" MODIFIED_BY="[Empty name]">
<P>The following electronic databases have been searched:<BR/>The Cochrane Central Library of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2013, Issue 6), MEDLINE in PubMed (from 1966 to July 2013), and EMBASE in Ovid (from 1980 to July 2013). The search strategies for the different electronic databases (using a combination of controlled vocabulary and text word terms) are detailed in the appendices (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<P>Information about trials not registered in CENTRAL, MEDLINE or EMBASE, either published or unpublished, was located by searching the reference lists of relevant articles and review articles. We also scanned the conference proceedings of the International Society for Paediatric Oncology (SIOP) (from 2002 to 2012) and American Society of Clinical Oncology (ASCO) (from 2002 to 2013), if available electronically and otherwise by handsearching. We have searched for ongoing trials in the ISRCTN register and the National Institute of Health register (both screened August 2013) (<A HREF="http://www.controlled-trials.com/">http://www.controlled-trials.com</A>). Language restrictions were not imposed.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-04 11:45:59 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-09-04 11:44:12 +0200" MODIFIED_BY="[Empty name]">
<P>For the original version of the review, after employing the search strategy described previously, initial screening of identified references was performed by one review author. Case reports, studies only including adults, studies in which all patients received anthracyclines, and review articles were excluded. Identification of studies meeting the inclusion criteria from the remaining references was undertaken by two review authors working independently. Any study which seemed to meet the inclusion criteria on the grounds of the title or abstract, or both, was obtained in full for closer inspection. Again, for the original version of the review, initial screening was performed by one review author who excluded case reports, studies only including adults, studies in which all patients received anthracyclines, and review articles. The remaining full text articles were evaluated by two independent review authors. For both updates of the review, two independent review authors performed all steps of the study identification process (that is no initial screening by one review author). Details of the reasons for exclusion of any study considered for the review were clearly stated. Discrepancies between review authors were resolved by consensus or if that was not possible by third party arbitration.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-09-04 11:44:44 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently performed the data extraction using standardised forms. Data on the following items were extracted:</P>
<P>(1) Study design.</P>
<P>(2) Risk of bias items.</P>
<P>(3) Participants, including:<BR/>a. age;<BR/>b. sex;<BR/>c. type of tumour;<BR/>d. stage of disease;<BR/>e. primary tumour or recurrence;<BR/>f. prior treatment;<BR/>g. number of patients entering the trial;<BR/>h. number of patients randomised;<BR/>i. number of patients excluded (with reasons);<BR/>j. number of patients evaluable (for each outcome).</P>
<P>(4) Interventions, including:<BR/>a. type of anthracycline;<BR/>b. cumulative anthracycline dose;<BR/>c. anthracycline peak dose (defined as the maximal dose received in one week);<BR/>d. anthracycline infusion duration;<BR/>e. other treatment, including:<BR/>i. chemotherapy (agent and cumulative dose),<BR/>ii. radiotherapy (location and cumulative dose),<BR/>iii. surgery (location and procedure),<BR/>iv. cardioprotective interventions (method).</P>
<P>(5) Outcome measures.</P>
<P>(6) Length of follow-up.</P>
<P>Discrepancies between review authors were resolved by consensus. No third party arbitration was needed.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-09-04 11:45:13 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed the risk of bias in the included RCTs. For this second update we used the most recent recommendations of the Childhood Cancer Group (that is selection bias, performance bias, detection bias (for each outcome separately), attrition bias (for each outcome separately), reporting bias (where 'all expected outcomes' was defined as reporting on both overall survival and cardiotoxicity and at least one of the following outcomes: event-free survival or tumour response) and other bias). We used the 'risk of bias' items and definitions of low risk, unclear risk and high risk as described in the module of the Cochrane Childhood Cancer Group (<LINK REF="REF-Kremer-2008" TYPE="REFERENCE">Kremer 2008</LINK>), which is based on the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). All RCTs (including those already included in earlier versions of the review) were scored using the new 'risk of bias' items. Discrepancies between authors were resolved by discussion. No third party arbitration was needed. The risk of bias in the included studies was taken into account in the interpretation of the review's results.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-09-04 11:45:59 +0200" MODIFIED_BY="[Empty name]">
<P>Data were entered into RevMan and analysed according to the guidelines of the <I>Cochrane</I> <I>Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). Dichotomous variables were related to risk using the relative risk or risk ratio (RR). If possible, data were extracted by allocation intervention, irrespective of compliance with the allocated intervention, in order to allow an 'intention-to-treat' (ITT) analysis. If this was not possible, this was stated and we performed an 'as treated' analysis. We assessed heterogeneity both by visual inspection of the forest plots and by a formal statistical test for heterogeneity, that is the I² statistic. If there was evidence of substantial heterogeneity (I² &gt; 50%) (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) this was reported. Studies for which pooling of results was not possible were summarised descriptively. We used a random-effects model for the estimation of treatment effects throughout the review. All results were presented with the corresponding 95% confidence interval (CI). For the assessment of survival, we used the generic inverse variance function of RevMan to combine logs of the hazard ratios (HRs). We used Parmar's method if HRs had not been explicitly presented in the study (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). Data were analysed separately for different types of tumour and, if possible, also for different stages of disease and different histological subtypes. When a particular outcome was not evaluated in more than 50% of the patients of a study, due to the associated high risk of attrition bias we did not report the results of this outcome measure. For all outcomes for which pooled analyses were possible we performed sensitivity analyses for all risk of bias criteria separately. We excluded studies with a high risk of bias and studies for which the risk of bias was unclear and compared the results of the studies with a low risk of bias with the results of all available studies. The risk of bias in the studies included in the analyses was taken into account in the interpretation of the results of the review. We were not able to construct a funnel plot to graphically ascertain the existence of publication bias. As a rule of thumb, tests for funnel plot asymmetry should be used only when there are at least 10 studies included in a meta-analysis. When there are fewer studies the power of the test is too low to distinguish chance from real asymmetry (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). Since only a maximum of three trials could be included in the separate meta-analyses, we did not construct funnel plots. For outcomes where only one study was available, we were unable to calculate a RR if one of the treatment groups experienced no events and the Fischer&#8217;s exact test was used instead; this option is not available in Revman and therefore we used http://graphpad.com/quickcalcs/contingency2/.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-09-04 11:57:28 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-09-04 11:47:43 +0200" MODIFIED_BY="[Empty name]">
<P>Running the searches in the electronic databases of CENTRAL, MEDLINE in PubMed and EMBASE in Ovid (in January 2007) yielded a total of 3277 references. Initial screening excluded 987 references based on them being case reports, review articles, studies only including adults, or studies in which all patients received anthracyclines. Of the 2290 remaining references 135 studies were assessed in full. Of the 67 articles remaining after initial screening, we included a total of seven articles which fulfilled all the criteria for this review. A total of 128 articles were excluded after assessing the full text articles, for reasons described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. The remaining 2155 references were excluded based on the title or abstract, or both, since they were not a RCT, were laboratory studies, were animal studies, did not include children with cancer, or there was a difference in treatment other than anthracyclines between the treatment groups.</P>
<P>Running the searches for the update in CENTRAL, MEDLINE in PubMed and EMBASE in Ovid (in March 2010) yielded a total of 1032 new references. Following screening of the titles, abstracts, or both, 1000 references which clearly did not meet all criteria for considering studies for this review were excluded. We obtained 32 articles in full, of which a single article fulfilled all the criteria for considering studies for this review (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>). The other 31 articles were excluded for reasons described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>Running the searches for the second update in CENTRAL, MEDLINE in PubMed and EMBASE in Ovid (in July 2013) yielded a total of 1167 new references. Following screening of the titles, abstracts, or both, 1151 references which clearly did not meet all criteria for considering studies for this review were excluded. We obtained 16 articles in full (five of these were only available as a conference proceeding), of which a single article fulfilled all the criteria for considering studies for this review (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>). Thirteen articles were excluded for reasons described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table; two studies have not been published in full yet (see <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table).</P>
<P>Scanning the reference lists of relevant articles and reviews did not identify any additional eligible studies. We did identify three ongoing trials during the original review. At the time of the first update one ongoing trial identified in the original version of this review was published in full text and identified in the update of the electronic database searches (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>); this trial was thus removed from the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> table. At the time of the second update it became clear that the SIOP-2001 trial was closed and preliminary results had been presented as a conference proceeding (identified in the second update of the electronic database searches as described above); this trial was thus removed from the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> table. Eleven other studies (nine from the original version and two from the first update) were added to the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>By scanning the conference proceedings of SIOP and ASCO for the original version, we identified one study (described in two abstracts) that had not been published in full yet and was awaiting further assessment during the original search. At the time of the updates this study is still not published in full (see the <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table); no other additional eligible studies were identified during the updates.</P>
<P>By scanning the ongoing trials databases for the original version we identified three additional ongoing trials (see the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> table); no other additional eligible studies were identified during the updates but it became clear that the ISRCTN94206677 and the NCT00186966 trials were in fact the same study and that the study was published in full text and identified in the second update of the electronic database searches (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>); these publications were thus removed from the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> table.</P>
<P>Finally, during the first update an expert in the field provided us with long-term follow-up data (<LINK REF="REF-Green-2004" TYPE="REFERENCE">Green 2004</LINK>) of one of the included studies (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>).</P>
<P>In summary, after the second update the total number of included RCTs was nine. We also identified two ongoing studies and three studies that have not been published in full yet and are awaiting further assessment.</P>
<P>Characteristics of the included studies are summarised below; for more information we refer to the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>The total number of patients included in the nine identified RCTs was 2668: 1318 children received no anthracyclines, whereas 1350 did receive anthracyclines. In three studies children were diagnosed with ALL (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>); and in one with acute myeloid leukemia (AML) (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>). In the other five studies they were diagnosed with a solid tumour: Wilms' tumour (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>), rhabdomyosarcoma or undifferentiated sarcoma (<LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>), Ewing's sarcoma (<LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>), non-Hodgkin lymphoma (<LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>) or hepatoblastoma (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>). In four studies patients were treated with daunorubicin (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). In all these studies the cumulative daunorubicin dose actually received by the patients was not mentioned, but according to protocol patients should have received 90 to 350 mg/m². The peak anthracycline dose (that is the maximal dose received in one week) ranged from 25 to 90 mg/m². Infusion durations were not mentioned. In four studies patients were treated with doxorubicin (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>). In all these studies the cumulative doxorubicin dose actually received by the patients was not mentioned, but according to protocol patients should have received either (maximal) 300 or 420 mg/m². The peak anthracycline dose (that is the maximal dose received in one week) was either 25 or 60 mg/m². Infusion durations were not mentioned in three studies, in the other study it was 30 mg/m<SUP>2</SUP>/24 hours. In the final study patients were treated with daunoxome, that is liposomally entrapped daunorubicin (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>). The cumulative daunoxome dose actually received by the patients was not mentioned, but according to protocol patients should have received 180 mg/m<SUP>2</SUP>. The peak anthracycline dose (that is the maximal dose received in one week) was 180 mg/m<SUP>2</SUP>. The infusion duration was not mentioned.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-04 11:50:29 +0200" MODIFIED_BY="[Empty name]">
<P>See the risk of bias section of the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for the exact scores per included study.<I>
<BR/>
</I>
</P>
<ALLOCATION MODIFIED="2014-09-04 11:49:34 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating selection bias we have assessed the random sequence generation and the allocation concealment. The risk of selection bias was low in two studies (22%) (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>), while in seven studies (78%) it was unclear (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). For the latter study only the random sequence generation was unclear and the allocation concealment was adequate; for the other six studies both items were unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-09-04 11:49:57 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating performance bias we have assessed the blinding of participants and personnel. In two studies (22%) there was a high risk of bias (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>), while in seven studies (78%) it was unclear (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>; <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>).</P>
<P>For evaluating detection bias we have evaluated the blinding of outcome assessors for all separate outcomes, with the exception of overall survival since for that outcome blinding is not relevant and the risk of detection bias was thus automatically judged as low for all eight studies (100%) evaluating this outcome (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). Six studies evaluated event-free survival; in all studies (100%) the risk of detection bias was unclear (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). Five studies evaluated tumour response; in four studies (80%) the risk of detection bias was unclear (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>) while in one study (20%) the risk was judged to be high (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>). Five studies evaluated cardiotoxicity; in four studies (80%) the risk of detection bias was unclear (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>) while in one study (20%) the risk was judged to be high (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-09-04 11:50:07 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating attrition bias we have assessed incomplete outcome data for all separate outcomes. Eight studies evaluated overall survival; in five studies (63%) there was a low risk of attrition bias (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>), in one study (12%) there was a high risk of attrition bias (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>) and in two studies (25%) the risk of attrition bias was unclear (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>). Six studies evaluated event-free survival; in three studies (50%) there was a low risk of attrition bias (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>), in one study (17%) there was a high risk of attrition bias (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>) and in two studies (33%) the risk of attrition bias was unclear (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>). Five studies evaluated tumour response; in all studies (100%) the risk of attrition bias was low (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). Five studies evaluated cardiotoxicity; in two studies (40%) the risk of attrition bias was high (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>) while in three studies (60%) it was unclear (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-09-04 11:50:12 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating reporting bias we have assessed selective reporting. We defined 'all expected outcomes' as reporting on both overall survival and cardiotoxicity and at least one of the following outcomes: event-free survival or tumour response. In five studies (56%) we judged the risk of reporting bias to be low (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>) while in four studies (44%) it was judged to be high (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-09-04 11:50:29 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating other potential sources of bias we have assessed the following items: block randomisation in unblinded trials, baseline imbalance between treatment groups related to outcome (prior cardiotoxic treatment, age, sex, prior cardiac dysfunction), difference in length of follow-up between treatment arms, and inappropriate influence of funders. In one study (11%) there was a high risk of other bias (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>) while in the other eight studies (89%) the risk was unclear (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>; <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>; <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). For a more detailed description of all the different items see the risk of bias section of the <A HREF="http://www.archie.cochrane.org/sections/documents/view?document=60533348873545919391101216111740&amp;format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES">Characteristics of included studies</A> table.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-09-04 11:57:28 +0200" MODIFIED_BY="[Empty name]">
<P>Not all articles allowed data extraction for all endpoints (see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for a more detailed description of the extractable endpoints of each article).</P>
<SUBSECTION>
<HEADING LEVEL="5">Overall survival</HEADING>
<P>(See 
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="6">ALL</HEADING>
<P>Data on overall survival could be extracted from three trials with a total of 912 patients (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). Parmar's method was used to obtain the necessary data for the meta-analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.22, 95% CI 0.95 to 1.57, P = 0.13). No heterogeneity was detected (I<SUP>2</SUP> = 0%).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Wilms' tumour</HEADING>
<P>Data on overall survival could be extracted from one trial with a total of 316 patients (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>). Data were presented separately for patients with stage II or III disease with favourable histology, stage II or III with unfavourable histology, and stage IV disease. Parmar's method was used to obtain the necessary data for the analysis. The combination of all patients showed a significant difference in favour of treatment including anthracyclines (HR 1.85, 95% CI 1.09 to 3.15, P = 0.02). No heterogeneity was detected (I<SUP>2</SUP> = 0%). For patients with stage II or III disease with favourable histology and patients with stage IV disease the analyses showed no significant difference between treatment not including and treatment including anthracyclines. However, the analysis of patients with stage II or III with unfavourable histology showed a significant difference in favour of treatment including anthracyclines (HR 3.10, 95% CI 1.03 to 9.28, P = 0.04).</P>
<P>Long-term follow-up data of this study have been published (<LINK REF="REF-Green-2004" TYPE="REFERENCE">Green 2004</LINK>; <LINK REF="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH" TYPE="STUDY">D'Angio 1981 II-III FH UH</LINK>; <LINK REF="STD-D_x0027_Angio-1981-IV" TYPE="STUDY">D'Angio 1981 IV</LINK>) on 275 of 316 patients: 227 patients with stage II or III disease with favourable or unfavourable histology (as opposed to <LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK> in which data were presented separately for favourable and unfavourable histology) and 48 patients with stage IV disease. The length of follow-up was not mentioned but at least some of the patients had a follow-up of 16 years. See <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> for the long-term follow-up data. In contrast to the earlier results, the long-term follow-up data showed no significant difference between treatment groups (HR 1.27, 95% CI 0.77 to 2.11, P = 0.34). No heterogeneity was detected (I<SUP>2</SUP> = 0%). The long-term follow-up data also showed no significant difference between treatment groups for patients with stage II or III disease with favourable or unfavourable histology and for patients with stage IV disease. These results are in line with the earlier data; in <LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK> the overall survival of patients with stage II or III disease with favourable or unfavourable histology combined was not significantly different between treatment groups (HR 1.92, 95% CI 0.91 to 4.04, P = 0.09, I<SUP>2</SUP> = 19%; data not shown in the figures). Please note that it was not possible to perform an ITT analysis: in the stage IV group 20 patients were included in the no anthracycline group and 28 in the anthracycline group, as opposed to the original data where 22 patients were randomised to the anthracycline group and 27 to the non-anthracycline group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rhabdomyosarcoma and undifferentiated sarcoma</HEADING>
<P>Data on overall survival could be extracted from one trial with a total of 413 patients (<LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>). Data were presented for patients in clinical groups III and IV separately. Parmar's method was used to obtain the necessary data for the analysis. The combination of both clinical groups showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.04, 95% CI 0.83 to 1.29, P = 0.76). The same was true for each clinical group separately. No heterogeneity was detected (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Ewing's sarcoma</HEADING>
<P>Overall survival was evaluated in one trial (<LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>). Only some of the patients included in this trial were eligible for inclusion in this review (N = 94) and, unfortunately, not all data needed for a correct analysis of overall survival in only the eligible patients were provided in the article. Therefore, we provided descriptive results of overall survival in only the eligible patients. There was evidence of a significant advantage in overall survival for patients treated with anthracyclines as compared to patients treated without anthracyclines (P = 0.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Non-Hodgkin lymphoma</HEADING>
<P>Overall survival could not be evaluated since we were not able to reliably extract the data needed to use Parmar's method for the assessment of this outcome from this study (<LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Hepatoblastoma</HEADING>
<P>Overall survival was evaluated in one trial with a total of 255 patients (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>). Parmar's method was used to obtain the necessary data for the analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.14, 95% CI 0.41 to 3.16, P = 0.80). Please note that it was not possible to perform an ITT analysis: 12 randomised patients were excluded (seven lacked proper documentation, five had wrong diagnosis; it was unclear to which treatment group these patients were randomised).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">AML</HEADING>
<P>Overall survival was evaluated in one trial with a total of 394 patients (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>). Parmar's method was used to obtain the necessary data for the analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.16, 95% CI 0.94 to 1.44, P = 0.17).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Event-free survival</HEADING>
<P>(See 
<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="6">ALL</HEADING>
<P>Data on event-free survival could be extracted from two trials with a total of 870 patients (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). Parmar's method was used to obtain the necessary data for the meta-analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.05, 95% CI 0.76 to 1.46, P = 0.77). However, unexplained heterogeneity was detected (I<SUP>2</SUP> = 56%). In the study of <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK> no information on event-free survival was provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Wilms' tumour</HEADING>
<P>Data on event-free survival could be extracted from one trial with a total of 316 patients (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>). Data were presented separately for patients with stage II or III disease with favourable histology, stage II or III with unfavourable histology, and stage IV disease. Parmar's method was used to obtain the necessary data for the analysis. The combination of all patients showed a significant difference in favour of treatment including anthracyclines (HR 2.21, 95% CI 1.44 to 3.40, P = 0.0003). No heterogeneity was detected (I<SUP>2 </SUP>= 0%). The analysis of patients with stage II or III disease with favourable histology also showed a significant difference in favour of treatment including anthracyclines (HR 2.56, 95% CI 1.42 to 4.61, P = 0.002). However, for patients with stage II or III disease with unfavourable histology and patients with stage IV disease the analyses showed no significant difference between treatment not including and treatment including anthracyclines.</P>
<P>Long-term follow-up data of this study have been published (<LINK REF="REF-Green-2004" TYPE="REFERENCE">Green 2004</LINK>; <LINK REF="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH" TYPE="STUDY">D'Angio 1981 II-III FH UH</LINK>; <LINK REF="STD-D_x0027_Angio-1981-IV" TYPE="STUDY">D'Angio 1981 IV</LINK>) on 275 of 316 patients: 227 patients with stage II or III disease with favourable or unfavourable histology (as opposed to <LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>, data were not presented separately for favourable and unfavourable histology) and 48 patients with stage IV disease. The length of follow-up was not mentioned but at least some of the patients had a follow-up of 16 years. See <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK> for the long-term follow-up data, which also showed a significant difference in favour of treatment including anthracyclines (HR 1.72, 95% CI 1.09 to 2.72, P = 0.02). No heterogeneity was detected (I<SUP>2</SUP> = 0%). For the different stages or histologies the results of the long-term follow-up data were also in line with the earlier data, that is a significant difference in favour of treatment including anthracyclines for patients with stage II or III disease with favourable or unfavourable histology (for the long-term follow-up: HR 1.80, 95% CI 1.04 to 3.12, P = 0.04; for the earlier follow-up: HR 2.21, 95% CI 1.35 to 3.62, P = 0.002, I<SUP>2</SUP> = 0%; data not shown in the figures); and no significant difference between treatment groups for patients with stage IV disease. Please note that it was not possible to perform an ITT analysis: in the stage IV group 20 patients were included in the no anthracycline group and 28 in the anthracycline group, as opposed to the original data where 22 patients were randomised to the anthracycline group and 27 to the non-anthracycline group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rhabdomyosarcoma and undifferentiated sarcoma</HEADING>
<P>Event-free survival could not be evaluated since we were not able to reliably extract the data needed to use Parmar's method for the assessment of this outcome from this study (<LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Ewing's sarcoma</HEADING>
<P>Event-free survival was evaluated in one trial (<LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>). Only some of the patients included in this trial were eligible for inclusion in this review and, unfortunately, not all data needed for a correct analysis of event-free survival in only these patients were provided in the article. Therefore, we provide descriptive results of event-free survival in only the eligible patients. There was evidence of a significant advantage in event-free survival for patients treated with anthracyclines as compared to patients treated without anthracyclines (P = 0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Non-Hodgkin lymphoma</HEADING>
<P>Data on event-free survival could be extracted from one trial with a total of 284 patients (<LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>). Parmar's method was used to obtain the necessary data for the analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.01, 95% CI 0.74 to 1.38, P = 0.95).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Hepatoblastoma</HEADING>
<P>Event-free survival was evaluated in one trial with a total of 255 patients (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>). Parmar's method was used to obtain the necessary data for the analysis. The data showed no significant difference between treatment not including and treatment including anthracyclines (HR 0.81, 95% CI 0.42 to 1.55, P = 0.52). Please note that it was not possible to perform an ITT analysis: 12 randomised patients were excluded (seven lacked proper documentation, five had wrong diagnosis; it was unclear to which treatment group these patients were randomised).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">AML</HEADING>
<P>No information on event-free survival was provided (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tumour response</HEADING>
<P>(See 
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>)</P>
<P>Please note that due to the nature of this outcome (that is the number of patients with a remission) a high event rate is favourable. Therefore, in the figures of the analyses, 'favours anthracyclines' is on the left and 'favours no anthracyclines' is on the right, as opposed to the figures of the other analyses.</P>
<SUBSECTION>
<HEADING LEVEL="6">ALL</HEADING>
<P>Data on tumour response (defined as the number of patients in complete remission) could be extracted from two studies with a total of 870 patients (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). The meta-analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 1.02, 95% CI 0.99 to 1.06, P = 0.22). No substantial heterogeneity was detected (I<SUP>2</SUP> = 15%).<BR/>We excluded the study of <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK> from this analysis since no data on tumour response was provided separately in either treatment group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Wilms' tumour</HEADING>
<P>No information on tumour response was provided (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rhabdomyosarcoma and undifferentiated sarcoma</HEADING>
<P>Data on tumour response (defined as the number of patients in complete or partial remission) could be extracted from one trial with a total of 413 patients (<LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>). The analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 1.00, 95% CI 0.91 to 1.09, P = 0.95).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Ewing's sarcoma</HEADING>
<P>No information on tumour response was provided (<LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Non-Hodgkin lymphoma</HEADING>
<P>No information on tumour response was provided (<LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Hepatoblastoma</HEADING>
<P>Tumour response (defined as complete surgical resection, that is resection of all tumour sites on the basis of surgical findings and on postsurgical imaging) was evaluated in one trial with a total of 255 patients (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>). The analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 1.02, 95% CI 0.96 to 1.08, P = 0.61). Please note that it was not possible to perform an ITT analysis: 12 randomised patients were excluded (seven lacked proper documentation, five had wrong diagnosis; it was unclear to which treatment group these patients were randomised).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">AML</HEADING>
<P>Tumour response (that is complete response after two courses defined as 5% or fewer leukaemic blasts in bone marrow with signs of normal haematopoiesis and of regeneration of normal peripheral blood cell production (platelets &gt; 50 x 10<SUP>9</SUP>/L without transfusions, neutrophils &gt; 1.0 x 10<SUP>9</SUP>/L) and no leukaemic cells in the peripheral blood or anywhere else) was evaluated in one trial with a total of 394 patients (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>). The analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 0.87, 95% CI 0.75 to 1.01, P = 0.06).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cardiotoxicity</HEADING>
<P>(See <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="6">Cardiac death</HEADING>
<P>Data on cardiac death could be extracted from two trials with a total of 410 patients with Wilms' tumour or Ewing's sarcoma (<LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK>; <LINK REF="STD-Nesbit-1990" TYPE="STUDY">Nesbit 1990</LINK>). The meta-analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 0.41, 95% CI 0.04 to 3.89, P = 0.44). No heterogeneity was detected (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Congestive heart failure</HEADING>
<P>Data on congestive heart failure could be extracted from one trial with a total of 413 patients with rhabdomyosarcoma and undifferentiated sarcoma (<LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>). Since in one of the treatment groups there were no events (0 out of 208 children in the group without anthracyclines experienced congestive heart failure as opposed to 1 out of 205 children in the group with anthracyclines) we were unable to calculate a RR, so we used the Fischer&#8217;s exact test instead. The analysis showed no significant difference between treatment not including and treatment including anthracyclines (Fischer's exact P = 0.50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Asymptomatic cardiac dysfunction</HEADING>
<P>We could collect data on asymptomatic cardiac dysfunction from one trial with a total of 255 patients with hepatoblastoma (<LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK>). However, due to the high risk of attrition bias (this outcome was evaluated in only 49% of the patients), results of this study were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Grade 3 or 4 acute cardiotoxicity according to National Cancer Institute Common Toxicity Criteria (NCI CTC) version 2</HEADING>
<P>Data on grade 3 or 4 acute cardiotoxicity according to the NCI CTC Criteria version 2 could be extracted from one trial with a total of 394 patients with AML (<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>). The analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 0.20, 95% CI 0.02 to 1.70, P = 0.14).</P>
<P>In the studies of <LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>; <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>; <LINK REF="STD-Van-der-Does-1975" TYPE="STUDY">Van der Does 1975</LINK> and <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK> no (reliable) information on cardiotoxicity was provided.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analyses for the used quality criteria</HEADING>
<P>The results of the sensitivity analyses were consistent among the trials and did not differ from the overall analyses.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-04 12:01:58 +0200" MODIFIED_BY="[Empty name]">
<P>Anthracycline-induced cardiotoxicity is a considerable and serious problem, causing severe morbidity and mortality. With the current improved cancer survival rates, the problem of late-onset cardiotoxicity is increasing. The risk of developing heart failure remains a lifelong threat, especially to children who have a long life-expectancy after successful antineoplastic treatment. If anthracycline therapy does not have an added value with regard to tumour response and survival compared to treatment without anthracyclines, it should not be used in treatment protocols for childhood cancer. As a result anthracycline-induced cardiotoxicity would not be an issue. This is the second update of the first systematic review evaluating the current state of evidence on the use of anthracyclines in the treatment of childhood cancer. Only RCTs were included since it is widely recognized that a RCT is the only study design which can be used to obtain unbiased evidence on the use of anthracyclines, provided that the design and execution are adequate.</P>
<P>We could identify RCTs for seven types of tumour, ALL, Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non-Hodgkin lymphoma, hepatoblastoma, and AML. Either the use of doxorubicin or (liposomally entrapped) daunorubicin was evaluated.</P>
<P>For ALL three trials were identified, all evaluating the use of daunorubicin. Our meta-analysis of these three trials showed no evidence of a significant difference in overall survival between the treatment groups. Our meta-analysis of two trials also showed no evidence of a significant difference in event-free survival between the treatment groups (unexplained heterogeneity was detected). However, a long-term cardiac follow-up study of one of these studies (<LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>) mentioned that the five-year and 10-year event-free survival of patients treated with anthracyclines were significantly better than for patients treated without anthracyclines (P = 0.047 and P = 0.038, respectively) (<LINK REF="STD-Rammeloo-2000" TYPE="STUDY">Rammeloo 2000</LINK>). Our meta-analysis of two trials showed no evidence of a significant difference in tumour response (defined as the number of patients in complete remission) between the treatment groups. Please note that the reason that no significant difference between the treatment groups was identified could be due to the fact that the numbers of patients included in these studies were too small to detect a difference between the treatment groups (that is low power). Also, the length of follow-up could be too short to detect a significant difference between the treatment groups. In most individual studies there is some suggestion of better survival in patients treated with anthracyclines. It should be noted that all these RCTs are performed in a different treatment era and not all RCTs stated the risk group(s) of included children. Nowadays most children with ALL are cured (<LINK REF="REF-Pieters-2008" TYPE="REFERENCE">Pieters 2008</LINK>), while in the studies included in this review approximately 70% of the children survived.</P>
<P>For Wilms' tumour one trial was identified, evaluating the use of doxorubicin. Our analysis of all patients included in this trial showed a significant difference in overall survival in favour of treatment including anthracyclines as compared to treatment without anthracyclines (HR 1.85, 95% CI 1.09 to 3.15, P = 0.02). However, when patients with different stages of disease and different tumour histologies were analysed separately, this result was confirmed only in patients with stage II or III disease with unfavourable histology (HR 3.10, 95% CI 1.03 to 9.28, P = 0.04). For patients with stage II or III disease with favourable histology and patients with stage IV disease there was no evidence of a significant difference in overall survival between the treatment groups. However, with long-term follow-up (that is the exact length of follow-up was unclear, but at least some of the patients had a follow-up of 16 years), the overall result changed from a significant difference in favour of treatment with anthracyclines into no significant difference between the treatment groups. A possible explanation could be the mortality caused by different late effects (<LINK REF="REF-Mertens-2001" TYPE="REFERENCE">Mertens 2001</LINK>; <LINK REF="REF-Reulen-2010" TYPE="REFERENCE">Reulen 2010</LINK>). Our analysis of all patients included in this trial showed a significant difference in event-free survival in favour of treatment including anthracyclines as compared to treatment without anthracyclines (HR 2.21, 95% CI 1.44 to 3.40, P = 0.0003). However, when patients with different stages of disease and different tumour histologies were analysed separately, this result was confirmed only in patients with stage II or III disease with favourable histology (HR 2.56, 95% CI 1.42 to 4.61, P = 0.002). For patients with stage II or III disease with unfavourable histology and patients with stage IV disease there was no evidence of a significant difference in event-free survival between the treatment groups. The results of event-free survival did not change with long-term follow-up (HR 1.72, 95% CI 1.09 to 2.72, P = 0.02). No information on tumour response was provided and, therefore, no conclusions can be made regarding this outcome. Please note that the reason that a significant difference between the treatment groups was not found for all stages of disease and tumour histologies could be due to the fact that the numbers of patients included in these studies were too small to detect a difference between the treatment groups (that is low power). The direction of the results of the different stages of disease and different tumour histologies were the same as the overall result.</P>
<P>For rhabdomyosarcoma and undifferentiated sarcoma one trial was identified, evaluating the use of doxorubicin. Our analysis of all patients included in this trial showed no evidence of a significant difference in overall survival between the treatment groups. When patients in different clinical groups (that is clinical groups III and IV) were analysed separately, again no evidence of a significant difference between the treatment groups was identified. It was not possible to evaluate event-free survival in this study and, therefore, no conclusions can be made regarding this outcome. Our analysis showed no significant difference in tumour response (defined as the number of patients in complete or partial remission) between the treatment groups.</P>
<P>For Ewing's sarcoma one trial was identified, evaluating the use of doxorubicin. Descriptive results of overall survival and event-free survival identified evidence of a significant advantage for patients treated with anthracyclines as compared to patients treated without anthracyclines (P = 0.02 and P = 0.01, respectively). No information on tumour response was provided and, therefore, no conclusions can be made regarding this outcome.</P>
<P>For non-Hodgkin lymphoma one trial was identified, evaluating the use of daunorubicin. It was not possible to evaluate overall survival in this study and, therefore, no conclusions can be made regarding this outcome. Our analysis of event-free survival showed no evidence of a significant difference between the treatment groups. No information on tumour response was provided and, therefore, no conclusions can be made regarding this outcome.</P>
<P>For hepatoblastoma one trial was identified, evaluating the use of doxorubicin. No significant difference in overall survival, event-free survival and tumour response (defined as complete surgical resection, that is resection of all tumour sites on the basis of surgical findings and on postsurgical imaging) was identified between treatment including and treatment not including anthracyclines.</P>
<P>For AML one trial was identified, evaluating the use of daunoxome, that is liposomally entrapped daunorubicin. No significant difference in overall survival and tumour response (defined as complete response after two courses) was identified between treatment including and treatment not including anthracyclines. No information on event-free survival was provided and, therefore, no conclusions can be made regarding this outcome. In addition to overall survival for all randomised patients, this study reported overall survival in a subgroup of patients with relapsed core binding factor (CBF)-AML (that is t(8:21) or inv(16)). In patients randomised to treatment without anthracyclines (n = 34) overall survival at seven years was 58%, while in patients randomised to treatment with anthracyclines (n = 36) it was 82%. Since this was a post hoc analysis it was not included in the results of this review. The authors clearly stated that since this was a post hoc analysis this finding needs to be confirmed.</P>
<P>Please note that the reason that no significant difference between treatment groups was identified in patients with rhabdomyosarcoma and undifferentiated sarcoma, non-Hodgkin lymphoma, hepatoblastoma and AML could be due to the fact that the numbers of patients included in these studies were too small to detect a difference between the treatment groups (that is low power). Also, the length of follow-up could be too short to detect a significant difference between the treatment groups.</P>
<P>As mentioned earlier, one of the most serious adverse effects of anthracycline treatment is cardiotoxicity. Therefore, we did not only evaluate the antitumour efficacy of treatment with and without anthracyclines but also the occurrence of cardiotoxicity in both treatment groups. Our meta-analysis of two trials evaluating cardiac death showed no significant difference between the treatment groups. The same was true for our analysis of one trial evaluating congestive heart failure and our analysis of one trial evaluating acute grade 3 or 4 cardiotoxicity (according to the NCI CTC version 2). One study provided information on asymptomatic cardiac dysfunction but due to the high risk of attrition bias (this outcome was evaluated in only 49% of the patients) results of this study were not included in this systematic review. Please note that the reason that no significant difference between the treatment groups was identified could be due to the fact that the numbers of patients included in these studies were too small to detect a difference between the treatment groups (that is low power). Also, the length of follow-up could be too short to detect a significant difference between the treatment groups. There is some suggestion of a lower rate of clinical cardiotoxicity in patients who were not treated with anthracyclines.</P>
<P>Although there is only a small amount of data on the occurrence of anthracycline-induced cardiotoxicity available from RCTs, both clinical and asymptomatic anthracycline-induced cardiac damage has been evaluated in many non-randomised studies. These studies show that anthracycline-induced cardiotoxicity is a widely prevalent problem in children. The incidence of clinical heart failure has been reported to be as high as 16% at 0.9 to 4.8 years after treatment (<LINK REF="REF-Kremer-2002a" TYPE="REFERENCE">Kremer 2002a</LINK>) and the prevalence of asymptomatic cardiac dysfunction has been reported to be more than 57% at a median of 6.4 years after treatment (<LINK REF="REF-Kremer-2002b" TYPE="REFERENCE">Kremer 2002b</LINK>). The incidence of anthracycline-induced cardiotoxicity, both clinical and asymptomatic, seems to increase with a longer follow-up period (<LINK REF="REF-Green-2001" TYPE="REFERENCE">Green 2001</LINK>; <LINK REF="REF-Kremer-2002b" TYPE="REFERENCE">Kremer 2002b</LINK>; <LINK REF="REF-Van-Dalen-2006" TYPE="REFERENCE">Van Dalen 2006</LINK>). For example, in a cohort study of 830 children with different types of tumour the estimated risk of anthracycline-induced clinical heart failure increased with time from 2% at two years after the first dose of anthracyclines to 5.5% at 15 years after the first dose of anthracyclines (<LINK REF="REF-Van-Dalen-2006" TYPE="REFERENCE">Van Dalen 2006</LINK>). In three of the four studies included in this review that adequately evaluated cardiotoxicity the length of follow-up was not mentioned, but it is likely that in all studies the follow-up was relatively short. In the other study the median follow-up was four years, but only acute cardiotoxicity was assessed. We did not include data on long-term cardiac follow-up from the included RCTs in this review because they included only data on some of the randomised patients and as a result the presence of selection bias could not be ruled out in these studies. Furthermore, in most long-term follow-up studies data for patients eligible for inclusion in our review could not be separated from results of patients ineligible for our review. However, in the study of <LINK REF="STD-Rammeloo-2000" TYPE="STUDY">Rammeloo 2000</LINK>, which was a long-term cardiac follow-up study of <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>, no late cardiac damage was demonstrated in 90 of the 136 eligible ALL survivors. The minimal follow-up was 11 years after the last dose of anthracycline therapy. The age at diagnosis ranged from 1.2 to 14.9 years; at the time of the study their age ranged from 14.7 to 31.3 years. It should be noted that in this RCT patients who were randomised to treatment with anthracyclines received a relatively low cumulative anthracycline dose (that is according to the protocol 100 mg/m<SUP>2</SUP> of daunorubicin) and that the occurrence of anthracycline-induced cardiotoxicity is dose-dependent (<LINK REF="REF-Green-2001" TYPE="REFERENCE">Green 2001</LINK>; <LINK REF="REF-Kremer-2002a" TYPE="REFERENCE">Kremer 2002a</LINK>; <LINK REF="REF-Van-Dalen-2006" TYPE="REFERENCE">Van Dalen 2006</LINK>; <LINK REF="REF-Von-Hoff-1979" TYPE="REFERENCE">Von Hoff 1979</LINK>). However, it is important not to forget that although the risk of anthracycline-induced clinical heart failure is significantly increased with a cumulative anthracycline dose of 300 mg/m² or more (<LINK REF="REF-Van-Dalen-2006" TYPE="REFERENCE">Van Dalen 2006</LINK>), both clinical and asymptomatic cardiac dysfunction can occur with a lower cumulative anthracycline dose (<LINK REF="REF-Lipshultz-2005" TYPE="REFERENCE">Lipshultz 2005</LINK>; <LINK REF="REF-Van-Dalen-2006" TYPE="REFERENCE">Van Dalen 2006</LINK>). The fact that the patients in the study of <LINK REF="STD-Rammeloo-2000" TYPE="STUDY">Rammeloo 2000</LINK> did not develop cardiac damage at the time of the study does not exclude the possibility that anthracycline-induced cardiotoxicity will become visible as they become older.</P>
<P>Just as the occurrence of anthracycline-induced cardiotoxicity is dose-dependent, it is possible that the cumulative anthracycline dose patients received influenced the antitumour efficacy of treatment. The exact cumulative anthracycline dose was not mentioned in any of the studies, but according to the different protocols the cumulative anthracycline dose ranged from 90 to 420 mg/m<SUP>2</SUP>. It should be noted that in the AML study and two of the three ALL studies patients received a relatively low cumulative anthracycline dose, that is either 180 mg/m<SUP>2 </SUP>(<LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>), 90 mg/m<SUP>2</SUP> (<LINK REF="STD-Eden-1991" TYPE="STUDY">Eden 1991</LINK>) or 100 mg/m<SUP>2</SUP> (<LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>). However, despite these low cumulative doses, in all studies there was still a suggestion of better antitumour efficacy with anthracycline therapy.</P>
<P>Patient age can be an important prognostic factor for the antitumour efficacy of treatments for different types of tumour (<LINK REF="REF-Biondi-2000" TYPE="REFERENCE">Biondi 2000</LINK>; <LINK REF="REF-Gratias-2008" TYPE="REFERENCE">Gratias 2008</LINK>; <LINK REF="REF-Pieters-2008" TYPE="REFERENCE">Pieters 2008</LINK>). For example, in ALL infants aged less than one year or children aged 10 years or older have a worse outcome than children aged between one and nine years at diagnosis (<LINK REF="REF-Biondi-2000" TYPE="REFERENCE">Biondi 2000</LINK>; <LINK REF="REF-Pieters-2008" TYPE="REFERENCE">Pieters 2008</LINK>). Patient's age can also be a prognostic factor for the occurrence of cardiotoxicity (<LINK REF="REF-Kremer-2002a" TYPE="REFERENCE">Kremer 2002a</LINK>; <LINK REF="REF-Kremer-2002b" TYPE="REFERENCE">Kremer 2002b</LINK>). Unfortunately, due to a lack of useful data, these factors could not be evaluated in this review and, therefore, no conclusions can be made regarding age as a prognostic factor for these outcomes.</P>
<P>The risk of bias in the included studies varied. In most studies bias could not be ruled out due to lack of reporting. However, at the moment this is the best available evidence from RCTs evaluating treatment with and without anthracyclines in children with cancer. With regard to performance bias it should be noted that due to the nature of the interventions, blinding of care providers and patients was virtually impossible.</P>
<P>In this review we tried to only perform intention-to-treat (ITT) analyses, since they provide the most realistic and unbiased answer to the question of clinical effectiveness (<LINK REF="REF-Lachin-2000" TYPE="REFERENCE">Lachin 2000</LINK>; <LINK REF="REF-Lee-1991" TYPE="REFERENCE">Lee 1991</LINK>). However, for the long-term results of <LINK REF="STD-D_x0027_Angio-1981" TYPE="STUDY">D'Angio 1981</LINK> (<LINK REF="REF-Green-2004" TYPE="REFERENCE">Green 2004</LINK>) and for <LINK REF="STD-Perilongo-2009" TYPE="STUDY">Perilongo 2009</LINK> an ITT analysis was not possible and, therefore, we performed an as-treated analysis.</P>
<P>Eligible RCTs were identified for only seven types of tumour. No appropriate studies were found for other childhood cancers and, therefore, no conclusions can be made regarding the use of anthracyclines in the treatment of these tumours. It should be noted that in this review RCTs including both children and adults were only eligible for inclusion if the majority of participants were children, and the maximal age of the participants did not exceed 30 years. It is possible that there might be evidence on antitumour efficacy and cardiotoxicity of treatment with and without anthracyclines from studies including both children and adults (for examples see the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table).</P>
<P>We are awaiting the results of the currently ongoing studies and studies presented as abstracts during a conference on the use of anthracyclines for the following childhood cancers: hepatoblastoma (N = 1), ALL (N = 2), rhabdomyosarcoma (N = 1) and Wilms' tumour (N = 1).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-09-04 12:03:00 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-09-04 12:02:33 +0200" MODIFIED_BY="[Empty name]">
<P>Anthracycline-induced cardiotoxicity is a serious and widely prevalent problem in children treated for childhood cancer. Therefore, if anthracycline therapy does not have an added value with regard to antitumour efficacy and adverse effects compared to treatment without anthracyclines, it should not be used in treatment protocols for childhood cancer.</P>
<SUBSECTION>
<HEADING LEVEL="6">ALL</HEADING>
<P>At the moment no evidence from RCTs is available which underscores the use of anthracyclines in ALL. However, it should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'; the fact that no significant difference in favour of treatment with anthracyclines was identified in this review can be the result of low power, a too short follow-up period, or the use of low cumulative anthracycline doses. Based on the currently available evidence, we are not able to favour treatment with or without anthracyclines in patients with ALL.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Wilms' tumour</HEADING>
<P>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with a Wilms' tumour. A significant difference in survival in favour of the use of anthracyclines was identified in this study (especially for patients with stage II and III disease) but this finding should be confirmed in other RCTs. Also, it should be kept in mind that with long-term follow-up the result of the analysis of all available patients changed from a significant difference in overall survival in favour of treatment with anthracyclines into no significant difference between the treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rhabdomyosarcoma<I> and </I>undifferentiated sarcoma</HEADING>
<P>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with a rhabdomyosarcoma and undifferentiated sarcoma. No difference in antitumour efficacy between treatment with and treatment without anthracyclines was identified, but this finding should be confirmed in other RCTs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Ewing's sarcoma</HEADING>
<P>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with Ewing's sarcoma. A significant difference in survival in favour of the use of anthracyclines was identified in this study, but this finding should be confirmed in other RCTs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Non-Hodgkin lymphoma</HEADING>
<P>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with a non-Hodgkin lymphoma. No difference in antitumour efficacy was identified between treatment with and without anthracyclines, but this finding should be confirmed in other RCTs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Hepatoblastoma</HEADING>
<P>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with a hepatoblastoma. No difference in antitumour efficacy between treatment with and without anthracyclines was identified, but this finding should be confirmed in other RCTs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">AML</HEADING>
<P>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with AML. No difference in antitumour efficacy between treatment with and treatment without anthracyclines was identified (with the exception of overall survival in a post hoc analysis in a subgroup of patients with relapsed CBF-AML in which patients treated with anthracyclines had a better survival) but this finding should be confirmed in other RCTs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Other childhood cancers</HEADING>
<P>For other childhood cancers no RCTs were identified and, therefore, no conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients diagnosed with these malignancies.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-09-04 12:03:00 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="6">ALL, Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non-Hodgkin lymphoma, hepatoblastoma, and AML</HEADING>
<P>Future trials on the use of anthracyclines in patients with these types of tumour should be performed in homogeneous study populations with a long-term follow-up using valid outcome definitions (including antitumour efficacy and cardiotoxicity). Different risk groups, different cumulative anthracycline doses, and the age of the patients should be taken into account. It might be feasible to start these RCTs in children with unfavourable prognostic factors. The number of included patients should be sufficient to obtain the power needed for the results to be reliable. We are awaiting the results of the ongoing studies and the studies presented as abstracts during a conference, for patients with ALL, Wilms' tumour, hepatoblastoma and rhabdomyosarcoma. Also, it will be very interesting to examine long-term survival data from the already performed RCTs. The performance of an individual patient data (IPD) analysis is another possibility to assess the antitumour efficacy of treatment with and without anthracyclines for these childhood cancers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Other childhood cancers</HEADING>
<P>No RCTs were identified for other childhood cancers. Therefore, before definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients diagnosed with other malignancies, high quality RCTs need to be undertaken. Again, it might be feasible to start these RCTs in children with unfavourable prognostic factors. Also, these RCTs should be performed in homogeneous study populations with a long-term follow-up using valid outcome definitions (including antitumour efficacy and cardiotoxicity). Different risk groups, different cumulative anthracycline doses, and the age of the patients should be taken into account. The number of included patients should be sufficient to obtain the power needed for the results to be reliable. The performance of an IPD analysis is another possibility to assess the antitumour efficacy of treatment with and without anthracyclines for these childhood cancers.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-09-04 12:03:18 +0200" MODIFIED_BY="[Empty name]">
<P>Leontien Kremer and Elvira van Dalen, the Co-ordinating Editors of the Childhood Cancer Group, are co-authors of this review and therefore they could not act as the Co-ordinating Editors for this review. Rob Pieters (department of Paediatric Oncology of the Sophia Children's Hospital, Rotterdam, the Netherlands) was willing to take on this task for the original version of the review, for which we would like to thank him. For the updates, Marianne van de Wetering (department of Paediatric Oncology of the Emma Children's Hospital, Amsterdam, the Netherlands) was willing to take on this task, for which we are very grateful. Also, we would like to thank Edith Leclercq, the Trials Search Co-ordinator of the Childhood Cancer Group, for running the search strategy in the different databases and providing us with the titles and abstracts of the searches, Lieke Feijen for screening some of the identified titles and abstracts of the second update, Valentina Gracchi for translating an Italian article, and Vasya Vlassov and Boris Liberov for translating Russian articles, Szymon Skoczen for providing additional information on his article, Daniel Green for providing the reference with the long-term follow-up data of one of the included studies and, finally, the Foundation of Paediatric Cancer Research (SKK), the Netherlands and Stichting Kinderen Kankervrij (KIKA), the Netherlands for the financial support which made it possible to perform this systematic review. For survival analyses, the hazard ratio and associated statistics were calculated using an Excel spreadsheet developed by Matthew Sydes and Jayne Tierney of the MRC Clinical Trials Unit, London, the United Kingdom. the editorial base of the Cochrane Childhood Cancer Group is funded by Stichting Kinderen Kankervrij (KiKa).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-09-04 12:03:24 +0200" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-09-04 12:03:23 +0200" MODIFIED_BY="[Empty name]">
<P>Elvira van Dalen designed the study and wrote the protocol. She developed the search strategy. She identified the studies meeting the inclusion criteria (both by initial screening and thereafter). She searched for unpublished and ongoing studies. She performed the data extraction and risk of bias assessment of the included studies. She analysed the data and interpreted the results. She wrote and revised the manuscript.</P>
<P>Martine Raphaël identified the studies meeting the inclusion criteria and performed the data extraction and risk of bias assessment of the included studies. She contributed to the interpretation of the results. She critically reviewed the manuscript.</P>
<P>Leontien Kremer critically reviewed the protocol. She acted as third party arbitrator. She contributed to the interpretation of the results. She critically reviewed the manuscript.</P>
<P>Huib Caron critically reviewed the protocol. He contributed to the interpretation of the results. He critically reviewed the manuscript.</P>
<P>All authors approved the final version.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-09-04 12:03:29 +0200" MODIFIED_BY="[Empty name]">
<P>For the second update we used the most recent recommendations of the Childhood Cancer Group for the assessment of risk of bias in the included studies. All RCTs (including those already included in earlier versions of the review) were scored using the new 'risk of bias' items. Also, since performing the original review and the first update of this review, the Childhood Cancer Group has adjusted some of its recommendations regarding analyses: when for a particular outcome only one study is available and there are no events in one of the treatment groups, it is impossible to calculate an adequate risk ratio using the RevMan software, instead the Fischer's exact test should be used. We have adjusted this where necessary.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-09-04 12:18:58 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-09-04 12:18:03 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-09-04 12:07:34 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Angio-1981" MODIFIED="2010-06-01 15:21:56 +0200" MODIFIED_BY="[Empty name]" NAME="D'Angio 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al</AU>
<TI>The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<PG>2302-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Angio-1981-II_x002d_III-FH" MODIFIED="2014-06-16 09:35:10 +0200" MODIFIED_BY="[Empty name]" NAME="D'Angio 1981 II-III FH" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al</AU>
<TI>The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<PG>2302-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH" MODIFIED="2010-06-01 15:21:50 +0200" MODIFIED_BY="[Empty name]" NAME="D'Angio 1981 II-III FH UH" YEAR="">
<REFERENCE MODIFIED="2010-06-01 15:21:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al</AU>
<TI>The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<PG>2302-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-01 15:21:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green DM</AU>
<TI>The treatment of stages I-IV favorable histology Wilms' tumor</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>1366-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Angio-1981-II_x002d_III-UH" MODIFIED="2014-06-16 09:35:45 +0200" MODIFIED_BY="[Empty name]" NAME="D'Angio 1981 II-III UH" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al</AU>
<TI>The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<PG>2302-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Angio-1981-IV" MODIFIED="2014-06-16 09:35:30 +0200" MODIFIED_BY="[Empty name]" NAME="D'Angio 1981 IV" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al</AU>
<TI>The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<PG>2302-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-01 15:19:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green DM</AU>
<TI>The treatment of stages I-IV favorable histology Wilms' tumor</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>1366-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eden-1991" NAME="Eden 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eden OB, Lilleyman JS, Richards S, Shaw MP, Peto J</AU>
<TI>Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)</TI>
<SO>British Journal of Haematology</SO>
<YR>1991</YR>
<VL>78</VL>
<PG>187-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaspers-2013" MODIFIED="2014-03-13 15:14:50 +0100" MODIFIED_BY="[Empty name]" NAME="Kaspers 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-13 15:14:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaspers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY, Aleinikova O, et al</AU>
<TI>Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>5</NO>
<PG>599-607</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maurer-1988" NAME="Maurer 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al</AU>
<TI>The Intergroup Rhabdomyosarcoma Study-I. A final report</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>61</VL>
<PG>209-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maurer-1988-Group-3" NAME="Maurer 1988 Group 3" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al</AU>
<TI>The Intergroup Rhabdomyosarcoma Study-I. A final report</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>61</VL>
<PG>209-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maurer-1988-Group-4" NAME="Maurer 1988 Group 4" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al</AU>
<TI>The Intergroup Rhabdomyosarcoma Study-I. A final report</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>61</VL>
<PG>209-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nesbit-1990" NAME="Nesbit 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, et al</AU>
<TI>Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1990</YR>
<VL>8</VL>
<PG>1664-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perilongo-2009" MODIFIED="2014-09-04 12:07:34 +0200" MODIFIED_BY="[Empty name]" NAME="Perilongo 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-09-04 12:07:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al</AU>
<TI>Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>361</VL>
<PG>1662-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sposto-2001" NAME="Sposto 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sposto R, Meadows AT, Chilcote RR, Steinherz PG, Kjeldsberg C, Kadin ME, et al</AU>
<TI>Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>2001</YR>
<VL>37</VL>
<PG>432-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Does-1975" NAME="Van der Does 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van der Does-van den Berg A, de Koning J, Reerink H, de Vries JA, van Zanen GE</AU>
<TI>Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972-1973; Dutch Childhood Leukemia Study Group</TI>
<TO>Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972-1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)</TO>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1975</YR>
<VL>119</VL>
<PG>1445-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Does-1989" NAME="Van der Does 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van der Does-van den Berg A, van Wering ER, Suciu S, Solbu G, van 't Veer MB, Rammeloo JA, et al</AU>
<TI>Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG)</TI>
<SO>The American Journal of Pediatric Hematology/Oncology</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>125-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-09-04 12:18:03 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alvegard-1989a" NAME="Alvegard 1989a" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, et al</AU>
<TI>Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1989</YR>
<VL>7</VL>
<PG>1504-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvegard-1989b" NAME="Alvegard 1989b" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvegard TA, Berg NO, Ranstam J, Rydholm A, Rooser B</AU>
<TI>Prognosis in high-grade soft tissue sarcomas. The Scandinavian Sarcoma Group experience in a randomized adjuvant chemotherapy trial</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>1989</YR>
<VL>60</VL>
<PG>517-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvegard-1990" NAME="Alvegard 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvegard TA, Berg NO, Baldetorp B, Ferno M, Killander D, Ranstam J, et al</AU>
<TI>Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1990</YR>
<VL>8</VL>
<PG>538-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1987" MODIFIED="2010-10-12 21:28:02 +0200" MODIFIED_BY="[Empty name]" NAME="Anonymous 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-10-12 21:28:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>2</VL>
<PG>353-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antillon-2008" MODIFIED="2010-05-16 22:07:20 +0200" MODIFIED_BY="[Empty name]" NAME="Antillon 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 22:07:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antillon F, Castellanos M, Valverde P, Luna-Fineman S, Garrido C, Serrato T, et al</AU>
<TI>Treating pediatric soft tissue sarcomas in a country with limited resources: The experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2008</YR>
<VL>51</VL>
<PG>760-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antman-1984a" NAME="Antman 1984a" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Antman KH, Amato D, Lerner H, Suit H, Corson J, Wood W, et al</AU>
<TI>Pooled results of two randomized trials of adjuvant doxorubicin for sarcomas: Eastern Cooperative Oncology Group and Dana-Farber Cancer Institute/Massachusetts General Hospital Study</TI>
<SO>Adjuvant Therapy of Cancer IV</SO>
<YR>1984</YR>
<PG>611-20</PG>
<ED>Jones S, Salmon S</ED>
<PB>Grune and Stratton</PB>
<CY>Orlando</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antman-1984b" NAME="Antman 1984b" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, et al</AU>
<TI>Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1984</YR>
<VL>2</VL>
<PG>601-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antman-1985" NAME="Antman 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antman KH, Amato D, Lerner H, Suit HD, Corson J, Wood WC, et al</AU>
<TI>Adjuvant doxorubicin for sarcoma: data from the ECOG and DFCI/MGH studies</TI>
<SO>Cancer Treatment Symposia</SO>
<YR>1985</YR>
<VL>3</VL>
<PG>109-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antman-1987" NAME="Antman 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Antman K, Amato D, Pilepich M, Lerner H, Balcerzak S, Borden E, et al</AU>
<TI>A preliminary analysis of a randomized intergroup (SWOG, ECOG, CALGB, NCOG) trial of adjuvant doxorubicin for soft tissue sarcomas</TI>
<SO>Adjuvant Therapy of Cancer V</SO>
<YR>1987</YR>
<PG>725-34</PG>
<ED>Salmon S</ED>
<PB>Grune and Stratton</PB>
<CY>Orlando</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antman-1990" NAME="Antman 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Antman K, Ryan I, Borden E, Wood WC, Lerner HL, Corson JM, et al</AU>
<TI>Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10-year results and review of the literature</TI>
<SO>Adjuvant Therapy of Cancer VI</SO>
<YR>1990</YR>
<PG>529-44</PG>
<ED>Salmon S</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aur-1972" NAME="Aur 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aur RJ, Verzosa MS, Hustu HO, Simone JV</AU>
<TI>Response to combination therapy after relapse in childhood acute lymphocytic leukemia</TI>
<SO>Cancer</SO>
<YR>1972</YR>
<VL>30</VL>
<PG>334-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bacci-1989" NAME="Bacci 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bacci G, Pignatti G, Dallari D, Mercuri M, Bertoni F, Bacchini P, et al</AU>
<TI>Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for telangiectatic osteogenic sarcoma of the extremities</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>190-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balwierz-2013" MODIFIED="2014-09-04 12:11:56 +0200" MODIFIED_BY="[Empty name]" NAME="Balwierz 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-09-04 12:11:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balwierz W, Pawinska-Wasikowska K, Klelawka T, Czogala M, Matysiak M, Fic-Sikorska B, et al</AU>
<TI>Development of treatment and clinical results in childhood acute myeloid leukemia in Poland</TI>
<SO>Magazine of European Medical Oncology</SO>
<YR>2013</YR>
<VL>6</VL>
<PG>54-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-1992" NAME="Barr 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr RD, DeVeber LL, Pai KM, Andrew M, Halton J, Cairney AE, et al</AU>
<TI>Management of children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols. An update of the Ontario experience</TI>
<SO>American Journal of Pediatric Hematology/Oncology</SO>
<YR>1992</YR>
<VL>14</VL>
<PG>136-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellani-1978" MODIFIED="2010-08-30 15:32:37 +0200" MODIFIED_BY="[Empty name]" NAME="Bellani 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-08-30 15:32:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellani FF, Gasparini M, Gennari L, Fontanillas L, Bonadonna G</AU>
<TI>Adjuvant treatment with adriamycin in primary operable osteosarcoma</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1978</YR>
<VL>62</VL>
<PG>279-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berman-1989" NAME="Berman 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, et al</AU>
<TI>Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center</TI>
<SO>Seminars of Oncology</SO>
<YR>1989</YR>
<VL>16</VL>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernthal-2012" MODIFIED="2014-03-19 13:27:14 +0100" MODIFIED_BY="[Empty name]" NAME="Bernthal 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-19 13:27:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, et al</AU>
<TI>Long-term results (&gt;25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma</TI>
<SO>Cancer</SO>
<YR>2012</YR>
<VL>118</VL>
<NO>23</NO>
<PG>5888-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bessho-1994" NAME="Bessho 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bessho F, Kinumaki H, Yokota S, Hayashi Y, Kobayashi M, Kamoshita S</AU>
<TI>Liver function studies in children with acute lymphocytic leukemia after cessation of therapy</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1994</YR>
<VL>23</VL>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biondi-2006" NAME="Biondi 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biondi A, Rizzari C, Valsecchi MG, De Lorenzo P, Arico M, Basso G, et al</AU>
<TI>Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies</TI>
<SO>Haematologica</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>534-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birch-1986" NAME="Birch 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, et al</AU>
<TI>Prognostic factors for favorable outcome in disseminated germ cell tumors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1986</YR>
<VL>4</VL>
<PG>400-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blakely-2003" NAME="Blakely 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blakely ML, Shamberger RC, Norkool P, Beckwith JB, Green DM, Ritchey ML</AU>
<TI>Outcome of children with cystic partially differentiated nephroblastoma treated with or without chemotherapy</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>897-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradford-1998" NAME="Bradford 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradford WB, Jose BO, Butler D, Lindberg RD, Paris K, Spanos WJ, et al</AU>
<TI>Rhabdomyosarcoma in children--a ten year review</TI>
<SO>The Journal of the Kentucky Medical Association</SO>
<YR>1998</YR>
<VL>96</VL>
<PG>399-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breslow-2004" NAME="Breslow 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breslow NE, Ou SS, Beckwith JB, Haase GM, Kalapurakal JA, Ritchey ML, et al</AU>
<TI>Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies</TI>
<SO>Cancer</SO>
<YR>2004</YR>
<VL>101</VL>
<PG>1072-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brouwer-2007" MODIFIED="2010-05-16 21:27:02 +0200" MODIFIED_BY="[Empty name]" NAME="Brouwer 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-16 21:26:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brouwer CA, Gietema JA, van den Berg MP, Bink-Boelkens MT, Elzenga NJ, Haaksma J, et al</AU>
<TI>Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment</TI>
<SO>Journal of Cancer Survivorship</SO>
<YR>2007</YR>
<VL>1</VL>
<PG>255-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burnett-2006" MODIFIED="2010-05-16 22:19:08 +0200" MODIFIED_BY="[Empty name]" NAME="Burnett 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-16 22:19:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK</AU>
<TI>Long-term result of the MRC AML10 trial</TI>
<SO>Clinical Advances in Hematology and Oncology</SO>
<YR>2006</YR>
<VL>4</VL>
<PG>445-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caceres-1978" NAME="Caceres 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caceres E, Zaharia M, Moran M, Tejada F</AU>
<TI>Adjuvant whole-lung radiation with or without adriamycin treatment in osteogenic sarcoma</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1978</YR>
<VL>62</VL>
<PG>297-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canter-2007" MODIFIED="2010-05-16 22:12:44 +0200" MODIFIED_BY="[Empty name]" NAME="Canter 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-16 22:12:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canter RJ, Qin L-X, Downey RJ, Brennan MF, Singer S, Maki RG</AU>
<TI>Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity: a retrospective analysis</TI>
<SO>Cancer</SO>
<YR>2007</YR>
<VL>110</VL>
<PG>2050-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlsen-1989" NAME="Carlsen 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlsen NL, Schroeder H, Bro PV, Hesselbjerg U, Jensen KB, Nielsen OH, et al</AU>
<TI>Response to multimodal treatment in advanced neuroblastomas. Factors associated with complete remission induction, and factors associated with prolonged survival</TI>
<SO>Anticancer Research</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>837-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castellino-2008" MODIFIED="2010-05-16 22:11:29 +0200" MODIFIED_BY="[Empty name]" NAME="Castellino 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 22:11:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castellino SM, Alonzo TA, Buxton A, Gold S, Lange BJ, Woods WG</AU>
<TI>Outcomes in childhood AML in the absence of transplantation in first remission - Children's Cancer Group (CCG) studies 2891 and CCG 213</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2008</YR>
<VL>50</VL>
<PG>9-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chau-2003" NAME="Chau 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR, et al</AU>
<TI>Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?</TI>
<SO>British Journal of Cancer</SO>
<YR>2003</YR>
<VL>89</VL>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chessells-1992" NAME="Chessells 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chessells JM, Bailey CC, Richards S</AU>
<TI>MRC UKALL X. The UK protocol for childhood ALL: 1985-1990</TI>
<SO>Leukemia</SO>
<YR>1992</YR>
<VL>6</VL>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chessells-2002" NAME="Chessells 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chessells JM, Harrison G, Richards SM, Gibson BE, Bailey CC, Hill FG, et al</AU>
<TI>Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI</TI>
<SO>British Journal of Haematology</SO>
<YR>2002</YR>
<VL>118</VL>
<PG>445-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Craft-1993" NAME="Craft 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Craft AW, Burgers JM</AU>
<TI>The European Osteosarcoma Intergroup (E.O.I.) studies 1980-1991</TI>
<SO>Cancer Treatment and Research</SO>
<YR>1993</YR>
<VL>62</VL>
<PG>279-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creutzig-2005" NAME="Creutzig 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al</AU>
<TI>Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials</TI>
<SO>Leukemia</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>2030-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creutzig-2006" MODIFIED="2014-09-04 12:12:27 +0200" MODIFIED_BY="[Empty name]" NAME="Creutzig 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-04 12:12:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al</AU>
<TI>Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>4499-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crist-1995" NAME="Crist 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al</AU>
<TI>The Third Intergroup Rhabdomyosarcoma Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>610-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Culbert-1991" NAME="Culbert 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culbert SJ, Shuster JJ, Land VJ, Wharam MD, Thomas PR, Nitschke R, et al</AU>
<TI>Remission induction and continuation therapy in children with their first relapse of acute lymphoid leukemia. A Pediatric Oncology Group study</TI>
<SO>Cancer</SO>
<YR>1991</YR>
<VL>67</VL>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Angio-1989" NAME="D'Angio 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, DeLorimier A, et al</AU>
<TI>Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study</TI>
<SO>Cancer</SO>
<YR>1989</YR>
<VL>64</VL>
<PG>349-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Bernardi-2003" MODIFIED="2014-09-04 12:12:45 +0200" MODIFIED_BY="[Empty name]" NAME="De Bernardi 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-04 12:12:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero di Montezemolo L, et al</AU>
<TI>Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>1592-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Bernardi-2009" MODIFIED="2010-05-16 21:00:04 +0200" MODIFIED_BY="[Empty name]" NAME="De Bernardi 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-16 21:00:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Cataldo AD, et al</AU>
<TI>Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>1034-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dluzniewska-2003" NAME="Dluzniewska 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dluzniewska A, Balwierz W, Balcerska A, Chybicka A, Dobaczewski G, Kowalczyk J, et al</AU>
<TI>Efficacy of idarubicin in the treatment of childhood acute non-lymphoblastic leukemia: report of Polish Pediatric Leukemia/Lymphoma Study Group</TI>
<SO>Przeglad Lekarski</SO>
<YR>2003</YR>
<VL>60 Suppl 5</VL>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobashi-2006" MODIFIED="2010-05-16 21:58:57 +0200" MODIFIED_BY="[Empty name]" NAME="Dobashi 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-16 21:58:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobashi N, Yamaguchi Y, Asai O, Yano S, Osawa H, Yahagi Y, et al</AU>
<TI>Intensifying daunorubicin in induction for patients with core binding factor leukemia</TI>
<SO>International Journal of Hematology</SO>
<YR>2006</YR>
<VL>84</VL>
<PG>463-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunst-1998" NAME="Dunst 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunst J</AU>
<TI>Therapy results of the British ET-1 study for Ewing's sarcoma</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1998</YR>
<VL>174</VL>
<PG>289-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eilber-1988" NAME="Eilber 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eilber FR, Giuliano AE, Huth JF, Morton DL</AU>
<TI>A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>11</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Einhorn-1981" MODIFIED="2014-09-04 12:13:01 +0200" MODIFIED_BY="[Empty name]" NAME="Einhorn 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-09-04 12:13:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Einhorn LH, Williams SD, Troner M, Birch R, Greco FA</AU>
<TI>The role of maintenance therapy in disseminated testicular cancer</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1981</YR>
<VL>305</VL>
<PG>727-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elomaa-1993" NAME="Elomaa 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elomaa I</AU>
<TI>An update of Scandinavian studies of osteosarcoma</TI>
<SO>Cancer Treatment and Research</SO>
<YR>1993</YR>
<VL>62</VL>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etcubanas-1984" NAME="Etcubanas 1984" YEAR="1">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Etcubanas E, Hustu O, Sklar M, Pratt C</AU>
<TI>Influence of different treatment modalities on the curability of childhood rhabdomyosarcoma of the head or neck</TI>
<SO>European Paediatric Haematology &amp; Oncology</SO>
<YR>1</YR>
<VL>1984</VL>
<PG>239-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1985" NAME="Evans 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans R, Nesbit M, Askin F, Burgert O, Cangir A, Foulkes M, et al</AU>
<TI>Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1985</YR>
<VL>11</VL>
<PG>129-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1991" NAME="Evans 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans AE, Norkool P, Evans I, Breslow N, D'Angio GJ</AU>
<TI>Late effects of treatment for Wilms' tumor. A report from the National Wilms' Tumor Study Group</TI>
<SO>Cancer</SO>
<YR>1991</YR>
<VL>67</VL>
<PG>331-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fink-1990" NAME="Fink 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fink FM, Gadner H, Grumayer ER, Kardos G, Revesz T, Urban C, et al</AU>
<TI>Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian-Hungarian study AML-IGCI-84</TI>
<SO>Haematology and Blood Transfusion</SO>
<YR>1990</YR>
<VL>33</VL>
<PG>233-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frappaz-2002" MODIFIED="2014-09-04 12:13:13 +0200" MODIFIED_BY="[Empty name]" NAME="Frappaz 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-09-04 12:13:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frappaz D, Perol D, Michon J, Berger C, Coze C, Bernard JL, et al</AU>
<TI>The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>87</VL>
<PG>1197-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukuoka-1994" NAME="Fukuoka 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukuoka M, Masuda N, Takada M, Kodama N, Kawahara M, Furuse K</AU>
<TI>Dose-intensive chemotherapy in extensive-stage small cell lung cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>1994</YR>
<VL>21</VL>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallegos_x002d_Castorena-2009" MODIFIED="2014-09-04 12:13:29 +0200" MODIFIED_BY="[Empty name]" NAME="Gallegos-Castorena 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-09-04 12:13:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallegos-Castorena S, Medina-Sanson A, Gonzalez-Ramella O, Sanchez-Zubieta F, Martinez-Avalos A</AU>
<TI>Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol</TI>
<SO>Leukemia and Lymphoma</SO>
<YR>2009</YR>
<VL>50</VL>
<PG>1132-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garbes-1987" NAME="Garbes 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garbes ID, Gomez GA, Han T, Henderson ES</AU>
<TI>Salvage chemotherapy for advanced Hodgkin's disease</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1987</YR>
<VL>15</VL>
<PG>45-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaynon-1993" NAME="Gaynon 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, et al</AU>
<TI>Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>2234-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelderblom-2011" MODIFIED="2014-03-19 13:08:35 +0100" MODIFIED_BY="[Empty name]" NAME="Gelderblom 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-19 13:08:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelderblom H, Jinks RC, Sydes M, Bramwell VH, van Glabbeke M, Grimer RJ, et al</AU>
<TI>Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials</TI>
<SO>European Journal of Cancer</SO>
<YR>2011</YR>
<VL>47</VL>
<NO>6</NO>
<PG>895-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glanzmann-1998" NAME="Glanzmann 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P</AU>
<TI>Cardiac risk after mediastinal irradiation for Hodgkin's disease</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1998</YR>
<VL>46</VL>
<PG>51-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1994" NAME="Green 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green DM, Breslow NE, Beckwith JB, Moksness J, Finklestein JZ, D'Angio GJ</AU>
<TI>Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1994</YR>
<VL>12</VL>
<PG>2132-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1996" NAME="Green 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green DM, Breslow NE, Evans I, Moksness J, D'Angio GJ</AU>
<TI>Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1996</YR>
<VL>26</VL>
<PG>147-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1999" NAME="Green 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green DM, Hyland A, Chung CS, Zevon MA, Hall BC</AU>
<TI>Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>3207-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grier-1990" NAME="Grier 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grier HE, Gelber RD, Clavell LA, Camitta BM, Link MP, Garcea MJ, et al</AU>
<TI>Intensive sequential chemotherapy for children with acute myelogenous leukemia</TI>
<SO>Haematology and Blood Transfusion</SO>
<YR>1990</YR>
<VL>33</VL>
<PG>193-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grundy-2012" MODIFIED="2014-03-19 13:01:46 +0100" MODIFIED_BY="[Empty name]" NAME="Grundy 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-19 13:01:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grundy PE, Green DM, Dirks AC, Berendt AE, Breslow NE, Anderson JR, et al</AU>
<TI>Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children's Oncology Group</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2012</YR>
<VL>59</VL>
<NO>4</NO>
<PG>631-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gururangan-2000" NAME="Gururangan 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gururangan S, Sposto R, Cairo MS, Meadows AT, Finlay JL</AU>
<TI>Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>2017-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hainsworth-1985" NAME="Hainsworth 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hainsworth JD, Williams SD, Einhorn LH, Birch R, Greco FA</AU>
<TI>Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1985</YR>
<VL>3</VL>
<PG>666-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halazun-1974" MODIFIED="2010-05-17 15:47:37 +0200" MODIFIED_BY="[Empty name]" NAME="Halazun 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-05-17 15:47:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halazun JF, Wagner HR, Gaeta JF, Sinks LF</AU>
<TI>Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia</TI>
<SO>Cancer</SO>
<YR>1974</YR>
<VL>33</VL>
<PG>545-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harms-2000" NAME="Harms 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harms D, Janka-Schaub GE</AU>
<TI>Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92</TI>
<SO>Leukemia</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>2234-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayashi-2008" MODIFIED="2010-05-16 21:38:55 +0200" MODIFIED_BY="[Empty name]" NAME="Hayashi 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:38:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayashi K, Tsuchiya H, Yamamoto N, Takeuchi A, Tomita K</AU>
<TI>Functional outcome in patients with osteosarcoma around the knee joint treated by minimised surgery</TI>
<SO>International Orthopaedics</SO>
<YR>2008</YR>
<VL>32</VL>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hays-1988" MODIFIED="2014-09-04 12:13:40 +0200" MODIFIED_BY="[Empty name]" NAME="Hays 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-09-04 12:13:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hays DM, Shimada H, Raney RB Jr, Tefft M, Newton W, Crist WM, et al</AU>
<TI>Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>61</VL>
<PG>1893-903</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henze-1989" MODIFIED="2014-09-04 12:13:45 +0200" MODIFIED_BY="[Empty name]" NAME="Henze 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-09-04 12:13:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henze G, Fengler R, Hartmann R, Dopfer R, Gobel U, Graf N, et al</AU>
<TI>Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia</TI>
<SO>Cancer Chemotherapy &amp; Pharmacology</SO>
<YR>1989</YR>
<VL>24</VL>
<PG>S16-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hitchcock_x002d_Bryan-1986" NAME="Hitchcock-Bryan 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hitchcock-Bryan S, Gelber R, Cassady JR, Sallan SE</AU>
<TI>The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1986</YR>
<VL>14</VL>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hodgson-2003" NAME="Hodgson 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hodgson DC, Tsang RW, Pintilie M, Sun A, Wells W, Crump M, et al</AU>
<TI>Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2003</YR>
<VL>57</VL>
<PG>1374-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holland-1971" NAME="Holland 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holland JF</AU>
<TI>E Pluribus Unum: Presidential address</TI>
<SO>Cancer Research</SO>
<YR>1971</YR>
<VL>31</VL>
<PG>1319-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Humphrey-1975" MODIFIED="2008-10-27 13:06:01 +0100" MODIFIED_BY="[Empty name]" NAME="Humphrey 1975" YEAR="1975">
<REFERENCE MODIFIED="2008-10-27 13:06:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Humphrey GB, Fernbach DJ, Razek AA, Stuckey WJ, Komp D, George S</AU>
<TI>Evaluation of daunorubicin (NSC-82151) and methotrexate (NSC-740) in combination as a remission maintenance regimen in the treatment of acute leukemia</TI>
<SO>Cancer Chemotherapy Reports</SO>
<YR>1975</YR>
<VL>59</VL>
<PG>395-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iarussi-2003" NAME="Iarussi 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iarussi D, Indolfi P, Pisacane C, Casale F, Martino V, Fusco A, et al</AU>
<TI>Comparison of left ventricular function by echocardiogram in patients with Wilms' tumor treated with anthracyclines versus those not so treated</TI>
<SO>The American Journal Of Cardiology</SO>
<YR>2003</YR>
<VL>92</VL>
<PG>359-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ihde-1977" NAME="Ihde 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD</AU>
<TI>Adriamycin therapy in American patients with hepatocellular carcinoma</TI>
<SO>Cancer Treatment Report</SO>
<YR>1977</YR>
<VL>61</VL>
<PG>1385-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isu-1992" NAME="Isu 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isu K, Yamawaki S, Usui M</AU>
<TI>A group study of neoadjuvant chemotherapy for osteosarcoma - Results and problems of T-12 protocol</TI>
<SO>Journal of the Japanese Orthopaedic Association</SO>
<YR>1992</YR>
<VL>66</VL>
<PG>S9-S10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwenofu-2008" MODIFIED="2010-05-16 21:42:32 +0200" MODIFIED_BY="[Empty name]" NAME="Iwenofu 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:42:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS</AU>
<TI>Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy</TI>
<SO>Modern Pathology</SO>
<YR>2008</YR>
<VL>21</VL>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffe-1981" NAME="Jaffe 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffe N, Link MP, Cohen D, Traggis D, Frei E III, Watts H, et al</AU>
<TI>High-dose methotrexate in osteogenic sarcoma</TI>
<SO>National Cancer Institute Monograph</SO>
<YR>1981</YR>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janka_x002d_Schaub-1988" NAME="Janka-Schaub 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janka-Schaub GE, Winkler K, Gobel U, Graubner U, Schwenger M, Haas RJ, et al</AU>
<TI>First results of the CO ALL-85 cooperative study for high-risk patients with acute lymphatic leukemia</TI>
<SO>Klinische Padiatrie</SO>
<YR>1988</YR>
<VL>200</VL>
<PG>171-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalapurakal-2010" MODIFIED="2010-10-13 13:54:32 +0200" MODIFIED_BY="[Empty name]" NAME="Kalapurakal 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-13 13:54:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalapurakal JA, Li SM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, et al</AU>
<TI>Intraoperative spillage of favorable histology Wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2010</YR>
<VL>76</VL>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karachunskii-2007" MODIFIED="2010-05-16 21:54:48 +0200" MODIFIED_BY="[Empty name]" NAME="Karachunskii 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-16 21:54:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karachunskii AI, Miakova NV, Rumiantseva I, Timakov AM, Makhortykh TZ, Fechina LG, et al</AU>
<TI>The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>2007</YR>
<VL>79</VL>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karachunskiy-2008" MODIFIED="2010-05-16 21:34:55 +0200" MODIFIED_BY="[Empty name]" NAME="Karachunskiy 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:34:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karachunskiy A, Herold R, von Stackelberg A, Miakova N, Timakow A, Mahortih T, et al</AU>
<TI>Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia</TI>
<SO>Leukemia</SO>
<YR>2008</YR>
<VL>22</VL>
<PG>1144-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaspers-2010" MODIFIED="2014-03-19 14:24:44 +0100" MODIFIED_BY="[Empty name]" NAME="Kaspers 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-19 14:24:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kaspers G, Zimmermann M, Reinhardt D, Gibson B, Tamminga R, Aleinikova O, et al</AU>
<TI>Central Nervous System (CNS) involvement in pediatric relapsed acute myeloid leukemia: Results and lessons from study relapsed AML 2001/01</TI>
<SO>Blood (Annual Meeting of the American Society of Hematology)</SO>
<YR>2010</YR>
<PG>116 (abstract 184)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazanowska-2006" MODIFIED="2010-05-16 22:15:19 +0200" MODIFIED_BY="[Empty name]" NAME="Kazanowska 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-16 22:15:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazanowska B, Reich A, Wrobel G, Balcerska A, Balwierz W, Bodalski J, et al</AU>
<TI>Metastatic soft tissue sarcomas in children - A remaining challenge for paediatric oncology. A retrospective multicenter study from the Polish Pediatric Solid Tumors' Group</TI>
<SO>Nowotwory</SO>
<YR>2006</YR>
<VL>56</VL>
<PG>517-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khattab-2008" MODIFIED="2010-05-16 21:30:52 +0200" MODIFIED_BY="[Empty name]" NAME="Khattab 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:30:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khattab TM, Atra AA, Elimam NA, Kassar A, Zayed A, Baothman A</AU>
<TI>Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols</TI>
<SO>Saudi Medical Journal</SO>
<YR>2008</YR>
<VL>29</VL>
<PG>776-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinsella-1991" NAME="Kinsella 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella TJ, Miser JS, Waller B, Venzon D, Glatstein E, Weaver-McClure L, et al</AU>
<TI>Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy</TI>
<SO>International Journal Of Radiation Oncology, Biology, Physics</SO>
<YR>1991</YR>
<VL>20</VL>
<PG>389-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobe-2008" MODIFIED="2010-05-16 21:24:40 +0200" MODIFIED_BY="[Empty name]" NAME="Kobe 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:24:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al</AU>
<TI>Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>112</VL>
<PG>3989-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komp-1976" MODIFIED="2010-05-17 15:42:45 +0200" MODIFIED_BY="[Empty name]" NAME="Komp 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-05-17 15:42:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komp DM, George SL, Falletta J, Land VJ, Starling KA, Humphrey GB, et al</AU>
<TI>Cyclophosphamide-asparaginase-vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia</TI>
<SO>Cancer</SO>
<YR>1976</YR>
<VL>37</VL>
<PG>1243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konopka-1989" NAME="Konopka 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konopka L, Pawelski S</AU>
<TI>Results of three polychemotherapy programs in non-Hodgkin's lymphomas</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>1259-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuleva-2008" MODIFIED="2014-09-04 12:13:59 +0200" MODIFIED_BY="[Empty name]" NAME="Kuleva 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-09-04 12:13:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuleva SA, Anishkin MI, Kolygin BA</AU>
<TI>A comparison of two risk-adapted regimens of therapy for Hodgkin's disease in children and adolescents</TI>
<SO>Voprosy Onkologii</SO>
<YR>2008</YR>
<VL>54</VL>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurrle-1988" NAME="Kurrle 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurrle E, Ehninger G, Freund M, Heil G, Hoelzer D, Link H, et al</AU>
<TI>A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia</TI>
<SO>Blut</SO>
<YR>1988</YR>
<VL>56</VL>
<PG>233-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lager-2006" NAME="Lager 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP</AU>
<TI>Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>3415-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006" MODIFIED="2010-05-16 22:20:26 +0200" MODIFIED_BY="[Empty name]" NAME="Li 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-16 22:20:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li CK, Chik KW, Ha SY, Lee ACW, Yuen HL, Ling SC, et al</AU>
<TI>Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL 97 study</TI>
<SO>Hong Kong Medical Journal</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>33-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lilleyman-1997" NAME="Lilleyman 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lilleyman JS, Gibson BE, Stevens RF, Will AM, Hann IM, Richards SM, et al</AU>
<TI>Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia</TI>
<SO>British Journal of Haematology</SO>
<YR>1997</YR>
<VL>97</VL>
<PG>603-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindberg-1977" NAME="Lindberg 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Lindberg RD, Murphy WK, Benjamin RS, Sinkovics JG, Martin RG, Romsdahl MM, et al</AU>
<TI>Adjuvant chemotherapy in the treatment of primary soft tissue sarcomas: a preliminary report</TI>
<SO>Management of Bone and Soft Tissue Tumors</SO>
<YR>1977</YR>
<PG>343-52</PG>
<PB>Book Medical Publishers</PB>
<CY>Chicago</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Link-1986" MODIFIED="2014-09-04 12:14:17 +0200" MODIFIED_BY="[Empty name]" NAME="Link 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-09-04 12:14:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Link MP, Goorin AM, Miser AW</AU>
<TI>The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<PG>1600-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madej-1987" NAME="Madej 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madej G, Siedlecki P, Meyza J</AU>
<TI>Preliminary evaluation of the effectiveness of a modified treatment program in patients with malignant testicular neoplasms</TI>
<SO>Polski Tygodnik Lekarski</SO>
<YR>1987</YR>
<VL>42</VL>
<PG>836-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madon-1985" MODIFIED="2010-10-13 13:55:02 +0200" MODIFIED_BY="[Empty name]" NAME="Madon 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-10-13 13:55:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madon E, Pastore G, Cordero Di Montezemolo L, Brach del Prever A, Lanino E</AU>
<TI>Italian multicenter experience in the treatment of neuroblastoma and soft tissue sarcoma</TI>
<SO>Minerva Pediatrica</SO>
<YR>1985</YR>
<VL>37</VL>
<PG>603-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahajan-2008" MODIFIED="2010-05-16 21:40:34 +0200" MODIFIED_BY="[Empty name]" NAME="Mahajan 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:40:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahajan A, Woo SY, Kornguth DG, Hughes D, Huh W, Chang EL, et al</AU>
<TI>Multimodality treatment of osteosarcoma: radiation in a high-risk cohort</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2008</YR>
<VL>50</VL>
<PG>976-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmoud-1993" MODIFIED="2014-09-04 12:15:04 +0200" MODIFIED_BY="[Empty name]" NAME="Mahmoud 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-09-04 12:15:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, et al</AU>
<TI>Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<PG>314-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maiakova-1986" MODIFIED="2010-10-12 22:11:00 +0200" MODIFIED_BY="[Empty name]" NAME="Maiakova 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-10-12 22:11:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maiakova SA, Makhonova LA</AU>
<TI>Consolidating chemotherapy in the treatment program of acute lymphoblastic leukemia in children</TI>
<SO>Vestnik Akademii Meditsinskikh Nauk SSSR</SO>
<YR>1986</YR>
<PG>15-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malpas-1974" NAME="Malpas 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malpas J, Mathe G, Hayat M</AU>
<TI>Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia</TI>
<SO>Bulletin du Cancer</SO>
<YR>1974</YR>
<VL>61</VL>
<PG>411-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcus-1987" NAME="Marcus 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcus RE, Catovsky D, Prentice HG, Newland AC, Chessells JM, Stevens RF, et al</AU>
<TI>Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985</TI>
<SO>Haematology and Blood Transfusion</SO>
<YR>1987</YR>
<VL>30</VL>
<PG>346-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsuzaki-2001" NAME="Matsuzaki 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsuzaki A, Ishii E, Nagatoshi Y, Eguchi H, Koga H, Yanai F, et al</AU>
<TI>Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group</TI>
<SO>International Journal of Hematology</SO>
<YR>2001</YR>
<VL>73</VL>
<PG>369-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maurer-1981" MODIFIED="2010-10-13 13:54:46 +0200" MODIFIED_BY="[Empty name]" NAME="Maurer 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-10-13 13:54:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maurer HM</AU>
<TI>The Intergroup Rhabdomyosarcoma Study: update, November 1978</TI>
<SO>National Cancer Institute Monograph</SO>
<YR>1981</YR>
<VL>56</VL>
<PG>61-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meisel-1999" NAME="Meisel 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meisel JA, Guthrie KA, Breslow NE, Donaldson SS, Green DM</AU>
<TI>Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1999</YR>
<VL>44</VL>
<PG>579-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meza-2006" NAME="Meza 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meza JL, Anderson J, Pappo AS, Meyer WH</AU>
<TI>Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>3844-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miser-1993" NAME="Miser 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miser JS, Pritchard DJ, Rock MG, Shives TC, Gilchrist GS, Smithson WA, et al</AU>
<TI>Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies</TI>
<SO>Cancer Treatment and Research</SO>
<YR>1993</YR>
<VL>62</VL>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moricke-2008" MODIFIED="2010-05-16 22:22:10 +0200" MODIFIED_BY="[Empty name]" NAME="Moricke 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 22:22:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al</AU>
<TI>Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>111</VL>
<PG>4477-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muus-1993" NAME="Muus 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E, et al</AU>
<TI>Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent</TI>
<SO>Seminars of Oncology</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nachman-1993" MODIFIED="2010-10-13 13:55:26 +0200" MODIFIED_BY="[Empty name]" NAME="Nachman 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-10-13 13:55:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nachman J, Sather HN, Buckley JD, Gaynon PS, Steinherz PG, Tubergen DG, et al</AU>
<TI>Young adults 16-21 years of age at diagnosis entered on Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols: Results of treatment</TI>
<SO>Cancer</SO>
<YR>1993</YR>
<VL>71</VL>
<PG>3377-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishimura-1983" MODIFIED="2010-10-13 13:55:46 +0200" MODIFIED_BY="[Empty name]" NAME="Nishimura 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-10-13 13:55:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishimura H, Yamada T, Hagio Y, Inoue T, Tsunawaki A, Yakushiji M, et al</AU>
<TI>Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or CDDP in combination with adriamycin (ADM)</TI>
<SO>Gan To Kagaku Ryoho</SO>
<YR>1983</YR>
<VL>10</VL>
<PG>938-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ochiai-1993" NAME="Ochiai 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ochiai K</AU>
<TI>Strategy for the ovarian cancer treatment</TI>
<SO>Japanese Journal of Cancer and Chemotherapy</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>2454-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oh-2006" MODIFIED="2010-05-16 22:05:33 +0200" MODIFIED_BY="[Empty name]" NAME="Oh 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-16 22:05:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, et al</AU>
<TI>Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma</TI>
<SO>Annals of Hematology</SO>
<YR>2006</YR>
<VL>85</VL>
<PG>781-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okamura-1987" NAME="Okamura 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okamura J, Ikuno Y, Yamada S, Tasaka H, Nibu K, Ikeda N, et al</AU>
<TI>Results of treatment in children with diffuse large cell lymphoma</TI>
<SO>Rinsho Ketsueki</SO>
<YR>1987</YR>
<VL>28</VL>
<PG>1365-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Omura-1985" NAME="Omura 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al</AU>
<TI>A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1985</YR>
<VL>3</VL>
<PG>1240-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega-1991" NAME="Ortega 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortega JA, Wharam M, Gehan EA, Ragab AH, Crist W, Webber B, et al</AU>
<TI>Clinical features and results of therapy for children with paraspinal soft tissue sarcoma: A report of the intergroup Rhabdomyosarcoma study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>796-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paulino-1996" NAME="Paulino 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paulino AC, Wilimas J, Marina N, Jones D, Kumar M, Greenwald C, et al</AU>
<TI>Local control in synchronous bilateral Wilms tumor</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1996</YR>
<VL>36</VL>
<PG>541-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paulino-2003" NAME="Paulino 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paulino AC, Bauman N, Simon JH, Nguyen TX, Ritchie JM, Tannous R</AU>
<TI>Local control of parameningeal rhabdomyosarcoma: outcomes in non-complete responders to chemoradiation</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>118-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavlovsky-1981" NAME="Pavlovsky 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavlovsky S</AU>
<TI>Argentinian Group for the Treatment of Acute Leukemia: our experience in the treatment of acute lymphoblastic leukemias</TI>
<SO>Sangre</SO>
<YR>1981</YR>
<VL>26</VL>
<PG>845-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pawson-2001" MODIFIED="2014-09-04 12:15:41 +0200" MODIFIED_BY="[Empty name]" NAME="Pawson 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-09-04 12:15:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, et al</AU>
<TI>Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG ± Ida) and second allogeneic stem cell transplant</TI>
<SO>British Journal of Haematology</SO>
<YR>2001</YR>
<VL>115</VL>
<PG>622-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peeters-2009" MODIFIED="2014-09-04 12:16:02 +0200" MODIFIED_BY="[Empty name]" NAME="Peeters 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-09-04 12:16:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peeters J, Meitert J, Paulides M, Beck JD, Langer T</AU>
<TI>Late effects surveillance system after childhood cancer in Germany, Austria and parts of Switzerland-update 2009</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>2009</YR>
<VL>185 Suppl 2</VL>
<PG>5-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez-1981" NAME="Perez 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez CA, Tefft M, Nesbit ME Jr, Burgert EO Jr, Vietti TJ, Kissane J, et al</AU>
<TI>Radiation therapy in the multimodal management of Ewing's sarcoma of bone: report of the Intergroup Ewing's Sarcoma Study</TI>
<SO>National Cancer Institute Monograph</SO>
<YR>1981</YR>
<PG>263-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfreundschuh-2008" MODIFIED="2010-05-16 21:48:31 +0200" MODIFIED_BY="[Empty name]" NAME="Pfreundschuh 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:48:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pfreundschuh M, Zwick C, Zeynalova S, Duhrsen U, Pfluger KH, Vrieling T, et al</AU>
<TI>Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)</TI>
<SO>Annals of Oncology</SO>
<YR>2008</YR>
<VL>19</VL>
<PG>545-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Picci-1997" MODIFIED="2010-10-12 22:21:19 +0200" MODIFIED_BY="[Empty name]" NAME="Picci 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-10-12 22:21:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Picci P, Bacci G, Ferrari S, Mercuri M</AU>
<TI>Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors</TI>
<SO>Annals of Oncology</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>1107-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pontz-1981" MODIFIED="2010-08-30 15:32:25 +0200" MODIFIED_BY="[Empty name]" NAME="Pontz 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-08-30 15:32:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pontz BF, Gutjahr P</AU>
<TI>Aggressive cytostatic treatment of osteogenic sarcoma in childhood</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1981</YR>
<VL>106</VL>
<PG>200-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pratt-1981" NAME="Pratt 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pratt CB, Hustu HO, Kumar AP, Johnson WW, Ransom JL, Howarth CB, et al</AU>
<TI>Treatment of childhood rhabdomyosarcoma at St. Jude Children's Research Hospital, 1962--78</TI>
<SO>National Cancer Institute Monograph</SO>
<YR>1981</YR>
<PG>93-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pratt-1993" NAME="Pratt 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pratt CB, Meyer WH, Rao BN, Parham DM, Fleming ID</AU>
<TI>Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990</TI>
<SO>Cancer Treatment and Research</SO>
<YR>1993</YR>
<VL>62</VL>
<PG>323-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pritchard_x002d_Jones-2011" MODIFIED="2014-09-02 15:01:57 +0200" MODIFIED_BY="[Empty name]" NAME="Pritchard-Jones 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-09-02 15:01:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pritchard-Jones K, Graf N, Bergeron C, de Camargo B, Van Den Heuvel M, Sandstedt B, et al</AU>
<TI>Doxorubicin can be safely omitted from the treatment of stage II/III, Intermediate risk histology Wilms tumour - Results of the siop WT 2001 randomised trial, on behalf of the SIOP Renal Tumours Study Group</TI>
<SO>European Journal of Cancer (European Multidisciplinary Cancer Congress)</SO>
<YR>2011</YR>
<PG>S284-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pritchard_x002d_Jones-2012" MODIFIED="2014-03-19 13:04:43 +0100" MODIFIED_BY="[Empty name]" NAME="Pritchard-Jones 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-19 13:04:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pritchard-Jones K, Moroz V, Vujanic G, Powis M, Walker J, Messahel B, et al</AU>
<TI>Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial</TI>
<SO>Annals of Oncology</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>9</NO>
<PG>2457-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quattrin-1975" NAME="Quattrin 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quattrin N, Montuori R, Di Girolamo R, Cimino R</AU>
<TI>Our recent therapeutic experiences in acute leukemia</TI>
<SO>Minerva Medica</SO>
<YR>1975</YR>
<VL>66</VL>
<PG>2538-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rai-1981" NAME="Rai 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, et al</AU>
<TI>Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B</TI>
<SO>Blood</SO>
<YR>1981</YR>
<VL>58</VL>
<PG>1203-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rammeloo-2000" NAME="Rammeloo 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rammeloo LA, Postma A, Sobotka-Plojhar MA, Bink-Boelkens MT, Berg A, Veerman AJ, et al</AU>
<TI>Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>2000</YR>
<VL>35</VL>
<PG>13-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raney-1983" NAME="Raney 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raney RB Jr, Lawrence W Jr, Maurer HM, Lindberg RD, Newton WA Jr, Ragab AH, et al</AU>
<TI>Rhabdomyosarcoma of the ear in childhood. A report from the Intergroup Rhabdomyosarcoma Study-I</TI>
<SO>Cancer</SO>
<YR>1983</YR>
<VL>51</VL>
<PG>2356-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raney-1987" NAME="Raney 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raney B, Schnaufer L, Ziegler M, Chatten J, Littman P, Jarrett P</AU>
<TI>Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958-1984</TI>
<SO>Cancer</SO>
<YR>1987</YR>
<VL>59</VL>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raney-1988" NAME="Raney 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raney RB Jr, Tefft M, Maurer HM, Ragab AH, Hays DM, Soule EH, et al</AU>
<TI>Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>62</VL>
<PG>1257-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raney-1990" NAME="Raney 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raney RB Jr, Crist W, Hays D, Newton W, Ruymann F, Tefft M, et al</AU>
<TI>Soft tissue sarcoma of the perineal region in childhood. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1972 through 1984</TI>
<SO>Cancer</SO>
<YR>1990</YR>
<VL>65</VL>
<PG>2787-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raza-2008" MODIFIED="2010-05-16 21:19:01 +0200" MODIFIED_BY="[Empty name]" NAME="Raza 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:19:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raza S, Ullah K, Ahmed P, Khan B</AU>
<TI>Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia</TI>
<SO>Journal of the College of Physicians and Surgeons-Pakistan</SO>
<YR>2008</YR>
<VL>18</VL>
<PG>546-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1990" NAME="Rees 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rees JK, Gray RG</AU>
<TI>Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study</TI>
<SO>Haematology and Blood Transfusion</SO>
<YR>1990</YR>
<VL>33</VL>
<PG>243-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchey-1994" NAME="Ritchey 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchey ML, Pringle KC, Breslow NE, Takashima J, Moksness J, Zuppan CW, et al</AU>
<TI>Management and outcome of inoperable Wilms tumor. A report of National Wilms Tumor Study-3</TI>
<SO>Annals of Surgery</SO>
<YR>1994</YR>
<VL>220</VL>
<PG>683-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritter-1990" NAME="Ritter 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritter J, Creutzig U, Schellong G</AU>
<TI>Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83</TI>
<SO>Haematology and Blood Transfusion</SO>
<YR>1990</YR>
<VL>33</VL>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roy-2005" NAME="Roy 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, et al</AU>
<TI>Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial</TI>
<SO>British Journal of Haematology</SO>
<YR>2005</YR>
<VL>129</VL>
<PG>35-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakic-2006" MODIFIED="2010-05-16 21:56:57 +0200" MODIFIED_BY="[Empty name]" NAME="Sakic 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-16 21:56:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakic M, Berbic-Fazlagic J</AU>
<TI>Results of treatment with protocols BFM 90 and BFM 95</TI>
<SO>Medicinski Arhiv</SO>
<YR>2006</YR>
<VL>60</VL>
<PG>369-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sallan-1977" NAME="Sallan 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sallan SE, Camitta BM, Frei E III, Furman L, Leavitt P, Bishop Y, et al</AU>
<TI>Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): addition of an anthracycline to vincristine and prednisone</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1977</YR>
<VL>3</VL>
<PG>281-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salodof-MacNeil-2010" MODIFIED="2014-03-19 13:52:48 +0100" MODIFIED_BY="[Empty name]" NAME="Salodof MacNeil 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-19 13:52:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salodof MacNeil J</AU>
<TI>MRC AML 15 trial: similar survival rates from multiple regimens</TI>
<SO>The Oncology Report</SO>
<YR>2010</YR>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaison-1992" NAME="Schaison 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaison G, Sommelet D, Bancillon A, Perel Y, Leblanc T, Bergeron C, et al</AU>
<TI>Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87</TI>
<SO>Leukemia</SO>
<YR>1992</YR>
<VL>6 Suppl 2</VL>
<PG>148-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scherrer-1994" MODIFIED="2010-10-13 13:56:08 +0200" MODIFIED_BY="[Empty name]" NAME="Scherrer 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-10-13 13:56:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scherrer R, Bettelheim P, Geissler K, Jager U, Knobl P, Kyrle PA, et al</AU>
<TI>High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) - a single-institution study</TI>
<SO>Annals of Hematology</SO>
<YR>1994</YR>
<VL>69</VL>
<PG>181-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmits-2001" NAME="Schmits 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmits R, Glass B, Trumper L, Pfreundschuh M</AU>
<TI>Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL</TI>
<SO>Annals of Hematology</SO>
<YR>2001</YR>
<VL>80 Suppl 3</VL>
<PG>B77-B83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seibel-2008" MODIFIED="2010-05-16 21:01:38 +0200" MODIFIED_BY="[Empty name]" NAME="Seibel 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:01:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al</AU>
<TI>Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the children's oncology group</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>111</VL>
<PG>2548-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silverman-2000" NAME="Silverman 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al</AU>
<TI>Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)</TI>
<SO>Leukemia</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>2247-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Skoczen-2006" MODIFIED="2010-05-16 22:03:08 +0200" MODIFIED_BY="[Empty name]" NAME="Skoczen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-16 22:03:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skoczen S, Balwierz W, Moryl-Bujakowska A, Pawinska K, Luszczynska A, Balcerska A, et al</AU>
<TI>Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group</TI>
<SO>Przeglad Lekarski</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smithson-1982" NAME="Smithson 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smithson WA, Telander RL, Carney JA</AU>
<TI>Mesenchymoma of the liver in childhood: five-year survival after combined-modality treatment</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>1982</YR>
<VL>17</VL>
<PG>70-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sotnikov-1989" NAME="Sotnikov 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sotnikov VM, Polianskaia AM, Pan'shin GA, Ingberman I, Kaplanskaia IB</AU>
<TI>Chemoradiation treatment of patients with aggressive non-Hodgkin's lymphomas in stages I to II of the disease</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>1989</YR>
<VL>61</VL>
<PG>20-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spears-1992" NAME="Spears 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spears WT, Morphis II JG, Lester SG, Williams SD, Einhorn LH</AU>
<TI>Brain metastases and testicular tumors: long-term survival</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>22</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spreafico-2008" MODIFIED="2010-05-16 21:36:32 +0200" MODIFIED_BY="[Empty name]" NAME="Spreafico 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:36:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D'Angelo P, et al</AU>
<TI>Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2008</YR>
<VL>51</VL>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sramkova-2013" MODIFIED="2014-09-04 12:16:35 +0200" MODIFIED_BY="[Empty name]" NAME="Sramkova 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-09-04 12:16:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sramkova L, Sterba J, Hrstkova H, Mihal V, Blazek B, Timr P, et al</AU>
<TI>Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic</TI>
<SO>Magazine of European Medical Oncology</SO>
<YR>2013</YR>
<VL>6</VL>
<PG>41-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stary-2003" NAME="Stary 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stary J, Gajdos P, Blazek B, Ptoszkova H, Mihal V, Pospisilova D, et al</AU>
<TI>Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic</TI>
<SO>Casopis Lekary Ceskych</SO>
<YR>2003</YR>
<VL>142</VL>
<PG>404-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinherz-1993" NAME="Steinherz 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G</AU>
<TI>Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol</TI>
<SO>Cancer</SO>
<YR>1993</YR>
<VL>72</VL>
<PG>3120-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinherz-1996" NAME="Steinherz 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al</AU>
<TI>Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: report from the Childrens Cancer Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>389-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinherz-1998" NAME="Steinherz 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al</AU>
<TI>Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group</TI>
<SO>Cancer</SO>
<YR>1998</YR>
<VL>82</VL>
<PG>600-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarella-2001" MODIFIED="2014-09-04 12:16:49 +0200" MODIFIED_BY="[Empty name]" NAME="Tarella 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-09-04 12:16:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarella C, Cuttica A, Caracciolo D, Zallio F, Ricca I, Bergui L, et al</AU>
<TI>High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments</TI>
<SO>Annals of Hematology</SO>
<YR>2001</YR>
<VL>80 Suppl 3</VL>
<PG>B123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-2006" MODIFIED="2014-09-04 12:17:03 +0200" MODIFIED_BY="[Empty name]" NAME="Taylor 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-04 12:17:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, et al</AU>
<TI>The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>2006</YR>
<VL>47</VL>
<PG>2321-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tefft-1978" NAME="Tefft 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tefft M, Razek A, Perez C, Burgert EO, Gehan EA, Griffin P, et al</AU>
<TI>Local control and survival related to radiation dose and volume and to chemotherapy in non-metastatic Ewing's sarcoma of pelvic bones</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1978</YR>
<VL>4</VL>
<PG>367-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thirugnanam-2009" MODIFIED="2010-05-16 21:05:34 +0200" MODIFIED_BY="[Empty name]" NAME="Thirugnanam 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-16 21:05:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, et al</AU>
<TI>Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen</TI>
<SO>Biology of Blood and Marrow Transplantation</SO>
<YR>2009</YR>
<VL>15</VL>
<PG>1479-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-1988" NAME="Thomas 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas PR, Tefft M, D'Angio GJ, Norkool P</AU>
<TI>Acute toxicities associated with radiation in the second National Wilms' Tumor Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>1694-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toft-2013" MODIFIED="2014-03-13 15:19:12 +0100" MODIFIED_BY="[Empty name]" NAME="Toft 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-13 15:19:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toft N, Birgens H, Abrahamsson J, Bernell P, Gri&#353;kevi&#269;ius L, Hallböök H, et al</AU>
<TI>Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol</TI>
<SO>European Journal of Haematology</SO>
<YR>2013</YR>
<VL>90</VL>
<NO>5</NO>
<PG>404-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tournade-1993" NAME="Tournade 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tournade MF, Com-Nougue C, Voute PA, Lemerle J, De Kraker J, Delemarre JFM, et al</AU>
<TI>Results of the Sixth International Society of Pediatric Oncology Wilms' tumor trial and study: A risk-adapted therapeutic approach in Wilms' tumor</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>1014-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuchiya-1998" NAME="Tsuchiya 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, et al</AU>
<TI>Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma</TI>
<SO>Anticancer Research</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>657-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Does-1988" MODIFIED="2010-10-09 13:01:36 +0200" MODIFIED_BY="[Empty name]" NAME="Van der Does 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Does-van den Berg A, van Wering ER, Suciu S, Solbu G, Rammeloo JA, de Koning J, et al</AU>
<TI>Results of treatment of children with acute lymphatic leukemia (ALL) according to the ALL V protocol of the Netherlands Working Group on Leukemia in Children</TI>
<SO>Tijdschrift voor Kindergeneeskunde</SO>
<YR>1988</YR>
<VL>56</VL>
<PG>61-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinogradova-2008" MODIFIED="2010-05-16 21:23:06 +0200" MODIFIED_BY="[Empty name]" NAME="Vinogradova 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-16 21:23:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinogradova I, Lutsenko IN, Kaplanskaia IB, Vorob'ev IA, Samoilova RS, Gorgidze LA, et al</AU>
<TI>Efficacy of therapy of different variants of anaplastic large T-cell lymphomas</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>2008</YR>
<VL>80</VL>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Virchis-2004" NAME="Virchis 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, et al</AU>
<TI>Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes</TI>
<SO>British Journal of Haematology</SO>
<YR>2004</YR>
<VL>124</VL>
<PG>26-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vora-2010" MODIFIED="2014-09-04 12:17:29 +0200" MODIFIED_BY="[Empty name]" NAME="Vora 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-09-04 12:17:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vora AJ, Mitchell C, Goulden N, Richards S</AU>
<TI>UKALL 2003, a randomised trial investigating treatment reduction for children and young adults with minimal residual disease defined low risk acute lymphoblastic leukaema</TI>
<SO>Blood (ASH Annual Meeting Abstracts)</SO>
<YR>2010</YR>
<PG>116 (abstract 496)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vose-1994" NAME="Vose 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger D, Chan WC, et al</AU>
<TI>Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group</TI>
<SO>Seminars in Hematology</SO>
<YR>1994</YR>
<VL>31</VL>
<PG>4-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watts-2002" NAME="Watts 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watts RG, Hilliard LM, Berkow RL</AU>
<TI>Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2002</YR>
<VL>24</VL>
<PG>622-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinstein-1992" NAME="Weinstein 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinstein H, Ravindranath Y, Krischer J, Steuber P, Civin C, Gresik M, et al</AU>
<TI>The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML)</TI>
<SO>Leukemia</SO>
<YR>1992</YR>
<VL>6 Suppl 2</VL>
<PG>52-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilimas-1988" NAME="Wilimas 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilimas JA, Douglass EC, Lewis S, Fairclough D, Fullen G, Parham D, et al</AU>
<TI>Reduced therapy for Wilms' tumor: analysis of treatment results from a single institution</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>1630-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Willemze-1982" NAME="Willemze 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willemze R, Haanen C, Dekker A, Sizoo W, Abels J, Tricot G, et al</AU>
<TI>Results of a multicentre study of the treatment of acute lymphoblastic leukaemia in adolescents and adults (1978-1981)</TI>
<SO>The Netherlands Journal of Medicine</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>303-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Willnow-1986" NAME="Willnow 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willnow U, Lindner H, Rothe K, Kamprad F</AU>
<TI>The results of a prospective study for treatment of rhabdomyosarcoma in children</TI>
<SO>Kinderarztliche Praxis</SO>
<YR>1986</YR>
<VL>54</VL>
<PG>661-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaharia-1986" NAME="Zaharia 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zaharia M, Caceres E, Valdivia S, Moran M, Tejada F</AU>
<TI>Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1986</YR>
<VL>12</VL>
<PG>907-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zdrahalova-2011" MODIFIED="2014-09-04 12:17:48 +0200" MODIFIED_BY="[Empty name]" NAME="Zdrahalova 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-09-04 12:17:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zdrahalova K, Sedlacek P, Smisek P, Keslova P, Sterba J, Hrstkova H, et al</AU>
<TI>The relapsed AML 2001/01, 02 study for children with relapsed acute myeloid leukaemia or initially resistant disease has improved outcome</TI>
<TO>Lecebna studie relapsed AML 2001/01, 02 pro deti s relapsem akutni myeloidni leukemie nebo primarne rezistentni nemoci zlepsila jejich nadeji na vyleceni</TO>
<SO>Transfuze a Hematologie Dnes</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>3</NO>
<PG>113-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimmermann-2012" MODIFIED="2014-09-04 12:18:03 +0200" MODIFIED_BY="[Empty name]" NAME="Zimmermann 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-09-04 12:18:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann C, Pötschger U, Amann G, Horcher E, Dieckmann K, Lakatos K, et al</AU>
<TI>Results of children with renal tumors treated in the Austrian-Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria</TI>
<SO>Magazine of European Medical Oncology</SO>
<YR>2012</YR>
<VL>5</VL>
<PG>289-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zintl-1987" NAME="Zintl 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zintl F, Plenert W, Malke H</AU>
<TI>Results of acute lymphoblastic leukemia therapy in childhood with a modified BFM protocol in a multicenter study in the German Democratic Republic</TI>
<SO>Haematology and Blood Transfusion</SO>
<YR>1987</YR>
<VL>30</VL>
<PG>471-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zittoun-1992" NAME="Zittoun 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, et al</AU>
<TI>Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group</TI>
<SO>Leukemia</SO>
<YR>1992</YR>
<VL>6 Suppl 2</VL>
<PG>76-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-09-02 15:12:46 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-FRALLE-2000_x002d_A" MODIFIED="2014-09-02 15:12:46 +0200" MODIFIED_BY="[Empty name]" NAME="FRALLE 2000-A" YEAR="">
<REFERENCE MODIFIED="2014-09-02 15:12:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baruchel A, Auvrignon A, Auclere M-F, Perel Y, Mechinaud F, Landman-Parker J, et al</AU>
<TI>Childhood standard-risk B-cell precursor acute lymphoblastic leukemia (SR-BCP-ALL): toxicity and efficacy interim results of the FRALLE 2000-A protocol (O.093)</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2006</YR>
<VL>47</VL>
<PG>380</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cayuela J-M, Beldjord K, Preudhomme C, Cave H, Eliahou J-F, Auclerc M-F, et al</AU>
<TI>Minimal residual disease (MRD) in childhood standard-risk B-cell precursor acute lymphoblastic leukemia (SR-BCP-ALL) at the end of induction (EOI) after a three or four drug induction (O.094)</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2006</YR>
<VL>47</VL>
<PG>380-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SIOP2001" MODIFIED="2014-03-26 13:59:09 +0100" MODIFIED_BY="[Empty name]" NAME="SIOP2001" YEAR="">
<REFERENCE MODIFIED="2014-03-26 13:58:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pritchard-Jones K, Graf N, Bergeron C, de Camargo B, Van Den Heuvel M, Sandstedt B, et al</AU>
<TI>Doxorubicin can be safely omitted from the treatment of stage II/III, intermediate risk histology Wilms tumour: Results of the SIOP WT 2001 randomised trial</TI>
<SO>Pediatric Blood and Cancer (Congress of the International Society of Paediatric Oncology)</SO>
<YR>2011</YR>
<PG>741</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Stackelberg-2011" MODIFIED="2014-03-19 14:17:14 +0100" MODIFIED_BY="[Empty name]" NAME="Von Stackelberg 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-19 14:17:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>von Stackelberg A, Yamanaka J, Escherich G, Eckert C, Ratei R, Hitzler JK, et al</AU>
<TI>Conventional reinduction/consolidation-type therapy versus short course high intensity combination chemotherapy as post-induction treatment for children with relapsed acute lymphoblastic leukemia. Early results of study ALL-REZ BFM 2002</TI>
<SO>Blood (Annual Meeting of the American Society of Hematology)</SO>
<YR>2011</YR>
<PG>118 (abstract 871)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2014-03-26 14:14:07 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-COG-AHEP0531" NAME="COG AHEP0531" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Not mentioned</AU>
<TI>COG AHEP0531</TI>
<SO>Not mentioned</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00379457" NAME="NCT00379457" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<TI>A protocol for nonmetastatic rhabdomyosarcoma [RMS-2005]</TI>
<SO>www.controlled-trials.com</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-04 12:18:58 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-09-04 12:18:58 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Billingham-1978" NAME="Billingham 1978" TYPE="JOURNAL_ARTICLE">
<AU>Billingham ME, Mason JW, Bristow MR, Daniels JR</AU>
<TI>Anthracycline cardiomyopathy monitored by morphologic changes</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1978</YR>
<VL>62</VL>
<PG>865-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Biondi-2000" MODIFIED="2008-06-17 13:41:32 +0200" MODIFIED_BY="[Empty name]" NAME="Biondi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Biondi A, Cimino G, Pieters R, Pui CH</AU>
<TI>Biological and therapeutic aspects of infant leukemia</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<PG>24-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gratias-2008" MODIFIED="2010-10-13 13:56:47 +0200" MODIFIED_BY="[Empty name]" NAME="Gratias 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gratias EJ, Dome JS</AU>
<TI>Current and emerging chemotherapy treatment strategies for Wilms tumor in North America</TI>
<SO>Paediatric Drugs</SO>
<YR>2008</YR>
<VL>10</VL>
<PG>115-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2001" NAME="Green 2001" TYPE="JOURNAL_ARTICLE">
<AU>Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, et al</AU>
<TI>Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>1926-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2004" MODIFIED="2010-06-01 15:23:36 +0200" MODIFIED_BY="[Empty name]" NAME="Green 2004" TYPE="JOURNAL_ARTICLE">
<AU>Green DM</AU>
<TI>The treatment of stages I-IV favorable histology Wilms' tumor</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>1366-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2010-10-13 13:56:58 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3</SO>
<YR>2006</YR>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-10-13 13:57:06 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-04-02 12:46:13 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</TI>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kremer-2002a" NAME="Kremer 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Kremer LCM, van Dalen EC, Offringa M, Voute PA</AU>
<TI>Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<PG>503-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kremer-2002b" NAME="Kremer 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Kremer LCM, van der Pal HJH, Offringa M, van Dalen EC, Voute PA</AU>
<TI>Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<PG>819-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kremer-2008" MODIFIED="2014-04-02 12:44:58 +0200" MODIFIED_BY="[Empty name]" NAME="Kremer 2008" TYPE="OTHER">
<AU>Kremer LCM, van Dalen EC, Moher D, Caron HN</AU>
<TI>Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lachin-2000" MODIFIED="2010-08-26 13:22:20 +0200" MODIFIED_BY="[Empty name]" NAME="Lachin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lachin JM</AU>
<TI>Statistical considerations in the intent-to-treat principle</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2000</YR>
<VL>21</VL>
<PG>167-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1991" MODIFIED="2010-08-26 13:23:07 +0200" MODIFIED_BY="[Empty name]" NAME="Lee 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB</AU>
<TI>Analysis of clinical trials by treatment actually received: is it really an option?</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>1595-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefrak-1973" NAME="Lefrak 1973" TYPE="JOURNAL_ARTICLE">
<AU>Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA</AU>
<TI>A clinicopathologic analysis of adriamycin cardiotoxicity</TI>
<SO>Cancer</SO>
<YR>1973</YR>
<VL>32</VL>
<PG>302-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipshultz-2005" NAME="Lipshultz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al</AU>
<TI>Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>2629-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mertens-2001" NAME="Mertens 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, et al</AU>
<TI>Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>3163-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Messinger-1999" MODIFIED="2014-09-04 12:18:32 +0200" MODIFIED_BY="[Empty name]" NAME="Messinger 1999" TYPE="JOURNAL_ARTICLE">
<AU>Messinger Y, Uckun FM</AU>
<TI>A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>1999</YR>
<VL>34</VL>
<PG>415-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pieters-2008" MODIFIED="2008-10-27 14:51:42 +0100" MODIFIED_BY="[Empty name]" NAME="Pieters 2008" TYPE="JOURNAL_ARTICLE">
<AU>Pieters R, Carroll WL</AU>
<TI>Biology and treatment of acute lymphoblastic leukemia</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>2008</YR>
<VL>55</VL>
<PG>1-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reulen-2010" MODIFIED="2014-09-04 12:18:58 +0200" MODIFIED_BY="[Empty name]" NAME="Reulen 2010" TYPE="JOURNAL_ARTICLE">
<AU>Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al</AU>
<TI>Long-term cause-specific mortality among survivors of childhood cancer</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>304</VL>
<PG>172-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Dalen-2006" NAME="Van Dalen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LCM</AU>
<TI>Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study</TI>
<SO>European Journal of Cancer</SO>
<YR>2006</YR>
<VL>42</VL>
<PG>3191-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Hoff-1979" NAME="Von Hoff 1979" TYPE="JOURNAL_ARTICLE">
<AU>Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al</AU>
<TI>Risk factors for doxorubicin-induced congestive heart failure</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1979</YR>
<VL>91</VL>
<PG>710-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-06-16 14:40:39 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Van-Dalen-2007" MODIFIED="2014-04-02 13:00:42 +0200" MODIFIED_BY="[Empty name]" NAME="Van Dalen 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Van Dalen EC, Caron HN, Kremer LCM</AU>
<TI>Anthracyclines versus no anthracyclines for childhood cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-04-02 13:00:34 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-02 13:00:34 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006647"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Dalen-2009" MODIFIED="2014-06-16 14:40:39 +0200" MODIFIED_BY="[Empty name]" NAME="Van Dalen 2009" TYPE="COCHRANE_REVIEW">
<AU>Van Dalen EC, Raphaël MF, Caron HN, Kremer LCM</AU>
<TI>Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-06-16 14:40:39 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-16 14:40:39 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006647.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Dalen-2011" MODIFIED="2014-04-02 13:04:15 +0200" MODIFIED_BY="[Empty name]" NAME="Van Dalen 2011" TYPE="COCHRANE_REVIEW">
<AU>van Dalen EC, Raphaël MF, Caron HN, Kremer LCM</AU>
<TI>Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-04-02 13:04:15 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-02 13:04:14 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006647.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-09-04 12:33:47 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-09-04 12:10:49 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-09-04 12:03:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Angio-1981">
<CHAR_METHODS MODIFIED="2014-09-04 12:03:30 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (patients were stratified by institution, age and risk group)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:03:32 +0200" MODIFIED_BY="[Empty name]">
<P>316 children (age nm; 151 boys and 165 girls) with <U>Wilms' tumour</U> (stage II, III or IV; primary disease)</P>
<P>No prior treatment</P>
<P>Prior cardiac dysfunction nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:03:36 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 159) versus chemotherapy including doxorubicin (N = 157)</P>
<P>Cumulative doxorubicin dose nm (according to protocol 300 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 60 mg/m<SUP>2</SUP>; infusion duration nm</P>
<P>All patients underwent radiotherapy (dose adjusted to age; location adjusted to stage of disease)</P>
<P>All patients underwent surgery (radical nephrectomy)</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:03:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from surgery to death without regard to cause)</P>
<P>
<I>Event-free survival </I>(defined as the length of time between initial surgery and the earliest detection of abdominal recurrence, distant metastasis or death (whether or not tumour related))</P>
<P>
<I>Cardiotoxicity</I> (clinical heart failure defined as cardiac death)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:03:40 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm</P>
<P>Age in treatment and control group nm</P>
<P>Long-term follow-up data of this study have been published (<LINK REF="REF-Green-2004" TYPE="REFERENCE">Green 2004</LINK>) on 275 of 316 patients: 227 patients with stage II or III disease with favourable or unfavourable histology (as opposed to D'Angio 1981 where data were presented for favourable and unfavourable histology separately) and 48 patients with stage IV disease. The length of follow-up was nm but at least part of the patients had a follow-up of 16 years. Since in the stage IV group 20 patients were included in the no anthracycline group and 28 in the anthracycline group, as opposed to the original data where 22 patients were randomised to the anthracycline group and 27 to the non-anthracycline group, intention-to-treat analyses were not possible.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:03:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<CHAR_METHODS MODIFIED="2014-09-04 12:03:55 +0200" MODIFIED_BY="[Empty name]">
<P>See D'Angio 1981</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:03:56 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from D'Angio 1981: 232 children with stage II or III disease with favourable histology (age and sex nm). For further information: see D'Angio 1981</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:03:56 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 121) versus chemotherapy including doxorubicin (N = 111). For further information: see D'Angio 1981</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:03:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from surgery to death without regard to cause)</P>
<P>
<I>Event-free survival </I>(defined as the length of time between initial surgery and the earliest detection of abdominal recurrence, distant metastasis or death (whether or not tumour related))</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:03:58 +0200" MODIFIED_BY="[Empty name]">
<P>See D'Angio 1981</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:04:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<CHAR_METHODS MODIFIED="2010-09-20 11:10:16 +0200" MODIFIED_BY="[Empty name]">
<P>See D'Angio 1981.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:03:59 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from D'Angio 1981 with stage II or III disease with favourable (N = 232) or unfavourable histology (N = 35) (age and sex nm). For further information: see D'Angio 1981 II-III FH and D'Angio 1981 II-III UH</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:04:00 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 137) versus chemotherapy including doxorubicin (N = 130). For further information: See D'Angio 1981</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:04:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from surgery to death without regard to cause)</P>
<P>
<I>Event-free survival </I>(defined as the length of time between initial surgery and the earliest detection of abdominal recurrence, distant metastasis or death (whether or not tumour related))</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:04:01 +0200" MODIFIED_BY="[Empty name]">
<P>See D'Angio 1981</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:04:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<CHAR_METHODS MODIFIED="2014-09-04 12:04:02 +0200" MODIFIED_BY="[Empty name]">
<P>See D'Angio 1981</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:04:02 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from D'Angio 1981: 35 children with stage II or III disease with unfavourable histology (age and sex nm). For further information: see D'Angio 1981</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:04:03 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 16) versus chemotherapy including doxorubicin (N = 19). For further information: see D'Angio 1981</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from surgery to death without regard to cause)</P>
<P>
<I>Event-free survival </I>(defined as the length of time between initial surgery and the earliest detection of abdominal recurrence, distant metastasis or death (whether or not tumour related))</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>See D'Angio 1981</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:04:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<CHAR_METHODS MODIFIED="2014-09-04 12:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>See D'Angio 1981</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:04:06 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from D'Angio 1981: 49 children with stage IV disease (age and sex nm). For further information: see D'Angio 1981</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:04:06 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 22) versus chemotherapy including doxorubicin (N = 27). For further information: see D'Angio 1981</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:04:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from surgery to death without regard to cause)</P>
<P>
<I>Event-free survival </I>(defined as the length of time between initial surgery and the earliest detection of abdominal recurrence, distant metastasis or death (whether or not tumour related))</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:04:08 +0200" MODIFIED_BY="[Empty name]">
<P>See D'Angio 1981</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:04:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eden-1991">
<CHAR_METHODS MODIFIED="2014-09-04 12:04:08 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:04:10 +0200" MODIFIED_BY="[Empty name]">
<P>630 children (age nm: an inclusion criterion for this study was age between 0 and 14 years; 337 boys and 293 girls) with <U>acute lymphoblastic leukaemia</U> (stage nm; nm if primary disease or relapse)</P>
<P>Prior treatment nm</P>
<P>Prior cardiac dysfunction nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:04:13 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without daunorubicin (N = 308) versus chemotherapy including daunorubicin (N = 322)</P>
<P>Cumulative daunorubicin dose nm (according to protocol 90 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 90 mg/m<SUP>2</SUP>; infusion duration nm.</P>
<P>Patients received cranial irradiation</P>
<P>No surgery</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:04:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (definition nm)</P>
<P>
<I>Event-free survival </I>(defined as time to relapse or death; patients who died without going into remission were counted as having an event on day 1)</P>
<P>
<I>Tumour response </I>(definition nm; we assumed that the number of total remitters provided in the article was the number of complete remissions)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:04:15 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm</P>
<P>Age in treatment and control group nm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:04:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaspers-2013">
<CHAR_METHODS MODIFIED="2014-09-04 12:04:28 +0200" MODIFIED_BY="[Empty name]">
<P>Block randomisation (block size 4) with a central interactive computerized system (stratified by study group and time to relapse on a 1:1 basis)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:04:29 +0200" MODIFIED_BY="[Empty name]">
<P>394 children (age 0-19 years; 231 boys and 163 girls) with <U>acute myeloid leukaemia</U> (non-FAB type M3; stage nm; first relapse or primary refractory disease).</P>
<P>Prior treatment yes (heterogenous first-line treatment, but all groups applied cytarabine-based treatment combined with an anthracycline and allogeneic stem cell transplant was used in a limited number of patients; no further information provided)</P>
<P>No prior cardiac dysfunction (patients with symptomatic cardiac disease and/or left ventricular shortening fraction &lt; 29% were excluded)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:04:31 +0200" MODIFIED_BY="[Empty name]">
<P>Re-induction chemotherapy without daunoxome (=liposomally entrapped daunorubicin; N = 197) versus chemotherapy including daunoxome (N = 197)</P>
<P>Cumulative daunoxome dose nm (according to protocol 180 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 180 mg/m<SUP>2</SUP>; infusion duration nm</P>
<P>Cranial irradiation was not recommended</P>
<P>No surgery</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:04:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from study enrolment untill last follow-up or death from any cause)</P>
<P>
<I>Tumour response </I>(complete response (after 2 courses) defined as 5% or less leukemic blasts in bone marrow with signs of normal haematopoiesis and of regeneration of normal peripheral blood cell production (platelets &gt; 50x109/L without transfusions, neutrophils &gt; 1.0x109/L) and no leukaemic cells in the peripheral blood or anywhere else)</P>
<P>
<I>Cardiotoxicity</I> (grade 3 or 4 acute toxicity according to National Cancer Institute Common Toxicity Criteria version 2)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:04:38 +0200" MODIFIED_BY="[Empty name]">
<P>Median length of follow-up 4 years</P>
<P>Age in treatment group ranged from 0 to 19 years (median 10 years); age in the control group ranged from 0 to 19 years (median 9 years)</P>
<P>Re-induction chemotherapy was followed by allogeneic stem cell transplant if available (different conditioning regimens); otherwise patients received consolidation chemotherapy (different schedules). An inclusion criterium for this systematic review was that therapy other than anthracyclines should have been the same in both treatment groups; timing of different aspects of the treatment could differ between the treatment groups, but the cumulative doses of therapy other than anthracyclines should not differ more than 25% between the treatment groups. Although this was not completely clear for this study, it was stated that treatment was well-balanced between the treatment groups and therefore we gave this study the benefit of the doubt and judged it to be eligible for inclusion.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:04:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maurer-1988">
<CHAR_METHODS MODIFIED="2014-09-04 12:04:48 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (patients randomised within each clinical group)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:04:49 +0200" MODIFIED_BY="[Empty name]">
<P>413 children (age nm: an inclusion criterion for this study was age &lt; 21 years; 240 males and 173 females) with <U>rhabdomyosarcoma or undifferentiated sarcoma</U> (clinical group III or IV; primary disease)</P>
<P>No prior treatment</P>
<P>Prior cardiac dysfunction nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:04:51 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 208) versus chemotherapy including doxorubicin (N = 205)</P>
<P>Cumulative doxorubicin dose nm (according to protocol 300 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 60 mg/m<SUP>2</SUP>; infusion duration nm</P>
<P>All patients received radiotherapy to the primary lesion (dose adjusted to age); in case of pulmonary metastases patients received pulmonary irradiation</P>
<P>No surgery</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:04:52 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from start of treatment to death)</P>
<P>
<I>Tumour response </I>(complete remission defined as complete disappearance of all signs and symptoms of disease; partial remission defined as at least 50% reduction in gross disease in widest diameter)</P>
<P>
<I>Cardiotoxicity</I> (clinical heart failure defined as congestive heart failure).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:04:52 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm</P>
<P>Exact age in treatment and control group nm, but it was balanced between treatment groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:05:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maurer-1988-Group-3">
<CHAR_METHODS MODIFIED="2014-09-04 12:05:01 +0200" MODIFIED_BY="[Empty name]">
<P>See Maurer 1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:05:02 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from Maurer 1988: 280 children in clinical group III (age and sex nm). The exact number of patients randomised to this subgroup is unclear. For further information: see Maurer 1988</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:05:02 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 146) versus chemotherapy including doxorubicin (N = 134). For further information: see Maurer 1988</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:05:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from start of treatment to death)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:05:03 +0200" MODIFIED_BY="[Empty name]">
<P>See Maurer 1988</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:05:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maurer-1988-Group-4">
<CHAR_METHODS MODIFIED="2014-09-04 12:05:03 +0200" MODIFIED_BY="[Empty name]">
<P>See Maurer 1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:05:04 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from Maurer 1988: 129 children in clinical group IV (age and sex nm). The exact number of patients randomised to this subgroup is unclear. For further information: see Maurer 1988</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:05:04 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 61) versus chemotherapy including doxorubicin (N = 68). For further information: see Maurer 1988</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:05:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as time from start of treatment to death)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:05:05 +0200" MODIFIED_BY="[Empty name]">
<P>See Maurer 1988</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:05:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nesbit-1990">
<CHAR_METHODS MODIFIED="2014-09-04 12:05:05 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (patients were randomised on a 2 to 3 patient basis to intervention and control group)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:05:07 +0200" MODIFIED_BY="[Empty name]">
<P>94 children (age nm; 56 boys and 38 girls) with non-metastatic <U>Ewing's sarcoma of the bone</U> (primary disease)</P>
<P>No prior treatment</P>
<P>Prior cardiac dysfunction nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:05:09 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 37) versus chemotherapy including doxorubicin (N = 57)</P>
<P>Cumulative doxorubicin dose nm (according to protocol maximal 420 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 60 mg/m<SUP>2</SUP>; infusion duration nm</P>
<P>Radiotherapy to primary lesion (dose adjusted to age)</P>
<P>Part of the patients underwent surgical resection of the lesion: 3 in the intervention group and 19 in the control group</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:05:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival </I>(defined as time from start of treatment to death)</P>
<P>
<I>Event-free survival </I>(defined as time from start of treatment to first evidence of local recurrence or metastatic disease; patients dying before evidence of relapse were counted as failures)</P>
<P>
<I>Cardiotoxicity</I> (clinical heart failure defined as death of irreversible cardiac failure)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:05:11 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm</P>
<P>Age in treatment and control group nm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:10:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perilongo-2009">
<CHAR_METHODS MODIFIED="2014-09-04 12:10:49 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation by the United Kingdom Children's Cancer Study Group Data Centre (using the minimization method)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:06:02 +0200" MODIFIED_BY="[Empty name]">
<P>255 patients (age 0 to 11.2 years; 155 males and 100 females) with standard risk <U>hepatoblastoma</U> (standard risk was defined as a PRETEXT classification I, II or III with no evidence of extra-hepatic disease; during the trial the protocol was amended to exclude patients with an alpha-fetoprotein level of less than 100 ng/mL, in view of mounting evidence of a poor outcome in these patients; primary disease)</P>
<P>No prior treatment</P>
<P>Prior cardiac dysfunction nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:06:05 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without doxorubicin (N = 126) versus chemotherapy including doxorubicin (N = 129)</P>
<P>Cumulative doxorubicin dose nm (according to protocol maximal 300 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 60 mg/m<SUP>2</SUP>; infusion duration 30 mg/m<SUP>2</SUP>/24 hours</P>
<P>No radiotherapy</P>
<P>Radical surgery of the tumour was attempted in all patients</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:06:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (defined as the interval between diagnosis and death from any cause or last contact)</P>
<P>
<I>Event-free survival</I> (defined as the interval between diagnosis and disease progression, relapse or death, whichever occurred first)</P>
<P>
<I>Tumour response</I> (defined as complete surgical resection, i.e. resection of all tumour sites on the basis of surgical findings and on postsurgical imaging)</P>
<P>
<I>Cardiotoxicity</I> (asymptomatic cardiac dysfunction defined as a left ventricular shortening fraction of &lt; 30%; test to determine left ventricular shortening fraction nm)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:06:08 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm</P>
<P>Age in treatment group ranged from 0 to 11.2 years (median 1 year); age in the control group ranged from 0.02 to 11.1 years (median 1.3 years)</P>
<P>A total of 267 patients were randomized, but 12 patients were excluded (7 lacked proper documentation; 5 had wrong diagnosis; it was unclear to which treatment group these patients were randomized). As a result, intention-to-treat analyses were not possible</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:06:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sposto-2001">
<CHAR_METHODS MODIFIED="2014-09-04 12:06:19 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (patients were stratified according to histology (large cell versus non-large cell) and principal disease site (abdomen versus other)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:06:20 +0200" MODIFIED_BY="[Empty name]">
<P>284 patients (age nm: an inclusion criterion for this study was age &lt; 21 years; 197 males and 87 females) with <U>non-lymphoblastic Non-Hodgkin lymphoma</U> (stage I to IV; nm if primary disease or relapse)</P>
<P>Prior treatment nm</P>
<P>Prior cardiac dysfunction nm<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:06:22 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without daunorubicin (N = 139) versus chemotherapy including daunorubicin (N = 145)</P>
<P>Cumulative daunorubicin dose nm (according to protocol 350 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 50 mg/m<SUP>2</SUP>; infusion duration nm</P>
<P>Craniospinal radiotherapy if CNS disease at diagnosis, parameningeal disease, or isolated CNS relapse (dose depending on reason to give radiotherapy)</P>
<P>No surgery</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:06:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Event-free survival </I>(defined as the minimal time from study entry to failure to induce remission, disease progression, disease relapse, the occurrence of secondary malignant disease or death from any cause; isolated CNS relapses as first event for which treatment was specified in the protocol are not counted as events in this definition although subsequent CNS relapses or persistent CNS disease were counted as events)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:06:24 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm</P>
<P>Exact age in treatment and control group nm, but it was balanced between treatment groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:06:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-der-Does-1975">
<CHAR_METHODS MODIFIED="2014-09-04 12:06:31 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:06:32 +0200" MODIFIED_BY="[Empty name]">
<P>42 children (age nm: an inclusion criterion for this study was age between 1 and 14 years; sex nm) with <U>acute lymphocytic leukaemia</U> (stage nm; primary disease)</P>
<P>No prior treatment</P>
<P>Prior cardiac dysfunction unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:06:33 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without daunorubicin (N = 22) versus chemotherapy including daunorubicin (N = 20)</P>
<P>Cumulative daunorubicin dose nm (according to protocol maximal 300 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 30 mg/m<SUP>2</SUP>; infusion duration nm</P>
<P>No radiotherapy or surgery</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:06:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival</I> (definition nm)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:06:34 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up for all patients maximal 18 months</P>
<P>Age in treatment and control group nm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 12:06:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-der-Does-1989">
<CHAR_METHODS MODIFIED="2014-09-04 12:06:40 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation by the DCLSG Central Office (patients were stratified by institution and sex)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:06:42 +0200" MODIFIED_BY="[Empty name]">
<P>240 children (age 0 to 15 years; 119 boys and 121 girls) with standard risk <U>acute lymphocytic leukaemia</U> (nm if primary disease or relapse)</P>
<P>Prior treatment nm</P>
<P>Prior cardiac dysfunction nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:06:44 +0200" MODIFIED_BY="[Empty name]">
<P>Chemotherapy without daunorubicin (N = 122) versus chemotherapy including daunorubicin (N = 118)</P>
<P>Cumulative daunorubicin dose nm (according to protocol 100 mg/m<SUP>2</SUP>); peak dose (i.e. the maximal dose received in one week) 25 mg/m<SUP>2</SUP>; infusion duration nm.</P>
<P>Patients achieving complete remission within 6 weeks of the start of induction chemotherapy underwent cranial irradiation (dose adjusted to age) in combination with intrathecal methotrexate and prednisone</P>
<P>No surgery</P>
<P>No cardioprotective interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:06:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Overall survival </I>(defined as time from diagnosis to time of death)</P>
<P>
<I>Event-free survival </I>(defined as time from diagnosis to induction failure, relapse, death in remission, or the occurrence of a second tumour)</P>
<P>
<I>Tumour response</I> (complete remission defined as &lt; 5% blast cells and normal hematopoiesis in the bone marrow without evidence of disease at any other site)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:06:46 +0200" MODIFIED_BY="[Empty name]">
<P>Median follow-up for all patients 64 months (range 34 to 87 months)</P>
<P>Age in treatment group ranged from 0 to 15 years; age in the control group ranged from 1 to 15 years</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>nm: not mentioned; DCLSG: Dutch Childhood Leukemia Study Group; CNS: central nervous system; FH: favourable histology; UH: unfavourable histology; FAB: French-American-British</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-04 12:33:47 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:20:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvegard-1989a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:20:26 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:20:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvegard-1989b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:20:29 +0200" MODIFIED_BY="[Empty name]">
<P>Double publication of <LINK REF="STD-Alvegard-1989a" TYPE="STUDY">Alvegard 1989a</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:20:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvegard-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:20:32 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:12 +0200" MODIFIED_BY="[Empty name]">
<P>Adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antillon-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:14 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT (2 different protocols)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antman-1984a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:16 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:20:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antman-1984b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:20:18 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antman-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:20 +0200" MODIFIED_BY="[Empty name]">
<P>Double publication of <LINK REF="STD-Antman-1984a" TYPE="STUDY">Antman 1984a</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antman-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:25 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antman-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:26 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aur-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:32 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bacci-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:35 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:20:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balwierz-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:20:15 +0200" MODIFIED_BY="[Empty name]">
<P>No randomization to treatment with and without anthracyclines; consecutive trials; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barr-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:30 +0200" MODIFIED_BY="[Empty name]">
<P>No RCTs; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellani-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:38 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berman-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:41 +0200" MODIFIED_BY="[Empty name]">
<P>Comparison of two types of anthracycline analogues; adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernthal-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:57 +0200" MODIFIED_BY="[Empty name]">
<P>Difference in treatment other than anthracyclines between study groups; possibly all patients received anthracyclines; possibly including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bessho-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:00 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biondi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:01 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Birch-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:02 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blakely-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:05 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs; comparison of chemotherapy and surgery versus only surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bradford-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:06 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breslow-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:08 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brouwer-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:10 +0200" MODIFIED_BY="[Empty name]">
<P>Follow-up study of <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>, but only 23/240 patients (9.5%) included; no survival data presented</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burnett-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:11 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caceres-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:29 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; preliminary results of <LINK REF="STD-Zaharia-1986" TYPE="STUDY">Zaharia 1986</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canter-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:30 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carlsen-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:31 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castellino-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:32 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chau-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:33 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chessells-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:33 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chessells-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:35 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Craft-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:38 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Creutzig-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:38 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Creutzig-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:40 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crist-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:40 +0200" MODIFIED_BY="[Empty name]">
<P>No data provided for only randomised patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Culbert-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:42 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Angio-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:40 +0200" MODIFIED_BY="[Empty name]">
<P>More than a 25% difference in cumulative doses of agents other than anthracyclines between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Bernardi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:39 +0200" MODIFIED_BY="[Empty name]">
<P>No RCTs; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Bernardi-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:38 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; treatment with and without anthracyclines not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dluzniewska-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:37 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dobashi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:36 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear if RCT; including adults aged 30 years or more; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunst-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:35 +0200" MODIFIED_BY="[Empty name]">
<P>Commentary on ineligible study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eilber-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:44 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Einhorn-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:46 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elomaa-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:50 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Etcubanas-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:52 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:54 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:01 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fink-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:05 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frappaz-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:08 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines; only poor responders received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fukuoka-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:11 +0200" MODIFIED_BY="[Empty name]">
<P>Adults aged 30 years or more; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallegos_x002d_Castorena-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:55 +0200" MODIFIED_BY="[Empty name]">
<P>No RCTs (3 different protocols); all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garbes-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:56 +0200" MODIFIED_BY="[Empty name]">
<P>Most likely no RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:22:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaynon-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:22:57 +0200" MODIFIED_BY="[Empty name]">
<P>Difference in treatment other than anthracyclines between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gelderblom-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:06 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glanzmann-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:02 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; difference in treatment other than anthracyclines between study groups; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:02 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:09 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:09 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grier-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:10 +0200" MODIFIED_BY="[Empty name]">
<P>Most likely no RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grundy-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:15 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:23:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gururangan-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:23:16 +0200" MODIFIED_BY="[Empty name]">
<P>Review (one study eligible for inclusion: published full text as <LINK REF="STD-Sposto-2001" TYPE="STUDY">Sposto 2001</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hainsworth-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:03 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear if RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halazun-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:03 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear if treatment other than anthracyclines was the same in both treatment groups; no survival data presented</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harms-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:04 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayashi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:06 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear if RCT; including adults aged 30 years or more; results treatment with and without anthracyclines were not presented</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hays-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:07 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henze-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:08 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hitchcock_x002d_Bryan-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:10 +0200" MODIFIED_BY="[Empty name]">
<P>After the initial randomisation to treatment with and without anthracyclines all patients received anthracyclines; outcomes were measured at the time all patients received anthracyclines; update of <LINK REF="STD-Sallan-1977" TYPE="STUDY">Sallan 1977</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hodgson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:11 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holland-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:13 +0200" MODIFIED_BY="[Empty name]">
<P>Difference in treatment other than anthracyclines between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Humphrey-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:13 +0200" MODIFIED_BY="[Empty name]">
<P>No data on any of the eligible outcomes provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iarussi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:18 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ihde-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:19 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Isu-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:20 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iwenofu-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:21 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jaffe-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:25 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janka_x002d_Schaub-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:24 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalapurakal-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:39 +0200" MODIFIED_BY="[Empty name]">
<P>Included patients from different studies; no randomisation between treatment with and without anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karachunskii-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:39 +0200" MODIFIED_BY="[Empty name]">
<P>Double publication of <LINK REF="STD-Karachunskiy-2008" TYPE="STUDY">Karachunskiy 2008</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karachunskiy-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:38 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaspers-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:37 +0200" MODIFIED_BY="[Empty name]">
<P>Conference proceeding of <LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kazanowska-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:34 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khattab-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:46 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinsella-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:47 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kobe-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:48 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Komp-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:52 +0200" MODIFIED_BY="[Empty name]">
<P>Some patients were randomised to treatment with and without anthracyclines; unclear if treatment other than anthracyclines was the same in that subgroup; results treatment with and without anthracyclines were not presented</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konopka-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:55 +0200" MODIFIED_BY="[Empty name]">
<P>Most likely no RCT; difference in treatment other than anthracyclines between study groups; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuleva-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:57 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:30:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kurrle-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:30:57 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lager-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:13 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:13 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lilleyman-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:12 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindberg-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:11 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Link-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:10 +0200" MODIFIED_BY="[Empty name]">
<P>Difference in treatment other than anthracyclines between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madej-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:09 +0200" MODIFIED_BY="[Empty name]">
<P>Most likely no RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madon-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:08 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahajan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:19 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahmoud-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:19 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maiakova-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:18 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malpas-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:27 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear if RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcus-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:30 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines; all patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matsuzaki-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:32 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maurer-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:34 +0200" MODIFIED_BY="[Empty name]">
<P>Preliminary report of <LINK REF="STD-Maurer-1988" TYPE="STUDY">Maurer 1988</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meisel-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:36 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meza-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:42 +0200" MODIFIED_BY="[Empty name]">
<P>No data on patients randomised to treatment with and without anthracyclines presented; subgroup of patients included in <LINK REF="STD-Crist-1995" TYPE="STUDY">Crist 1995</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miser-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:44 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moricke-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:47 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-02 14:32:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muus-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-02 14:32:45 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nachman-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:29 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nishimura-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:30 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear if RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ochiai-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:31 +0200" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oh-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:38 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okamura-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:37 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Omura-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:36 +0200" MODIFIED_BY="[Empty name]">
<P>Adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ortega-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:39 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs; data not presented for patients receiving or not receiving anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paulino-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:28 +0200" MODIFIED_BY="[Empty name]">
<P>Probably no RCT; difference in treatment other than anthracyclines between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paulino-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:30 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavlovsky-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:33 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pawson-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:12 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peeters-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:13 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perez-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:13 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfreundschuh-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:14 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Picci-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:15 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pontz-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:16 +0200" MODIFIED_BY="[Empty name]">
<P>Most likely no RCT; difference in treatment other than anthracyclines between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pratt-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:19 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pratt-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:21 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pritchard_x002d_Jones-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:25 +0200" MODIFIED_BY="[Empty name]">
<P>Double publication of <LINK REF="STD-SIOP2001" TYPE="STUDY">SIOP2001</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pritchard_x002d_Jones-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:05 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation to treatment with and without anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:31:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quattrin-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:31:53 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:32:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rai-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:32:41 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation to treatment with and without anthracyclines; all patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rammeloo-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:21 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raney-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:26 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raney-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:26 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation to treatment with and without anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raney-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:25 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raney-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:28 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCTs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raza-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:31 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rees-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:35 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines; all patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritchey-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:41 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritter-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:45 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:33:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:33:47 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sakic-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:22 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sallan-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:23 +0200" MODIFIED_BY="[Empty name]">
<P>After the initial randomisation to treatment with and without anthracyclines all patients received anthracyclines; preliminary results of <LINK REF="STD-Hitchcock_x002d_Bryan-1986" TYPE="STUDY">Hitchcock-Bryan 1986</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salodof-MacNeil-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:27 +0200" MODIFIED_BY="[Empty name]">
<P>No original research; commentary (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schaison-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:28 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scherrer-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:29 +0200" MODIFIED_BY="[Empty name]">
<P>Probably no RCT; all patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmits-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:30 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seibel-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:33 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silverman-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:34 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skoczen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:40 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smithson-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:42 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sotnikov-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:44 +0200" MODIFIED_BY="[Empty name]">
<P>Most likely no RCT; difference in treatment other than anthracyclines between study groups; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spears-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:47 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spreafico-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:49 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sramkova-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:56 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; historical controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:27:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stary-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:27:59 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinherz-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:00 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received the same agents; only the order and mode of administration were different between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinherz-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:04 +0200" MODIFIED_BY="[Empty name]">
<P>Double publication of <LINK REF="STD-Gaynon-1993" TYPE="STUDY">Gaynon 1993</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinherz-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:06 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; difference in treatment other than anthracyclines between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tarella-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:34 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; difference in treatment other than anthracyclines between study groups; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:36 +0200" MODIFIED_BY="[Empty name]">
<P>Including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tefft-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:38 +0200" MODIFIED_BY="[Empty name]">
<P>Preliminary report of <LINK REF="STD-Evans-1985" TYPE="STUDY">Evans 1985</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thirugnanam-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:40 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thomas-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:43 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup of patients from different RCT; no data on survival presented</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Toft-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:49 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tournade-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:32 +0200" MODIFIED_BY="[Empty name]">
<P>More than a 25% difference in cumulative doses of agents other than anthracyclines between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsuchiya-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:30 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; difference in treatment other than anthracyclines between study groups; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-der-Does-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:26 +0200" MODIFIED_BY="[Empty name]">
<P>Double publication of <LINK REF="STD-Van-der-Does-1989" TYPE="STUDY">Van der Does 1989</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vinogradova-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:27 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear if RCT; including adults aged 30 years or more (Russian article, no further information sought)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:28:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Virchis-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:28:58 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vora-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:13 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation to treatment with and without anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:29:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vose-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:29:08 +0200" MODIFIED_BY="[Empty name]">
<P>Probably no RCT; all patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watts-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:29 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinstein-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:30 +0200" MODIFIED_BY="[Empty name]">
<P>Review (no eligible studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilimas-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:31 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Willemze-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:32 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Willnow-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:00 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zaharia-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:00 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; update of <LINK REF="STD-Caceres-1978" TYPE="STUDY">Caceres 1978</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zdrahalova-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:45 +0200" MODIFIED_BY="[Empty name]">
<P>Double publication of <LINK REF="STD-Kaspers-2013" TYPE="STUDY">Kaspers 2013</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:24:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zimmermann-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:24:41 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation to treatment with and without anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zintl-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:00 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation between treatment with and without anthracyclines; all patients received anthracyclines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-04 12:21:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zittoun-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-04 12:21:00 +0200" MODIFIED_BY="[Empty name]">
<P>Difference in treatment other than anthracyclines between study groups; all patients received anthracyclines; including adults aged 30 years or more</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial; SIOP: International Society for Paediatric Oncology</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-09-04 12:06:56 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-09-04 12:06:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-FRALLE-2000_x002d_A">
<CHAR_METHODS MODIFIED="2014-09-04 12:06:52 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:06:52 +0200" MODIFIED_BY="[Empty name]">
<P>524 children (aged 1 to 9 years; sex nm) with standard-risk B-cell precursor <U>acute lymphoblastic leukaemia</U> with a good marrow response at day 21 (M1). Prior therapy not mentioned; prior cardiac dysfunction not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:06:53 +0200" MODIFIED_BY="[Empty name]">
<P>Treatment including (N = 247) or not including (N = 248) daunorubicin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:06:53 +0200" MODIFIED_BY="[Empty name]">
<P>No difference in efficacy and toxicity between the study groups at a follow-up of 31 months (unclear if this is a mean or median; range 3 to 59 months)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:06:53 +0200" MODIFIED_BY="[Empty name]">
<P>This study has not been published in full text (October 2013), but has been presented at the SIOP conference 2006</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-09-04 12:06:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SIOP2001">
<CHAR_METHODS MODIFIED="2014-09-04 12:06:53 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (stratified by participating group and tumour stage)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:06:54 +0200" MODIFIED_BY="[Empty name]">
<P>583 children with intermediate risk stage II or III <U>Wilms' tumour</U> (aged 6 months to 18 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:06:54 +0200" MODIFIED_BY="[Empty name]">
<P>Postoperative chemotherapy including (N=291) or not including (N=292) doxorubicin (total dose 250 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:06:54 +0200" MODIFIED_BY="[Empty name]">
<P>No difference in 2 year EFS and 5 year OS between the study groups at a median follow-up of 39 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:06:54 +0200" MODIFIED_BY="[Empty name]">
<P>This study has not been published in full text (October 2013), but has been presented at the SIOP conference 2011</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-09-04 12:06:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Von-Stackelberg-2011">
<CHAR_METHODS MODIFIED="2014-09-04 12:06:55 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-04 12:06:55 +0200" MODIFIED_BY="[Empty name]">
<P>420 children with relapsed <U>acute lymphoblastic leukaemia (aged 18 years or less)</U>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-04 12:06:55 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear from the current information: patients might have received anthracyclines in both treatment groups (N=210 in each group) and if not, there might be a difference in treatment other than anthracyclines between study groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-04 12:06:55 +0200" MODIFIED_BY="[Empty name]">
<P>No difference in 5 year EFS, 5 year OS and treatent related mortality between the treatment groups, significantly less relapses and mucositis, but significantly more hematological toxicity in the patients who definitely received anthracyclines (idarubicin)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 12:06:56 +0200" MODIFIED_BY="[Empty name]">
<P>This study has not been published in full text (October 2013), but has been presented at the ASH conference 2011</P>
<P>It is not yet clear if this study is eligible for inclusion in this review</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>EFS: event-free survival; OS: overall survival; SIOP: International Society for Paediatric Oncology; ASH: America Society of Hematology</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-03-26 14:14:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-10-27 14:16:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-COG-AHEP0531">
<CHAR_STUDY_NAME MODIFIED="2008-06-17 14:27:00 +0200" MODIFIED_BY="[Empty name]">
<P>Not mentioned</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-06-17 14:27:23 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-27 14:16:51 +0100" MODIFIED_BY="[Empty name]">
<P>Children with intermediate risk <U>hepatoblastoma</U>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-17 14:27:02 +0200" MODIFIED_BY="[Empty name]">
<P>Cisplatin, vincristine, 5-fluorouracil with and without doxorubicin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-17 14:27:03 +0200" MODIFIED_BY="[Empty name]">
<P>Not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-06-17 14:27:04 +0200" MODIFIED_BY="[Empty name]">
<P>Not mentioned</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-06-17 14:27:05 +0200" MODIFIED_BY="[Empty name]">
<P>Not mentioned</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>-</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-10-27 14:17:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00379457">
<CHAR_STUDY_NAME>
<P>A protocol for nonmetastatic rhabdomyosarcoma [RMS-2005]</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-06-17 14:27:33 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (patients are stratified according to risk group and participating country)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-27 14:17:34 +0100" MODIFIED_BY="[Empty name]">
<P>Children with high-risk <U>rhabdomyosarcoma</U> (maximal age 20 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ifosfamide, vincristine, dactinomycin with or without doxorubicin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response rate, survival and toxicity</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>June 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Study chairs Gianni Bisogno, Meriel Jenney, Joern Treuner and Hans Merks</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>It is unclear from the current information if the cumulative doses of agents other than anthracyclines differ less than 25% between study groups.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-09-04 12:06:52 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:46 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:54:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:57:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>Block randomisation was performed using a central interactive computerised system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:39:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>Randomisation was performed using the minimization method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>It was stated that randomisation was peformed by the DCLSG Central Office, but no further information on the methods of randomization was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:48 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:54:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:51 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>Block randomisation was performed using a central interactive computerised system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:39:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>Randomisation was performed by the United Kingdom Children's Cancer Study Group Data Centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION>
<P>It was stated that this was a randomised study, but no further information on the methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>Randomisation was performed by the DCLSG Central Office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:48 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>No information on blinding of participants and personnel was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:54:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:19 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>Clinicians were "bound to record therapy given" and were thus not blinded to treatment. No information on blinding of participants was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:42 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>It was an open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>No information on blinding of participants and personnel was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:39:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>No information on blinding of participants and personnel was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>No information on blinding of participants and personnel was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION>
<P>No information on blinding of participants and personnel was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION>
<P>No information on blinding of participants and personnel was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>No information on blinding of participants and personnel was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2014-06-03 11:35:00 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:49 +0200" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Blinding of outcome assessment (detection bias): overall survival</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>Since this was an open label study, outcome assessors were not blinded. However, blinding of outcome assessors is not applicable for overall survival, so we judged this as a low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:28:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:49 +0200" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Blinding of outcome assessment (detection bias): outcomes other than overall survival</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided for event-free survival and cardiotoxicity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided for event-free survival and tumour response</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:43 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>It was an open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided for tumour response and cardiotoxicity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:10:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided for event-free survival and cardiotoxicity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided for event-free survival, tumour response and cardiotoxicity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided for event-free survival</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:30:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided for event-free survival and tumour response</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:50 +0200" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Incomplete outcome data (attrition bias): overall survival</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>It was stated that all patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>Intention-to-treat analyses were performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:39:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>All patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:13 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>38% of participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:27:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION>
<P>All patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>All patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:50 +0200" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Incomplete outcome data (attrition bias): event-free survival</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>It was stated that all patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:06:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:10:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>All patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:13 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>36% of participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION>
<P>Unclear if all patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:30:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>All patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:50 +0200" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Incomplete outcome data (attrition bias): tumour response</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 14:52:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 10:15:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 10:14:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 10:16:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>It was stated that all patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>Intention-to-treat analyses were performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>Only 1% of participants were not evaluable for this outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:10:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:16:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>Only 1.6% of participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:27:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:30:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>All patients were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:14 +0200" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Incomplete outcome data (attrition bias): anthracycline-induced cardiotoxicity</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 10:15:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 10:14:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 10:16:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:01:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>7% of participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:10:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>It was unclear if outcome data were available for all patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>51% of participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:27:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:30:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:33:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:51 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but not all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:29 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but not all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:37 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but not all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but not all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-09-04 12:06:52 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:03:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> unclear (see information provided at earlier associated risk of bias items)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (unclear if age, sex and prior cardiac dysfunction were balanced between treatment arms; no prior cardiotoxic treatment)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (the study was supported by a US Public Health Service Grant and by the National Institutes of Health, but no information on the influence of funders was provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:55:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 11:56:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:41:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Angio-1981-IV">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1991">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> unclear (see information provided at earlier associated risk of bias items)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (for all four items it was unclear if balanced between treatment arms)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (no information provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:04:47 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaspers-2013">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> yes (see information provided at earlier associated risk of bias items)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (age and sex were balanced between treatment arms; no prior cardiac dysfunction; unclear if prior cardiotoxic treatment was balaned between the treatment arms)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (there was no outside funding for the trial and daunoxome was not provided free of charge, but two authors had a consultant/advisory role at the pharmaceutical company which delivered daunoxome and where compensated for this)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> unclear (see information provided at earlier associated risk of bias items)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (unclear if prior cardiotoxic treatment was balanced between treatment arms; age, sex, prior cardiac dysfunction were balanced between treatment arms)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (the study was supported by US Public Health Service Grants, but no information on the influence of funders was provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-3">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-03 16:40:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maurer-1988-Group-4">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:05:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nesbit-1990">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> unclear (see information provided at earlier associated risk of bias items and methods of the study)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (unclear if age and prior cardiac dysfunction were balanced between treatment arms; no prior cardiotoxic treatment; sex distribution was rather similar in both treatment arms)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (the study was supported by a Public Health Service Grant awarded by the National Cancer Institute, department of Health and Human Services, but no information on the influence of funders was provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perilongo-2009">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> not applicable (block randomization was not used)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (age, sex and prior cardiotoxic treatment were balanced between treatment arms; for prior cardiac dysfunction this was unclear)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (no information provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sposto-2001">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> unclear (see information provided at earlier associated risk of bias items)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (age and sex were balanced between treatment arms; for prior cardiotoxic treatment and prior cardiac dysfunction this was unclear)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (the study was supported by the Division of Cancer Treatment, National Cancer Institution, National Institutes of Health and the Department of Health and Human Services, but no information on the influence of funders was provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1975">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> unclear (see information provided at earlier associated risk of bias items)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (unclear if age, sex and prior cardiac dysfunction were balanced between treatment arms; no prior cardiotoxic treatment)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (the study was supported by Ministerie van Volksgezondheid en Milieuhygiëne, but no information on the influence of funders was provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 12:06:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Does-1989">
<DESCRIPTION>
<P>
<I>Block randomisation in unblinded trials:</I> unclear (see information provided at earlier associated risk of bias items)</P>
<P>
<I>Baseline imbalance between treatment arms related to outcome (prior cardiotoxic treatment, age, sex and/or prior cardiac dysfunction)</I>: unclear (age and sex were balanced between treatment arms; this was unclear for prior cardiotoxic treatment and prior cardiac dysfunction)</P>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (no information provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-04-03 12:43:28 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-04-03 12:43:28 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-04-03 12:43:28 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-04-03 12:43:28 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-06-16 12:53:14 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-07-10 13:12:45 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-07-10 13:12:45 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>No anthracyclines versus anthracyclines</NAME>
<IV_OUTCOME CHI2="6.378462872714879" CI_END="1.3196410690632991" CI_START="1.0238119829188412" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="1.1623529324860138" ESTIMABLE="YES" I2="0.0" I2_Q="3.0125811289909596" ID="CMP-001.01" LOG_CI_END="0.12045582293122024" LOG_CI_START="0.010220208321351716" LOG_DATA="YES" LOG_EFFECT_SIZE="0.06533801562628597" MODIFIED="2014-07-10 13:12:37 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7015236160284026" P_Q="0.38945230445825096" P_Z="0.020158215569827196" Q="4.124246264682953" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1141" TOTAL_2="1145" WEIGHT="500.0" Z="2.323389911727703">
<NAME>Overall survival (Parmar's method was used to obtain the necessary data for the meta-analysis)</NAME>
<GROUP_LABEL_1>No anthracyclines</GROUP_LABEL_1>
<GROUP_LABEL_2>Anthracyclines</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no anthra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anthra</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.9898759054107691" CI_END="1.5665284642450092" CI_START="0.9461685616005608" DF="2" EFFECT_SIZE="1.2174563580354887" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.19493829053737233" LOG_CI_START="-0.024031486376469572" LOG_EFFECT_SIZE="0.08545340208045138" MODIFIED="2008-10-31 12:07:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6096087882868105" P_Z="0.1260761743125709" STUDIES="3" TAU2="0.0" TOTAL_1="452" TOTAL_2="460" WEIGHT="100.0" Z="1.5297598855389571">
<NAME>ALL</NAME>
<IV_DATA CI_END="1.5128489539696823" CI_START="0.8403014372225825" EFFECT_SIZE="1.1274968515793757" ESTIMABLE="YES" ESTIMATE="0.12" LOG_CI_END="0.1797955693106186" LOG_CI_START="-0.07556489365383817" LOG_EFFECT_SIZE="0.05211533782839024" MODIFIED="2008-10-31 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.15" STUDY_ID="STD-Eden-1991" TOTAL_1="308" TOTAL_2="322" WEIGHT="73.5294026411941"/>
<IV_DATA CI_END="3.0563622623656637E307" CI_START="7.12390007E-315" EFFECT_SIZE="4.6661782370309847E-4" ESTIMABLE="YES" ESTIMATE="-7.67" LOG_CI_END="307.48520482870674" LOG_CI_START="-314.1472821810516" LOG_EFFECT_SIZE="-3.3310386761979416" MODIFIED="2008-10-31 12:06:52 +0100" MODIFIED_BY="[Empty name]" ORDER="2" SE="365.15" STUDY_ID="STD-Van-der-Does-1975" TOTAL_1="22" TOTAL_2="20" WEIGHT="1.2407976032065269E-5"/>
<IV_DATA CI_END="2.4595809653223157" CI_START="0.9231246580390038" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" ESTIMATE="0.41" LOG_CI_END="0.3908611233840472" LOG_CI_START="-0.03473964822338077" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2008-10-31 12:07:25 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.25" STUDY_ID="STD-Van-der-Does-1989" TOTAL_1="122" TOTAL_2="118" WEIGHT="26.470584950829874"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.246762577621157" CI_END="3.1531300860586255" CI_START="1.0885154074915335" DF="2" EFFECT_SIZE="1.8526280469916023" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.4987418884428049" LOG_CI_START="0.03683458068184058" LOG_EFFECT_SIZE="0.2677882345623227" MODIFIED="2008-10-31 12:04:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5361288894394693" P_Z="0.023052901814736623" STUDIES="3" TAU2="0.0" TOTAL_1="159" TOTAL_2="157" WEIGHT="100.0" Z="2.272556794002176">
<NAME>Wilms' tumour</NAME>
<IV_DATA CI_END="3.232270635895051" CI_START="0.6230148815842727" EFFECT_SIZE="1.4190675485932571" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.5095077168163777" LOG_CI_START="-0.20550157948410136" LOG_EFFECT_SIZE="0.1520030686661381" MODIFIED="2008-10-31 12:03:56 +0100" MODIFIED_BY="[Empty name]" ORDER="4" SE="0.42" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH" TOTAL_1="121" TOTAL_2="111" WEIGHT="41.73364232532913"/>
<IV_DATA CI_END="9.277386048783818" CI_START="1.0329514279532037" EFFECT_SIZE="3.0956565001247114" ESTIMABLE="YES" ESTIMATE="1.13" LOG_CI_END="0.9674256287509939" LOG_CI_START="0.014079900350355086" LOG_EFFECT_SIZE="0.49075276455067457" MODIFIED="2008-10-31 12:03:59 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.56" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH" TOTAL_1="16" TOTAL_2="19" WEIGHT="23.47517380799763"/>
<IV_DATA CI_END="4.444126927390053" CI_START="0.7322865111777759" EFFECT_SIZE="1.803988415397857" ESTIMABLE="YES" ESTIMATE="0.59" LOG_CI_END="0.6477864542017524" LOG_CI_START="-0.13531896555591516" LOG_EFFECT_SIZE="0.25623374432291857" MODIFIED="2008-10-31 12:04:09 +0100" MODIFIED_BY="[Empty name]" ORDER="6" SE="0.46" STUDY_ID="STD-D_x0027_Angio-1981-IV" TOTAL_1="22" TOTAL_2="27" WEIGHT="34.79118386667324"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.017578125000000003" CI_END="1.2927149405805833" CI_START="0.8296555935003987" DF="1" EFFECT_SIZE="1.0356197087996233" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.11150276820480245" LOG_CI_START="-0.08110215447157479" LOG_EFFECT_SIZE="0.015200306866613824" MODIFIED="2008-10-31 12:02:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8945235616530558" P_Z="0.7570482905196451" STUDIES="2" TAU2="0.0" TOTAL_1="207" TOTAL_2="202" WEIGHT="100.0" Z="0.30935921676911454">
<NAME>Rhabdomyosarcoma/undifferentiated sarcoma</NAME>
<IV_DATA CI_END="1.3959765937241992" CI_START="0.7455789580366128" EFFECT_SIZE="1.0202013400267558" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.14487813655244203" LOG_CI_START="-0.12750635727631188" LOG_EFFECT_SIZE="0.008685889638065021" MODIFIED="2008-10-31 12:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="7" SE="0.16" STUDY_ID="STD-Maurer-1988-Group-3" TOTAL_1="146" TOTAL_2="134" WEIGHT="50.0"/>
<IV_DATA CI_END="1.4384904102960876" CI_START="0.7682852177291665" EFFECT_SIZE="1.0512710963760241" ESTIMABLE="YES" ESTIMATE="0.05" LOG_CI_END="0.15790697100953957" LOG_CI_START="-0.11447752281921436" LOG_EFFECT_SIZE="0.021714724095162622" MODIFIED="2008-10-31 12:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="8" SE="0.16" STUDY_ID="STD-Maurer-1988-Group-4" TOTAL_1="61" TOTAL_2="68" WEIGHT="50.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="3.155608266805668" CI_START="0.41099210580361956" DF="0" EFFECT_SIZE="1.1388283833246218" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.4990830851191478" LOG_CI_START="-0.38616651982430233" LOG_EFFECT_SIZE="0.05645828264742272" MODIFIED="2010-06-01 12:13:30 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8025873488697859" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="129" WEIGHT="100.0" Z="0.25">
<NAME>Hepatoblastoma</NAME>
<IV_DATA CI_END="3.155608266805668" CI_START="0.41099210580361956" EFFECT_SIZE="1.1388283833246218" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.4990830851191478" LOG_CI_START="-0.38616651982430233" LOG_EFFECT_SIZE="0.05645828264742272" MODIFIED="2010-06-01 12:13:30 +0200" MODIFIED_BY="[Empty name]" ORDER="23" SE="0.52" STUDY_ID="STD-Perilongo-2009" TOTAL_1="126" TOTAL_2="129" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.4413728655994453" CI_START="0.9365091016991063" DF="0" EFFECT_SIZE="1.161834242728283" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.15877634203912194" LOG_CI_START="-0.028487997468146373" LOG_EFFECT_SIZE="0.06514417228548774" MODIFIED="2014-06-16 11:59:38 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.17268204142522786" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="197" WEIGHT="100.0" Z="1.3636363636363635">
<NAME>AML</NAME>
<IV_DATA CI_END="1.4413728655994453" CI_START="0.9365091016991063" EFFECT_SIZE="1.161834242728283" ESTIMABLE="YES" ESTIMATE="0.15" LOG_CI_END="0.15877634203912194" LOG_CI_START="-0.028487997468146373" LOG_EFFECT_SIZE="0.06514417228548774" MODIFIED="2014-06-16 11:59:38 +0200" MODIFIED_BY="[Empty name]" ORDER="28" SE="0.11" STUDY_ID="STD-Kaspers-2013" TOTAL_1="197" TOTAL_2="197" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.093013906655807" CI_END="1.4193632648018726" CI_START="0.9679793595725688" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="1.1721409232953806" ESTIMABLE="YES" I2="60.246508503155326" I2_Q="72.4931637286035" ID="CMP-001.02" LOG_CI_END="0.15209356086166362" LOG_CI_START="-0.014133903145436619" LOG_DATA="YES" LOG_EFFECT_SIZE="0.06897982885811355" MODIFIED="2014-07-10 13:12:45 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01954551572358698" P_Q="0.012243077745189734" P_Z="0.10380882509356194" Q="10.90637967376716" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.07464853249027441" TOTALS="SUB" TOTAL_1="854" TOTAL_2="871" WEIGHT="400.0" Z="1.626662369292529">
<NAME>Event-free survival (Parmar's method was used to obtain the necessary data for the meta-analysis)</NAME>
<GROUP_LABEL_1>No anthracyclines</GROUP_LABEL_1>
<GROUP_LABEL_2>Anthracyclines</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no anthra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anthra</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.2891089108910885" CI_END="1.4555138851996756" CI_START="0.7564018069008854" DF="1" EFFECT_SIZE="1.0492632332900846" ESTIMABLE="YES" I2="56.31487889273355" ID="CMP-001.02.01" LOG_CI_END="0.1630163528437651" LOG_CI_START="-0.1212474423783641" LOG_EFFECT_SIZE="0.0208844552327005" MODIFIED="2010-08-30 15:31:38 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13028482554247656" P_Z="0.7733532363800092" STUDIES="2" TAU2="0.03254999999999998" TOTAL_1="430" TOTAL_2="440" WEIGHT="100.0" Z="0.28799151197461753">
<NAME>ALL</NAME>
<IV_DATA CI_END="1.156265804080239" CI_START="0.7223859846618006" EFFECT_SIZE="0.9139311852712282" ESTIMABLE="YES" ESTIMATE="-0.09" LOG_CI_END="0.06305768181449001" LOG_CI_START="-0.14123068855707535" LOG_EFFECT_SIZE="-0.039086503371292665" MODIFIED="2008-10-31 12:08:09 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SE="0.12" STUDY_ID="STD-Eden-1991" TOTAL_1="308" TOTAL_2="322" WEIGHT="59.385813148788934"/>
<IV_DATA CI_END="1.863382076094568" CI_START="0.8848004345709153" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" ESTIMATE="0.25" LOG_CI_END="0.27030191368663564" LOG_CI_START="-0.0531546727350097" LOG_EFFECT_SIZE="0.10857362047581293" MODIFIED="2008-10-31 12:08:13 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SE="0.19" STUDY_ID="STD-Van-der-Does-1989" TOTAL_1="122" TOTAL_2="118" WEIGHT="40.61418685121106"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.7961413165580765" CI_END="3.3969823716279532" CI_START="1.4374565256026848" DF="2" EFFECT_SIZE="2.209754393016085" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.5310932931389212" LOG_CI_START="0.15759471876941158" LOG_EFFECT_SIZE="0.34434400595416637" MODIFIED="2008-10-31 12:05:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6716147929039167" P_Z="3.0157183171387685E-4" STUDIES="3" TAU2="0.0" TOTAL_1="159" TOTAL_2="157" WEIGHT="100.0" Z="3.6139460564297536">
<NAME>Wilms' tumour</NAME>
<IV_DATA CI_END="4.608899901090377" CI_START="1.4219238870084194" EFFECT_SIZE="2.5599814183292713" ESTIMABLE="YES" ESTIMATE="0.94" LOG_CI_END="0.6635972759535135" LOG_CI_START="0.15287635002459993" LOG_EFFECT_SIZE="0.4082368129890567" MODIFIED="2008-10-31 12:04:57 +0100" MODIFIED_BY="[Empty name]" ORDER="12" SE="0.3" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH" TOTAL_1="121" TOTAL_2="111" WEIGHT="53.48236351381711"/>
<IV_DATA CI_END="3.8635383434841337" CI_START="0.6366193091638591" EFFECT_SIZE="1.5683121854901687" ESTIMABLE="YES" ESTIMATE="0.45" LOG_CI_END="0.5869852267352971" LOG_CI_START="-0.19612019302237044" LOG_EFFECT_SIZE="0.1954325168564633" MODIFIED="2008-10-31 12:05:04 +0100" MODIFIED_BY="[Empty name]" ORDER="13" SE="0.46" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-UH" TOTAL_1="16" TOTAL_2="19" WEIGHT="22.747697146708603"/>
<IV_DATA CI_END="5.322716498461223" CI_START="0.9121199321137962" EFFECT_SIZE="2.203396426255937" ESTIMABLE="YES" ESTIMATE="0.79" LOG_CI_END="0.7261333351502541" LOG_CI_START="-0.039948053743116246" LOG_EFFECT_SIZE="0.343092640703569" MODIFIED="2008-10-31 12:05:09 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SE="0.45" STUDY_ID="STD-D_x0027_Angio-1981-IV" TOTAL_1="22" TOTAL_2="27" WEIGHT="23.769939339474274"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.3820863945343733" CI_START="0.7381603234510263" DF="0" EFFECT_SIZE="1.010050167084168" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.1405351917334095" LOG_CI_START="-0.13184930209534446" LOG_EFFECT_SIZE="0.004342944819032472" MODIFIED="2008-10-31 12:02:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9501646619403569" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="145" WEIGHT="100.0" Z="0.0625">
<NAME>Non-Hodgkin lymphoma</NAME>
<IV_DATA CI_END="1.3820863945343733" CI_START="0.7381603234510263" EFFECT_SIZE="1.010050167084168" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.1405351917334095" LOG_CI_START="-0.13184930209534446" LOG_EFFECT_SIZE="0.004342944819032472" MODIFIED="2008-10-31 12:02:24 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SE="0.16" STUDY_ID="STD-Sposto-2001" TOTAL_1="139" TOTAL_2="145" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.5477281017846527" CI_START="0.4245234153579236" DF="0" EFFECT_SIZE="0.8105842459701871" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.1896946680612196" LOG_CI_START="-0.37209835046058537" LOG_EFFECT_SIZE="-0.0912018411996829" MODIFIED="2010-06-01 12:12:14 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5245394401852961" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="129" WEIGHT="100.0" Z="0.6363636363636364">
<NAME>Hepatoblastoma</NAME>
<IV_DATA CI_END="1.5477281017846527" CI_START="0.4245234153579236" EFFECT_SIZE="0.8105842459701871" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.1896946680612196" LOG_CI_START="-0.37209835046058537" LOG_EFFECT_SIZE="-0.0912018411996829" MODIFIED="2010-06-01 12:12:14 +0200" MODIFIED_BY="[Empty name]" ORDER="22" SE="0.33" STUDY_ID="STD-Perilongo-2009" TOTAL_1="126" TOTAL_2="129" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="9.481937309967511" CI_END="1.040023696572256" CI_START="0.9848813200249217" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0120770282628107" ESTIMABLE="YES" EVENTS_1="821" EVENTS_2="839" I2="57.8145280944311" I2_Q="33.63374950285898" ID="CMP-001.03" LOG_CI_END="0.01704323465774979" LOG_CI_START="-0.0066160996177382" LOG_EFFECT_SIZE="0.005213567520005775" METHOD="MH" MODIFIED="2014-06-16 12:03:23 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05011975547835135" P_Q="0.21048057069357762" P_Z="0.38770065195192693" Q="4.520369883076695" RANDOM="YES" SCALE="2.3378644093513388" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0014019743947706626" TOTALS="SUB" TOTAL_1="961" TOTAL_2="971" WEIGHT="400.0" Z="0.863794767105164">
<NAME>Tumour response</NAME>
<GROUP_LABEL_1>No anthracyclines</GROUP_LABEL_1>
<GROUP_LABEL_2>Anthracyclines</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anthra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no anthra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1733318410052331" CI_END="1.0556414730203338" CI_START="0.9873957160606927" DF="1" EFFECT_SIZE="1.020948513959581" ESTIMABLE="YES" EVENTS_1="414" EVENTS_2="415" I2="14.772618874532021" ID="CMP-001.03.01" LOG_CI_END="0.023516444024390393" LOG_CI_START="-0.005508761353107043" LOG_EFFECT_SIZE="0.009003841335641683" MODIFIED="2008-10-27 13:52:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27871774645855285" P_Z="0.22398809785978258" STUDIES="2" TAU2="1.0793324767188552E-4" TOTAL_1="430" TOTAL_2="440" WEIGHT="100.0" Z="1.2159917224256511">
<NAME>ALL</NAME>
<DICH_DATA CI_END="1.0668189293536092" CI_START="0.9976465773366889" EFFECT_SIZE="1.0316531653165317" ESTIMABLE="YES" EVENTS_1="299" EVENTS_2="303" LOG_CI_END="0.028090713092907126" LOG_CI_START="-0.0010232830578844852" LOG_EFFECT_SIZE="0.013533715017511312" ORDER="15" O_E="0.0" SE="0.017101705455580225" STUDY_ID="STD-Eden-1991" TOTAL_1="308" TOTAL_2="322" VAR="2.9246832948942245E-4" WEIGHT="72.59889781994274"/>
<DICH_DATA CI_END="1.055062434386536" CI_START="0.9348153357331757" EFFECT_SIZE="0.9931206088992974" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="112" LOG_CI_END="0.023278160209314964" LOG_CI_START="-0.0292741715797005" LOG_EFFECT_SIZE="-0.0029980056851927686" MODIFIED="2008-10-27 13:52:48 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.0308694998311055" STUDY_ID="STD-Van-der-Does-1989" TOTAL_1="122" TOTAL_2="118" VAR="9.529260198226225E-4" WEIGHT="27.401102180057265"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.092168160922622" CI_START="0.9106905283965385" DF="0" EFFECT_SIZE="0.9973099816849816" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="168" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.03828951175531693" LOG_CI_START="-0.04062918026450938" LOG_EFFECT_SIZE="-0.001169834254596196" NO="2" P_CHI2="1.0" P_Z="0.953664028670451" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="205" WEIGHT="100.0" Z="0.05810620901607917">
<NAME>Rhabdomyosarcoma / undifferentiated sarcoma</NAME>
<DICH_DATA CI_END="1.092168160922622" CI_START="0.9106905283965385" EFFECT_SIZE="0.9973099816849816" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="168" LOG_CI_END="0.03828951175531693" LOG_CI_START="-0.04062918026450938" LOG_EFFECT_SIZE="-0.001169834254596196" ORDER="16" O_E="0.0" SE="0.04635723034627187" STUDY_ID="STD-Maurer-1988" TOTAL_1="208" TOTAL_2="205" VAR="0.0021489928053773097" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0771678761669126" CI_START="0.9570765791554519" DF="0" EFFECT_SIZE="1.0153482880755609" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="121" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.03228339318778769" LOG_CI_START="-0.019053311362066047" LOG_EFFECT_SIZE="0.006615040912860842" MODIFIED="2010-06-01 11:45:22 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6134843017418645" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="129" WEIGHT="100.0" Z="0.5051061247172768">
<NAME>Hepatoblastoma</NAME>
<DICH_DATA CI_END="1.0771678761669126" CI_START="0.9570765791554519" EFFECT_SIZE="1.0153482880755609" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="121" LOG_CI_END="0.03228339318778769" LOG_CI_START="-0.019053311362066047" LOG_EFFECT_SIZE="0.006615040912860842" MODIFIED="2010-06-01 11:45:22 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.030155434373370035" STUDY_ID="STD-Perilongo-2009" TOTAL_1="126" TOTAL_2="129" VAR="9.093502222466271E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0062122102478506" CI_START="0.7464738585572294" DF="0" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="135" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.0026895831259740517" LOG_CI_START="-0.12698539662366298" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2014-06-16 12:03:23 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.060290805966361306" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="197" WEIGHT="100.0" Z="1.8786609286920648">
<NAME>AML</NAME>
<DICH_DATA CI_END="1.0062122102478506" CI_START="0.7464738585572294" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="135" LOG_CI_END="0.0026895831259740517" LOG_CI_START="-0.12698539662366298" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2014-06-16 12:03:23 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.07617172500643901" STUDY_ID="STD-Kaspers-2013" TOTAL_1="197" TOTAL_2="197" VAR="0.0058021316904565655" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2423096289822136" CI_END="1.3243573395543615" CI_START="0.05963265233148125" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2810248045854506" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.12200518273048845" LOG_CI_START="-1.2245158737448318" LOG_EFFECT_SIZE="-0.5512553455071717" METHOD="MH" MODIFIED="2014-06-17 15:44:10 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8858968032734749" P_Q="0.6506923235088005" P_Z="0.10854040006409932" Q="0.20502840798138386" RANDOM="YES" SCALE="888.1819134572171" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="393" TOTAL_2="411" WEIGHT="200.0" Z="1.60478830729528">
<NAME>Clinical cardiotoxicity</NAME>
<GROUP_LABEL_1>No anthracyclines</GROUP_LABEL_1>
<GROUP_LABEL_2>Anthracyclines</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no anthra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anthra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03593923140525734" CI_END="3.892281128268317" CI_START="0.04313649792238984" DF="1" EFFECT_SIZE="0.4097552645212791" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.5902042005701934" LOG_CI_START="-1.3651551164128621" LOG_EFFECT_SIZE="-0.3874754579213344" MODIFIED="2014-06-17 15:44:03 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8496411065685784" P_Z="0.4372910371463383" STUDIES="2" TAU2="0.0" TOTAL_1="196" TOTAL_2="214" WEIGHT="100.0" Z="0.7767758445447516">
<NAME>Cardiac death</NAME>
<DICH_DATA CI_END="8.019362164295796" CI_START="0.013511136200687978" EFFECT_SIZE="0.32916666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9041398271940622" LOG_CI_START="-1.8693081280363915" LOG_EFFECT_SIZE="-0.4825841504211646" ORDER="18" O_E="0.0" SE="1.6291370576911617" STUDY_ID="STD-D_x0027_Angio-1981" TOTAL_1="159" TOTAL_2="157" VAR="2.6540875527426158" WEIGHT="49.70649139531081"/>
<DICH_DATA CI_END="12.165516842263251" CI_START="0.0212772609609287" EFFECT_SIZE="0.5087719298245614" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.0851305643128577" LOG_CI_START="-1.6720842798599282" LOG_EFFECT_SIZE="-0.29347685777353527" ORDER="17" O_E="0.0" SE="1.6196016479006923" STUDY_ID="STD-Nesbit-1990" TOTAL_1="37" TOTAL_2="57" VAR="2.6231094978826377" WEIGHT="50.29350860468919"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6963749045666479" CI_START="0.02357969331680152" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.22952183907130705" LOG_CI_START="-1.6274618477433447" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2014-06-17 15:44:10 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1400879136065908" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="197" WEIGHT="100.0" Z="1.4754637259332477">
<NAME>Cardiotoxicity grade 3 or 4 according to NCICTC version 2</NAME>
<DICH_DATA CI_END="1.6963749045666479" CI_START="0.02357969331680152" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22952183907130705" LOG_CI_START="-1.6274618477433447" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2014-04-29 09:21:48 +0200" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="1.0908014098524261" STUDY_ID="STD-Kaspers-2013" TOTAL_1="197" TOTAL_2="197" VAR="1.1898477157360408" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.23529411764705882" CI_END="2.1081717737237495" CI_START="0.7706802231426666" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.2746475171577791" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.32390599427345984" LOG_CI_START="-0.11312578554521192" LOG_DATA="YES" LOG_EFFECT_SIZE="0.105390104364124" MODIFIED="2014-07-10 13:12:11 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6276258293389784" P_Q="0.6276258293389785" P_Z="0.34451103293053287" Q="0.2352941176470587" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="134" WEIGHT="100.0" Z="0.945289649033324">
<NAME>Overall survival Wilms' tumour long-term follow-up (Parmar's method was used to obtain the necessary data for the meta-analysis)</NAME>
<GROUP_LABEL_1>No anthracyclines</GROUP_LABEL_1>
<GROUP_LABEL_2>Anthracyclines</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no anthra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anthra</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="2.175347615639547" CI_START="0.6205255646827499" DF="0" EFFECT_SIZE="1.161834242728283" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.33752866611424176" LOG_CI_START="-0.2072403215432661" LOG_EFFECT_SIZE="0.06514417228548774" MODIFIED="2010-06-01 15:42:39 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6392483445793793" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="106" WEIGHT="64.35781413156978" Z="0.46875">
<NAME>Stage II-III FH and UH</NAME>
<IV_DATA CI_END="2.175347615639547" CI_START="0.6205255646827499" EFFECT_SIZE="1.161834242728283" ESTIMABLE="YES" ESTIMATE="0.15" LOG_CI_END="0.33752866611424176" LOG_CI_START="-0.2072403215432661" LOG_EFFECT_SIZE="0.06514417228548774" MODIFIED="2010-06-01 15:42:39 +0200" MODIFIED_BY="[Empty name]" ORDER="24" SE="0.32" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH" TOTAL_1="121" TOTAL_2="106" WEIGHT="64.35781413156978"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.6665699897347634E-32" CI_END="3.500075407811316" CI_START="0.6487002629901066" DF="0" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.05.02" LOG_CI_END="0.5440774011627213" LOG_CI_START="-0.18795592600205488" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2010-06-01 15:43:35 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.3403426966783474" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="28" WEIGHT="35.64218586843022" Z="0.9534883720930231">
<NAME>Stage IV</NAME>
<IV_DATA CI_END="3.500075407811316" CI_START="0.6487002629901066" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" ESTIMATE="0.41" LOG_CI_END="0.5440774011627213" LOG_CI_START="-0.18795592600205488" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2010-06-01 15:43:35 +0200" MODIFIED_BY="[Empty name]" ORDER="25" SE="0.43" STUDY_ID="STD-D_x0027_Angio-1981-IV" TOTAL_1="20" TOTAL_2="28" WEIGHT="35.64218586843022"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.09722749715153814" CI_END="2.7243869344899774" CI_START="1.0859700340296221" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.7200588861890567" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.43526878884280124" LOG_CI_START="0.03581784161090222" LOG_DATA="YES" LOG_EFFECT_SIZE="0.2355433152268517" MODIFIED="2014-07-10 13:12:31 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.755182483291368" P_Q="0.755182483291368" P_Z="0.02080774429250653" Q="0.09722749715153814" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="134" WEIGHT="100.0" Z="2.3114548499282055">
<NAME>Event-free survival Wilms' tumour long-term follow-up (Parmar's method was used to obtain the necessary data for the meta-analysis)</NAME>
<GROUP_LABEL_1>No anthracyclines</GROUP_LABEL_1>
<GROUP_LABEL_2>Anthracyclines</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no anthra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anthra</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="3.122987000134422" CI_START="1.042071005338669" DF="0" EFFECT_SIZE="1.803988415397857" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.4945701764230783" LOG_CI_START="0.0178973122227589" LOG_EFFECT_SIZE="0.25623374432291857" MODIFIED="2010-06-01 15:50:27 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03510519837787376" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="106" WEIGHT="70.22407899734144" Z="2.1071428571428568">
<NAME>Stage II-III FH and UH</NAME>
<IV_DATA CI_END="3.122987000134422" CI_START="1.042071005338669" EFFECT_SIZE="1.803988415397857" ESTIMABLE="YES" ESTIMATE="0.59" LOG_CI_END="0.4945701764230783" LOG_CI_START="0.0178973122227589" LOG_EFFECT_SIZE="0.25623374432291857" MODIFIED="2010-06-01 15:50:27 +0200" MODIFIED_BY="[Empty name]" ORDER="27" SE="0.28" STUDY_ID="STD-D_x0027_Angio-1981-II_x002d_III-FH-UH" TOTAL_1="121" TOTAL_2="106" WEIGHT="70.22407899734144"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="3.5707816212437984" CI_START="0.6618048775782157" DF="0" EFFECT_SIZE="1.5372575235482815" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.5527632908007863" LOG_CI_START="-0.17927003636398983" LOG_EFFECT_SIZE="0.1867466272183983" MODIFIED="2010-06-01 15:50:36 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="28" WEIGHT="29.77592100265857" Z="1.0">
<NAME>Stage IV</NAME>
<IV_DATA CI_END="3.5707816212437984" CI_START="0.6618048775782157" EFFECT_SIZE="1.5372575235482815" ESTIMABLE="YES" ESTIMATE="0.43" LOG_CI_END="0.5527632908007863" LOG_CI_START="-0.17927003636398983" LOG_EFFECT_SIZE="0.1867466272183983" MODIFIED="2010-06-01 15:50:36 +0200" MODIFIED_BY="[Empty name]" ORDER="26" SE="0.43" STUDY_ID="STD-D_x0027_Angio-1981-IV" TOTAL_1="20" TOTAL_2="28" WEIGHT="29.77592100265857"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-09-04 12:06:53 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-09-04 12:06:53 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeoAAAOzCAIAAAD4EdJ7AAA9+0lEQVR42u3dsY4TydrGcUtIiGAC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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-10 13:12:38 +0200" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.1 Overall survival (Parmar's method was used to obtain the necessary data for the meta-analyses).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4gAAAKACAMAAADpSqYlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-07-10 13:12:46 +0200" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.2 Event-free survival (Parmar's method was used to obtain the necessary data for the meta-analyses).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2oAAAIACAMAAADE7W+xAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAABN10lEQVR42u29C3Bcx3km+g+AOWfODAjgDACLpKkIJBDJZVvaFfgA
8WAUDShracarex3ZWxWtdGVtlZxU4ui6wqtcqxzTdrzXlqtcWVUc61GbUlRaraJdOZa1ZqS1RUQ2
MBA5piCXojglGSCgBwlJAE4DIAaDmcHj9unzfszMmcHMwQDzfxJxek53/92nu7/uv/v0fzogAgKB
qDzqsAgQCKQaAoFUQyAQSLWyIBZ7XP6T079NyOttFeUlZHssFmvTfw2Hyyy+PGUChXOl+NOH4bmw
/jxt3h/H/4xynDBSQrkXhwakVG78UV7fG2CoCFkewq6p/xScPlpm8b5jCNpueMVcWkNVWs9DkDp5
3FzuFckojmp50NfCLk0818wcWYHnhCjt88QInwrSzo+NbSfkOxEBEmEuGE6BdIoGSgixdjpKhaQm
PhjJ6iOPHA/oPe6UBMMR2pcmzMll4Dxk5ZApIRTlFPHDYX6Y3mkUoJ2GD7WBtMFzkfZwLAuJmKCk
pYuX49H0OX5DgnZBDlepklGfNSYDshGOF+RcRkKQDfOmNe1Z2nUo+WaPIw8WTRzf5GMV6nljGdXq
LxwGSThhyqgA6+oz6Rml5dyEVPMLXSsS/dt86EzkICNdk5RO9i5Tx3q4/76sMpT8RWNavvPie3DT
XGb5qAj7xyJv997EUdJkge84dKalp1kXKMeD/Yd+1ji2H27peZ+Gs45qs7AqO65q7FvOKOJPTvTf
Qi8zl2CJz7zddwU6BsPJnqUg/Bw+BUElLV2AHI+m3xge7ID/s3epuWepUiWjPuvQ0DcgAc0vZJZ6
n6R3X7gMDUfDxsAMw1RrUvKtPg60HIoIh5r9q0I1b0NDX6f9mF5/cwvwZO85S0br1WfSMto0eCZS
3owi1fLgf/QdoH/T0DQBKfl36uqmP6HdH8DkDDyhhrlzht35RCukLpxqonRZgfE9Q6n36RiVAS4D
3TNDy7pAFi8NoXEaah32vvhsypSa1BsX4n3yGPWSIlPG1B7mTEUhVdd0D2zAYZgIDqV+ArdRJs8p
aekSWDx6b4ImPQFN2e+kKjEJkgdb9VlBOh4gsPz7TU2sPD4ZBR4mpoygp89HtHyrSMHERTjkz2xN
zuhynZI36dsj/2TUH1VJnrdm9NzP9WdScBi6J2hZlhEBfIWds67g2b13jcNQ8NgQxOJpuUvuvu1b
18NQjPZ7Mf2iOeGl/+98WPWl4DeSjYEV9YcSRA0cPEbvjGQe/+IAjArESC/6b88nIz2/knKIF29M
hG4wiR/pb0i5iecG5F46K6b6ID4vlL1Mhtgf9Vmh6dDYvJyz39yh5kzLNXOlmusuR035pv/4fnoZ
yfhQeUpm1LxB88HXiLn+rBkdjgXfi5rqjxVjuTOKo1oeROnwA3AcJAkC8u9luPPN3KFPwruybxxk
rROCA2I/B6PKDwvq4dmhoQx84f1fne1btuiPPbEeRYN0QxLeeYteRjXxNx8LQpeL+IAsPgvk8p2J
/oppauqztqdfmWc54zWPuFxY+gxI6OvQ8m0M3pKfjU7NWyL1CrHWnyWjxxqPdmjPpBNDq3Wkmh+4
OMoqZawTQvLPu+HaTtNMztHO07JvCLqmYwL8IxyBM8DBWHssbA3F7kUgfPsL1rrMwmtDv4KsqS3Y
amrXGIvdmaXiOeihytozSloWhKBzmiYp3P7/vENZXTGwZ031R1jOrhvTbvPQ2WEEWhhdmVbzPaI8
Ds3dAZp536Dm7eaBn9rqLwid+41g5JVUVn0mtdw5vdaRar4Ma3IznrpwMvnqvPyzN/5vTM3/2ZGr
LYEjXR2ypj95Yanj/CKERmD0GEydPblwfsEqlN2bh4VPHtt7bpept1+F/w0fwLqWQmTko5Zo4Xjk
RZabZCSxCB/EYXRGS8uCyQvJjvMvw8/PL151vrFSBTMfZ896BG6gMyJhdOGzmsccv2zmd2jgt9V8
Pzqyj+WuO3nwwqJ/NRhW8tYDp2lGzfU39MqyuZ/jjrWo9aeW+9SFbydfXcC5WvVD2rWr7/XZyomH
vX1nBCzm7QSkWmXAb9SFpcqJD63XheaxlJFqCAQC52oIBFINgUCqIRAIpBoCsa2oJjXy3GAkweyw
TMhju5PYGOT4SNZDyGLgEBPT7LHKYH8Uc5ehPXtM2QJeCVhFD0egvMVmFW+qQ5v4WBYkPsZJkI3x
jhCqqy1slRyOySYC7bETelIcd6LNS9WZ2kojx53K0lRZNlu4RwEeGlbL4gQ32JjYVDnkyGP7pvIY
pHmMlC+P9Uad7F2av/Lrm7+5evTqSXOI/TCZK/J/P/bUd5du/nevFg5ZDBxi9sOQcrNQAoo/Db62
FPvP2g6nt/dNwqQeb9Jdxvd7lGencScnJytCtclJWTiYclXWYrOKN9WhTfz+N4N/exh+66vLmWvf
z2hRbWGP7pu0lOqHe95NAyQP/HJFq481sW0y66HqDDx9RArCfDpz7dkpmt5d8bNr0595jPlMd793
6YGD38puphyMPCbSm8njP7dtGHkcpXn8L1oe37282TyaRrX7YRWEoZWgZrDDLJFCIoBse5WNsU0q
p3jZ2ojZT4G8lejjNMZjWmiA5hNCFhLhUAsbh8JhzdZLDRCLPc6Hs16ypaQjCSdabP1IheyPVpVn
90OPYPng5Vypz1JeMHsw9tCqTZkdtC5hmP5rh6Bs+9YkyaWj1pliH6eayhm4CP3076dhxrg1KxsJ
aXXB7OSUtqKVcyzWEuFbWkK8loEMSLLBwW5ggZ4IbsDH1FF1d78QlYaWN/ncM2oeZzeVR2Ec0u55
DG86j3VmZ7dc8VmTSW9Dj/weVra9elJuHdA8Fj7DjHhmLrEhEW60NpWNc70/gMNHf6KMKHPvmmy9
FNwXOerF7ltN57d6zxG7T2Xsj9Rn9wFKPtJyrnQ7rzJCsQdjD63alNmxRnsVnv5bgw87BsMLh9hO
QL3OZPu4jN2oO3o+3QbD6fNB41YbBI38Mzs5pa0Y5bwx39+9caX/PjXC3fLWwg2aboqLzNFWdreU
vqj4hODNMjx4sIg8NpvzuL7LmkdQ8pgtex5NVFschd7TEYtdMA/jvwSQba/+hO0RXYGJJpBH6FRU
9v65PcbUBDxPs9WkECTVarL1UgOMA+8hV2o6PTCxCtZZVoXsj4xnr9hczZkP3c6rjDDZg1mfX0Og
N5GJvzOSTfQGgodhIsWq06gz1T7OBo4OGgMQNNXFDYkFI//MTk5pK8bzTdLgs0H9+UIgdMlma4Gl
xp5rQIgcPMDv51kn3A/Rcjx5jjzWueTxkDmPczOmPHbpefyzsufRRLXg5bFR6LHYBQ9A9AjVxuKr
06ujsvawIf+Wa09J+MjlV60xolE6nqzDEeWBo3IXesSSRxrAi2GCms4wRI2iGxqSu1rxa+tMndmf
jhyBlhv+8h9gQElpQ5atBf3GMHTBS6cfboRjxjhH/Tdy9on6sw8p6VQMpnyI1yvPUl6wOpBhfX4N
5+CVYw3RhoEYdQ3D7bcrzDLX2YBT5sRwSBKGLxp18auRtStG/o/IkZS2YjyfXBtB0J/ve4mmdDwA
ybPBcdpzz2c+tzKbbmJdzgiUZQebnMeQJY9xOY9fy5VHcMvjFT2Pj5Q9j+bF/uj85dfUbjDOFEk5
BTmJ4MBvD3DqCCvBcVOMhctjtJpGQM0JM/GpB0mfj9Urt4a1AAlvOVbTCZhtihRUyv7I9OyVXvLV
82G28yofdHsw6/PrnQqdk3O0e8/Sv3WK5ZxST/nm0FG+X+zjTZ2mFO4VbflXKyBXOQeXsskNtbXJ
3l0Nwb6ZNWU4uq4sXQzNY78lj4IjjyOmPEKOPNZXKo8mqoVi0ejz0MDssAIwLS/mpqGrg15k2ytW
a89A5xiMmmKkov+Lxrgb2jqU1Z1OWpUpGGswRnVm9VMP7UqA412eFEg1ne9ajJ/U/FbE/kh79spD
zYecK7OdV7mg2oMptnTpTmeAf6V9+Dh90n5aKRwcyCrWdLTOWi0t0pHrQbbWouvW8x/ns9b8ryht
xVnOSiSBb48OCBC+t01pAikCo9Os9QncV6Wo3aivpJK153GUb7fmMe0hjyFTHgUtj6H45vNootqV
80nu64mXmR0Wid8jKxSr55YekhMagdE9bFn4QvLkBcOI5xeJ3wseT8xDb3xJsfarXx4dos38eyKo
r7VkW68L80BGr/yjktzS+TkvK9dKOr3nUnUwYvGpkP2R9uyVn6up+QjH91nsvMr2SkGxB5PrUH1+
G/bQumyFmVEYeYvm5WAksaB0Td8zlbRqW2bC+AiMjDMSanhqoMWaf7WtuJQz02cjdQvJOyWIPLV4
41k6qR6uDwLfwdaxZ3704u4kK/vNwZlHYWA5XEIew3oeZyCk5HF2/iubzqOXnf2ycVQRtldc+OL4
/3s+6eITK/IDe7xwcdet55Oxcn6XL1a1XyPcStA623XruYKL2e1XSngfMn0g5eejVG0evVCtSNur
4U+tQTA84zrEF/dZlJS4sUElcQBl+5wKBxtZZFYRdWZBpHAQJxpfOObno4QjVZpHtFdDIBAIRAXx
+/4m14CjGqJW4W/bRyMaBAKphkDsVKpFlFdKI2GOa8xa7zErnnb9DaGPR2UhEDuNatlwj+K4Ze3t
5iMt1ntwFYAvO5cQiB1PtVs1Ryq95031VZZ+j53+lcYCQyA2T7XEu4a7U/3eu3FvDV50s69AIBDF
Um3J2HE6nISw9V6iN3As0CthiSEQm6aagfbBgTEbq/4dnKP/dWKJIRDlo5q0WHfG/kX4VXb613/C
EkMgykS1WAyegV0C2Bb0s/Croa/DD7DEEIiS4GoN+WVmAW4xNpH2wAfBEKxKt7OvKQ2BdkEgEF6A
O/sRtYqYvyMFbsxCIJBqCARSDYFAINUQCKQaAlGjwBVIRG3BvDejBUc1BAIVSAQCUQrMu0WUs0gU
jZK4KpbKXaIEUi85glYFiP6pFlueXUJYH67ymcqVI3/EE6Wmzd5ECS96q1FH0eqxZBG6LwFnQuYE
TIVOQKwZqhV8VKKXDv2nXoBU78MRvdnY8uwSwvpwlc9Urhz5JV60Py1RbxDRE9PsRWtqB+ZkVbpb
80FcW5RIoHaoZhSAqYOnRa+PdMStzHdGCanPUfmOVfRFvJg/sfL3JrnbgZyW6B7UFMmPEY1tn/8H
+42hLaQaYQqA0V2Jph7K75bjG2psJdapSZvaf1nLzylOdLr8UR6HCt7wjWpGv27uosRcmiSQ7dnG
POhGFc6CqbGVf25IrNPtnPqjPk0y3yby/8U2fE/tIF+x6r15rc7VcpSgUh3aZbv02uasb/kAal0W
KHMr89JsRXt5EJPGWVzDL0eZ1oRK0VBCAYjboHzEkut0p3SveQc1Z3kQY5mDlJMn+qpLze+VqMuv
EhCoMe3RD/XRF/H5meaoQ1EUS+w7STHEr2W4zdUMDdG19NX7Iqn6gV/U1lBz5tkIoRdBpR/LmpWy
l6L2RNq7qpyatCl1Yn3lJXqYqzmKFrwUq+NFS8UmrFUI3AOJqIzmWvzY5vfIh1bYiO3OtarUrKt6
WQSBKEWFLclr56uQOKohEEg1BAKphkAgcK6GQHiGbpXd4h/VSD7rM8dtD/vg3azb/H2D4mavZttl
7r+9mrvVX7nFF3wcIroXkNedYnog+4NY7NXcH9M1bk3ZqxUFEQrUiZt1W+XNweytwWpU5djm6b+9
mrvVX7nFF3wc4lpAnu3VjKV554OIhQwF3ePWkL2aaDLys9ipOezXRGsU92GrqgzZCm/E8y27VsO4
StmNlfI4YvHJlPQErnnzdURT0v8h+xtwdAAVyk5D7rFA3+DttF9zCe7ovqpSGyCb2YhcVtZXWLxY
dHMnUMzGYLG8JeCz8qgkpuwWmferBTTkLglz0gXs1/IXJQHzNretGus0/ZF4+6yDXzmqrL7qfXeh
0k2WaK+WezNn/q2e2u2as1cTVd2QlNQGiXvdqnuXib43dSv1StFL29xJc4Zcc7WcptElN/wcKeWf
kmq3a9VeLee3eUSPmou1TMWtU8nzN64tViT9GNTydow515pJhYq2xmG1wrZ8PcltQHOZpzmUkHz1
sGW1Qjx+R8/f5dEtK5Fyrntuc6a1bAnVcuhQ7vZr2iuqAvZXFTbP8jJTIbrdVmF7Nd8yWMCgzJ+5
movVmUd7NVPn6lK0uQwF7fZq28f0sQxAezWEf6o62qshEOWdB/oYDUc1BKLKEawLhCUc1RCIikJq
5j98f3qCT+GohkBUkGj7kzOqcw8RfB/VpEaeG4wk9Ekj+6A5tIX1AMMRsHlGBUg0ctypLGRjMqCF
exTgoWE1/AlusDEhhw1FsXaNcuZo4bVFOE7IsjLfyJZVfJZndZOQL9kNjm906Ehh2ecUx9G6MdJP
NA7K9djMtwCcKtzVh2N6m9nQa581jJgmW/nF7osh7sSwEbkxZslrywlOGAZVgB9INH58SmMaTK/w
j/uSar1B6b1L81d+ffM3V9Wf+2FSvhzdN6kFeNtwKp7S+Uvpp49IQZhPZ649OzU5CXfFz65Nf+Yx
5Rm637v0wMFvZWnYyOd/9iByTMXDR2nh1WWb30p8sPadY7N833y6nOKjPaxunpFT+XNhLnjoVMZK
xcZe6iMGpOcufiVgpP/YsQeeo/UYaFpezb5ekM67jiqtQ42fuTbx5uSk0jCGNNn01+Tk5K+vPZeN
3jg7/97TWo8y/YiSQy2vYverQ3/7dHZyP0z6Uv7Z5oez7yjOVtanLP292OSDHmka1e6HVRCGVtiI
xXqYlpCQ4NhxHRs81wS87MxGOF7QOqjO9BnIgDRB/+xWXow8EdyAj/GK7+5+ISoNLTNCjx9Aimkt
rZ9Vb2ZmHOrh03BxHDJlbUgKb7NM6PdhYgKOWQPcyrayZ2C8GwRT+gJ0y/W4PrMGrXyhRG7VHGr8
qyBo8lVlK8OeOPwypEdIMJPUvO9Yt+Y1OyIdMXwrjXaBf3durlXmGYB2nZ7nh/2kWh10C5YE13/a
G8vIx3U0D56JHGpOM+cLmaXeJ9UAafg43A1UQdmgLE1xkTlabndL6YuKbwje1CSNQxY5pmL3ObV4
To8uwFmIRmnplRE/UBT+hp/Kfzdk8VfbtKcF3ecuU/p3Ka666Topc7GgBvae6lDjr8PyvXLtK1Bl
MxzoCx+BOwJh/iFdj73tkjWvf0B9Iz6tBKaEty7L+XT8e/+ToZR/VFschd7TxlwNYCoEPcxxSO7x
Vphzua6pCZ5QA9AOkBJK6JIrK7DU2HMNCJGDB/j9PNvs0g+mGRpSTWulYfX90eX/0PdnMKA0zfKh
7UXWaNv/8HeUKqD4O2uIpaDu84Qp/XHFFeoQDnCdXIHdSktazarxN+JNvT3f0HxV2WxQS41SrXC8
fy7yY53x90WteR3v/5tIz9X+lP5HN1pzea3v9Y9qwctjo9Bzk0nrPwK/UNY35G5Kgfi19YtKWap1
9L1EUzoegOTZoKxJzGc+tzKbbmK0HAG9q4oaBni1jpu1taXo5+ARWkYAZS2blQfYJamYPcZzhosr
9Wekr7rm0xdTU8vJz3tMTo2VTM/cRp/GKltGV3+KtZzUOKzmyisd59x8K7MktfLzfYrOaPu3e//7
xD+qQXT+8mt0pIprY5Akqd51slNBEt4xNPkAJVNwKZvcqNN+08JtCPZRfZ+Cg+v0J0SKaei5Iaae
VimX16BcsuWk2pHTTPxRJZWALH7Qvd6lBP1jpF+v1fEBPtoffMJjcub8B0yytZYzx5ShuPvYreY1
Xu6RPS+OJRv3tTKdsVXVHem1/sD0fMUXyU1UC8Wi0eehgRbZdBu70fEGLSh5bOJgrJNqinGQS/C6
MT1GAy0hgW+PDggQvretS144gRSB0WkmVeC+KkVjTB3fZZk21zSGhobkOa9wb3snLa+4XLJc+cWr
Fx66xuAf3cIFofNWeFBLPxaTb3QxXqRpJG/qfiymxRe49jdA74I56OyEv2JLa19i+9l5OPAvdGJv
Wc2nP/RMjgm0dfmGYHLm6lZ1jsa6g92vfkB8eBtlotqV80nu64mXgcTvUYhR/6lXfgmPjuyDqQvf
Tr66AOH4PgiPLnxWj/F9CEOkbiF5pwSRpxZvPDtFdc36IPAdbPlp5kcv7k5SeRSr+BE8GxqfWui+
sAhTiZPJs3MVS2X27NLJhKtiNNedTCZ6Tem/lEgudVM1rq1uBg5GvL7VVeM3BhduuTClpyrLPsic
j7E+dvHCwUFZtrs+u3jhZHMFy8AFrUuz1/wb7cdVB6aP+/Lad1O7RaS93KKngC2paXyJXROI5Tlf
uv3KSqlRKzBrO7A0A61zV4Uv+tUyN7cxK7qy7Clc6OEvYCusCXCQe/NLRJjNp9fVbWT8zWtD/fqu
cf+GANwDiajZERjt1RCIHQikGgKBVEMgkGoIBAKphkAg1RCIGoV5F4f9s6RFfyzM/slVdZ+C7bus
4Dx6qcBpXJYTppSv7xYnQftks8uRT2AS6vwYofvxa6aHzJUbEEs4sgxRK1TbNETnb9ePwxNni893
GpdVjFi8hBw9B7F4uZ0Xl+P4NcsJZG6fXS/tyDJEDSqQhBD1+7vMZXbSi3IElOZBwPwLjPB2eaD+
IwXbneVz5kT7hDJosp0SxJxsB1M8UoB6BQZsm3jjPL48nEaGIfKOakbfbTtrTe2kwX4Im3Eop3a4
gphjcNAPZiCFm6Joc2v6qXcJhl6rHUhgiiTmIJ2rXNshH0SEPM+jf5S7qCPLEDVENeJNNcx/2Jro
VJfcTqYpcIy262lc+SQ4ppjENct5PnLtpKCnnImu/YLRDZV2ZBliZ1NNm/ibZzH5WqYXknrxdmPV
5gaCEo5JE8uWM5cuoSbO6kOUsCziYbJRzLFpbie2kWLat/s5eJZ5nW1QE/OSXizcLxS9+ponFtnp
J6ojSqYa5F3zdz9sTf/lutxG7MOb6JVXYq6TL8U8uSVijmHVA4PE4hjvjIXjF8Ir1Ywjik0nXxln
YTkPWzP9cjuhz4jj2r0XOI3Lw+lbRH/fZT3tSx3hCmmTOdficx2/RvK+KbOfGlbckWWIHYqS7NWI
uBnvciVTRgnFpkTwpfQOgM/2akW/wiaeZmbbDEW+YkaWIXygmliGEGVLqmwSxOLFIt0QRQG3GyMQ
SDUEAqmGQCCQaghE9cG0LOJqXWbsKCxyH7x9C6/9zZJ5+zEUZX9W0LZM9VYuuFqIqDqq5XtXtMkG
m28LYH47Maf9WWHbMtHMUOQaonoVSGKyQVON02yma4YvuBu1WWUR1cjNsHhTTNs8EFksmdtl6CEQ
iIqMarbhwWxwbDNdA+t+CadRm02WaLFqY/+bLb7yaZIFxtccccxMw2ENUa1UKzCm2LYCW02OPVui
uBCjgPJKbAzD98iIbU81daggnlsycXU6f5OS54G2HcPIMMSOoJpYeJkk1yDlsEwTvU+88iqDYjFx
cKaG2DYKpFerYZE4TTPzjlpOczIi5iWiu/0ZDm+IHUA1m7kVsdqrgfOX1ajNYhpmiWSyeGNy1e/q
uLwlM8zCrPZnUIxtWRH6KQJRcWy/89VKsS1DIJzA89UK6qzINMQ2xDbcAylWMDQCgVRDIJBqCAQC
qYZAINUQCKQaAoFAqiEQSDUEAoFUQyCQaggEUg2BQCDVEAikGgKBQKohEEg1BAKphkAgkGoIBFIN
gUCqYREgEP5TLRJjl5EwxzVmZVdbmOf+VHbxsSxIfIyTIBvjYzGIxVyEKTfbBCxWBMKOehMvsruO
wqTseHr97ce752SGra83SU1SBmD1wJvBvz0Mv/XV5cy17785CfuVkFZceneN/j169SSWK6L6sd/f
dmoe1W7VHKn0njchI7tW0jNXmCsK7ZCFYfqvHYLK6BWLRQW+ueXeUBSGIxwnJCAoSwtSHza+sbFP
DHMtLTw/DLDBc01geERCWNeIWlUgE+8a7k6o111ymA9hDVaBp//WqFvF6mL/wfW/6VuGW3ref7v3
Jkim5LERwPR9vfWJge71qf5boGnwTORQs+HxwmUsfEStUm2pVXcOJyGsuNqSIOuYwUBvIhN/ZySb
6A0EtVAvBdm/NViHvS8+m3KTP7kHYG4PDXAYuidgxfD4ZBQLH1G7yyIa2gcHxiSFaVcGHmDfOD0H
rxxriDYMxKhLwxHl3zFYGOl7cq/rFxejiko5QHXPaBQ2rB4IRI1TTVqsOzOv6JRX4Mxx5grC/cBR
DTJL/zogvP+rs1SPNBBniqQ1IUmCAIxQmVjqCKQaW+2AZ2CXoLgOB6bUJcp/hX4Yhwb6t94pJXx7
/SrlkYIukDk13WYNwsFYJ4Roeu3HsdQRSDUFX+6/PqasMob67lBde0ZgtBVmRmHkLWeEhU8uNJ7b
pf54duRqIPF7gtYgUxe+nXx1AcKBKzyWOqIGEcBv2iNqFHgSDQJRMwokAoFAqiEQSDUEAoFUQyC2
FA1YBAhELswbzhYc1RAIVCARCISbAsm2FcuvtImo/LPBdkv5SdQo6gHvWhh6VZ2KSw8shyOii7hK
gOjHzusu91RdAlYwV+aCK38xENHl4vLAcvKW51ZuiN6y5BJTK2GbCCI6i5XYSptoSdfKXE0015Cz
vEVHZems1MhJCiTnb2EaXYbuIl4DVpT/poRIZcTbLjlqwvy0ot4vemKaS0zthvWpiEuxEpsUpQsm
UDtUUx5YNBcoUccsUeOTMToQtwrY7sXlw0grElNCZS8xVaD1kmvkE3NpLEWUkymmmLMdiHklVUez
cctDIL93Uc2loWA5qv/bOzNx6wet0hti9ZBZrJB4sYB44qKkiKWxTlcCDYli/hI33WORqqPZuOVi
vow11ZBTP2DDm1F4JG9vIHqc4hgzu6rotNzDib7xfkvblapQi+YbshZDPBYBscQ0zc6LeNpCkXa0
Allkw1TqJscUx8k/i3bvZ8syslm4EdZA5Yv2pxWt0/UiikDM2+u7CXJTOWuYap4n7GLVLIJ4ySaB
6iFSlTLaq47tMftaiVuWAKB2xjIDda4lyP5YipxscvSrjimvKIoF+E9qg2mO9UlScvbzx9RK3Py0
hWth549qJMdIpKpfbnMy9YZIqlEZUHOlzEHyroJ5DVjOxr6VRWatNvNzqxM2j9k3YroVnMEvI7ht
PaDKdciWMsrybIVN0FwbsdmWkr8R+d3EfLbC9rTdmNTYBBaxFarxDn+D7Y1qSDNEEcppiQ1pp7cy
3G6MQCDVEAikGgKBQKohENUHn+3VRItfxVd3iWW3ObispbqF8Gl+bjVb81m8rdr0uvdsr2Z9hy0a
jYeJyG8o6PBVXrpt9cKIsre4xQ+q+WCv5i/MXQZxewZnCB/s1dzKz2/xtmrTG7xnezVzTZsFKM78
hoIOX+WC9mo7yV7NW6P2h2lGUYmVFZ/nEcXiC8chn4iFBIheyrfChe5WGj+0/Q7kDFmW3NaKvZpm
Kpk7j1rj8UmPMe1ZEispvvhuyBPlRKcOnvPTCmJh6le80N3E23eLzFe2Dftsr5a3l/GngRdoSX5b
UFU8PZKfWsS+pdWzvZq3MnV9Pi0BrdnUhNmaz/Zq1l7G9230YuFOXfSf/JWUTor8ZEfp9mp5vYnd
9tw6k6uJ7Ui1Yq9W2ERqZxpRieBxUDM5SusBC2wl3gal21JZ8f7aqzGRW1HkqokUKRhih4F4ZVoF
kshZujt9X7GXUa3y9mr+GigZ5li5ki8cwp8s+i1esx9zmpF5tFezhHauMeaw/1NX1Oy+VW+2Vhag
vRqiMvPiEpRMtFdDezVE+WZtm9NEd+CySLUubyCqHmiv5nFZBIFAINUQCKQaAoFAqiEQW47K2av5
dohaHriYY+U8FSKXRVuF81apV0rE2PEjekldv1HK+Wo20zc3ezXb142NeqkeezUbym2+ViP2aoY5
luOznwUs2iqct0rZq6lyc51F4kjduFHs+WrOB3GzVyOuLQnt1UwFWrq9muiflaXnxleuUGVAhXc3
Fzg5bdOpF3nChaW1ENGnQsg/KDvs1Wzwbr4mlkY1Rz3tkPPVCnKosEXbtkTxfUclepvcWvsWQU6/
wG6RcpuvbZW92lZO3wrVAfH14yIVS66wYR44LMdKOV/Nw6b+3GVMoLKFUM0KpMcWaaJgLns10eNX
Kvzsy3KbbxW2aNuRcLMcK6ehpluJiy7p1wAqaq9WfXqUmLfz9bfWfRnUiFjsmFf8+Wpk8zaL1ci3
cpuvVdJereoGNQ/2amRnMa2g+lgG+fmP5c17j1Qx0yo7qu3c89WsN4oJUTnWmy3GKiW+gHc5zlez
irIXqyd7NQK1YLCG9moI/8ZTtFfzonch0xCV7ZXRXg1phihObS+xIVVbK8u2pTZ4EqzcsggCgQCp
JRSa+uDDd5dCTQm/52oIxA5D7rlaqi09o/9oDT3fHS3vqCY18txgROdwLMYubWE9wHAEbJ5RARKN
HHcqC9mYDGjhHgV4aFgNf4IbbEzIYUNRrFgDYVp4anlJEZ5rypZXfISKlxTxMeXilv4pjqN1I9f5
Bks/0Tgo12Mz3wJwKpU/hZEwjZxVWgfP/SlzNcbUhhHT8qBoYYPMJXF6LtojHB9uV335GGh5cMno
FimOjfzKewbTYO7SwfbG4c3LrRd0596l+Su/vvmbq+rP/TApX47um9QCvG04FU/p/KX000ekIMyn
M9eenZqchLviZ9emP/MYCzPd/d6lBw5+K0vDRj7/sweRYlpN9tLCU8vrb3r+ua17Pl1G8e2BHir+
sT3n36LiJycnf33tuaxL+mJAeu7iVwLfOTbL97H0Hzv2wHO0HgNNy6vZ1wuk8fT62493z8li19eb
pCYpA9OP9CjNZT/QoaK9Tv1FO+M9zPXwUe0G1GWbpN8dX1N85XB7l1geJvfrQXzCfpf0pEcCfReW
WtW+RrsK7/9g166p75VtVLsfVkEYWmEjFuthWkJCgqNugA3a9wIvO7O0TxI0inemz0AGpAn6Z7cy
q30iuAEf4xXf3f1CVBpaZoQeP4AcU3Er2zGullcWhHFaemXE9awRrwOnNh1x+GW39DMw3g0CfBou
qukL0C3X4/rMGrTyBdJIpfe8qcRaSc9ckV13rFvyoHXXkFB6kfZ+w3MpM3tOXY3LMt8X9Txs+QQt
Gmmbmn6FDmStMs8s15mpjwpitkxUq4NuwTJOrv+0N0aLYAiaB89EDjWnmfOFzFLvk2qANHwc7gaJ
UpGyNMVF5mjp3S2lLyq+IXhTkzQOWeSY1voW5L9qeW0opVdG3HZZEZ/kwlQ0HOgLH3FLfwOiUbgL
zsoXlv5diqtuuk7KXCycTCfU6y7ahm67ZPY8f1lzHVamHx+eM3uHTr/yDnP8gPleredha9HW9JmJ
92gTnoMc/y5fDEXay0K1xVHoPR0xrbdMhaCHOQ7JPd4Kcy7XNTXBE2oA2gFSQgldckEFlhp7rgEh
cvAAv59n28f6wTRDQ6rpvbqyfKyUFwc/FmC9nOLvUwo9PhI5ejXtp1Ojk67ps2HmCRhQaMd6Q+YK
dQgHuE6u0P6/4SSoc/i2JB0QtVRVJLVf7YzukA1b3pldfq33Ghb1RcmU8tZj7XyhEBsb/1AWqgUv
j41Cz03GjegR+IVSsHK/o0D82vpF0NQBuXy+l2hKxwOQPBuUtYD5zOdWZtNNjJYjIOmSVDs7hN4a
lfIiiS+2j1TghUsyfWSCDm3Q1Z9yX5GKK/U3wliv1BZzzacvpqaWk58vMCEcHBhTKrftysADud89
LyuBWiKWu9EJYJrjygNgSnnLMZv88MCeVlB1Rpd/u/fPLh8rC9UgOn/5NTpSxbUxSJJU7zrZqdYh
vGNo8gFKpuBSNrlRp/2mldsQ7Jth8wUOrtOVYOSWGwK09DJLgfrKpTCnKiMu9S4l6J9BuWZZM6/X
6vgAH+0PPpF/TrNYd0YxnExcgTPHcwfsOSnP+6HnBnYxr8bJf46cZrdpHrLV0RVHyUq6o6FV1Ret
14+s/SY9v6mFdBPVQrFo9Hk6YQ3AdBu70fEGrSh5bOJgrJNqinGQuXfdmB6jgfaLAt8eHRAgfG9b
l7xwAikCo9NMqsB9VYrGmJ6xC4JILAvU8hL46Wj/XPnFU7kCrTH4Uq7tQEHovBUepFVKa5aTV8Ho
jS7GyzQPXQXU/Wdgl7xwTWMdDkwJuUJR76GhIXmCr16U1XyBa3+DPrnhS/PwEW0VZ8sRXMi0trSp
3ZTWXUH7R9/IBo5sUrSJalfOJ7mvJ14GEr9HIUb9p175JTw6sg+mLnw7+eoChOP7IDy68Fk9xvep
wh6pW0jeKUHkqcUbz05RXbM+CHwHK/6ZH724O5l4WZmlNyC7LFDLKxLoWH5NKL/4xfqO5gt0lvZY
rj5urjuZTPTCVOJk8ixrUy8lkkvdVOVsq5uBg5H8Wfpy//XqW7BQ3x1FvA9jWmtjcOGWCwumu0Ye
qgMzgbXQR02/W/c89+FmFEddh9nMbhFpL7foKWBLahpfYtcEYpB7u3z7lZVSo1Ymr3nSkw6sHPwJ
tM7BRyIzZdLINrcxK7qy7Clc6OEvYCusCXCwkVP7jAiz+VS3uo1M9VBNnoce5te+/Hez5ZuZ4x5I
RK2OwP6OorizH4FAqiEQSDUEAoFUQyCQaggEUg2BQFQOlvPVbN/DLfrLR/YvULseo+Ty+a3cZ3VZ
bpqPwClOgnbwUM5TGtRP+joe2C5XCUXMXzbMnRsCIn7UD+FGtU1DdP52PaWNOBia86wucJwHIBYv
wb3nMIUxfa0+v1zjBKzCz+P5rDJEDSuQhBD1m7PMZXbSC2taugcB8y8wwtvlgfqPeG1+xmGJ6seV
SbES9ORd8lT8x9CsX/4mhnSkE6LEUU07xdF0Gqho7qtN/b1+AJtGCe2L4znGD+PwzsLNXbS5Nf3U
uwRDr9XUPtdIVq7kkEtMB82K6gBX8HmQhQhXqhFvqqH53AxnU3I560l0+VFCGxQ9SMjxzX09y2JO
JuhzLtHTPLTw8xRzVhmixqimn05CCrOPgDeSevEuI0o/FVjclHeuKETEkQ2RZ1nEw0nHYhEN0e1A
elJcA3Zpr6QUClgiuZMgr9zcx5K5a6YEmxgiH9Ug75q/+6lY+i/XVTdiH948UyTn8fVi0QyzRcpB
m9IGIRy6ECVQTdTfZJmmPpbTkm1zItMvtxP6jDiuvbzjvC3rqWcejjzLLyFHusapXjmX5POdE5Zb
Lyz2rDJETaAkezVPJ1KWZ97lj4RiUyL4bnoHoBrPV7OrYv4wzUcU+aYZWYbwgWpiGUL4Nv0RK5OU
iJMzRNHA7cYIBFINgUCqIRAIpBoCUX0wLYu4Wpfp78mKe2MsOrbw2l8wmbcfQ2H7M8srdW+2ZW4X
XDtEVAHV8r0r2mQTzbcT0JOdmHlXplfbMrcL2o8hqkmBJCYbNNU4zWa6ZviCu1GbVRZRjdwMizfF
tC0nkR0bLDfPEKQYompGNdvwYB4GbKZrYN0v4TRqs8kSLVZt7H+zxVc+TVJVXcUc42vRW45xWENU
D9UKDAXWzY2i5VMEXhu9q9WY6CBYTt2zgG1ZDi0WRzZElVFNHSqI55ZMXJ3O38T7PFB0JeCmtEFc
FEFUG9XEYqdIti3vOUkheiBskV8NwXkYYnsrkF6Nh0XisLIkeUct+wfwzHZuBQa6zQ1vOKIhqo5q
VpMvvY3mtFADq1GbxTTMEslk8cbkqt/VcXlLlstODIqxLXO9IOMQW4Ttd77a5siCVENowPPVCuqs
yDTENsQ23AMpblFcBKLGqIZAINUQCARSDYFAqiEQSDUEAoFUQyCQaggEAqmGQCDVEAikGgKBQKoh
EEg1BAKBVEMgkGoIBFINgUAg1RAIpBoCgVRDIBC+US0SY5eRMMc1ZmVXe5jnwm2yKxaLyn9cRLCb
Vh/jl+qyeLtKKeiFQOwYqmXDPYrjlrW3m4+0yK7ltV3Jo0vK3eVNJDM0hEWNQKppuFVzpNJ73oSM
7EqmZ6+CgHK3T/kGzgbPNcnDjxjhU1ZZTTzXTAkbCckBJeFEizJGJfhQlrrosBjmH1dChmLt0B4T
6C2BbxL5UFSWxwsS9WoTTtDh8xTPs0R0/2yE44VhrC/EjqBa4l3D3Qn1iuPefzt6SXHFUzIVmgbP
RA5RRsG60H+fRVTzoTORgy3Q0BOWwz3Ze075ilz2dwKTQeZam+j/IyUoDw9CFjiA1cX+Q2tLffKA
uRbufZJe/qIxvQzNY+EzLBHdv/mFzBLzRyC2P9WWWnXncBLCius7Y31XKy6h73/Sv4ehewJWqGNy
Fp7QZ1jy8JWGpglIURqN/5L+eh4mVpnnrr7QHiXY5B5YV1w/gT+moyYl4JTyT749NQH308udM/TX
Ckw0UXkm/+W6piY9PQRi+8H6deMYKHOq9oWBsXn1nnR7PM28nt270Q9D3MAQxEYyckg1NLvQP8Fj
9FY8rfqwcDAUg/j/9VRScWkxZF9IRgJaUN1XF8siD2dN/uKNid/cATjjQ5QP1fB1Y2mx7sy84240
1M8iSJI2e9PGMwXHFZ+4fKEcVi4A8/+jp80hKz3QMvAl662sSezdcuTjZt8kvMNj40DsEAVSYw88
A7sExRXip7sgpPpc7KJ/OBjr1O/AkGlpMa74rEBXB/31X6CzQ9E7Z0aSTtpCD/yd9VZrJ3xXcz8D
nWMwas3ndWNYW4gdRTWKL/dfrw5XV+o7li4saPzolWdPF76dfHXBLdbUhZPJV+dh9dzSQ/TXwXOp
OhiR7weDvY6lw4lhGJ215SR5rldzT15InrxgSSQ8uvBZrC3EjpmrlRG8cHHXreeT7p7Srqbe12fd
ZokIxA6dq1WMailxYyMYnnH35AKBsGS9o7zHQyB2KtUaKiVYWAHI5BjUZFqtOO4gEKhAIhA7Bs61
9RZf0sWd/QgEUg2BQKohEAikGgKBVEMgahSWxX7Z6iXXiiQRbSFFx8UWpgpA9OfJlUUjhOpFKn82
vSWh8qenPSIRXas0R+r6DdFjPeqB7EUri9DlMkMqR8nb47ILAbFmqKbUjddipv+sF6VYq4pperPJ
lUUjhOpFxIr3GMSlCMsuXr+K3lI3bhDRWxOwF6FRtGa5Gt0tJU9c25FIdjTTXBVIAkQpHdOFyOWj
3sjRD5Pq75TyZNHkJfqRB9GXR3Q8cLkqqQjBeYL63WII0Zuw43bFie7YLaKObPYxSyzcA2+D4V/0
4FVpPUb05xGJSNz0YbEEFnl6igJMIyKpgobCUp7fopZrppqoKfZeypHsUMVa7VJ8mUiKYFetKtG4
inkc2gRE4uesiSUlEoCdv2upwWVEc5Q+1NDuLdHHlGhZK227etRUsTK9TU55YmUmrNU+V8tR5aLb
hJXg3skyEa5CBUlIicNlmWtWW3QiQGq8puvcR/VCBESmbV5zqqj2SPtHqKJFYTU7eRtaLSmQxlzN
rEFrCqSyGqtNL5jTFqL6RgyiTVZyZdEI4be67E/ZFXhulwJSlVrvY5ZbEo5ideuhSfU3oLIiUEMr
Hgh/xmuxFC//2h0a0SB2mG7sU7RtPVfDQQ2xqXlZbq8S41UCf9148q+3XIFEIHY6UuJ06xz8+Z3H
kGoIROUw/MwP5hTXHtvnpPxRIKVGnhuMJLSf6neL28JGBiNg84wKkGjkuFNZyMZkQAv3KMBD6mcf
h09wg40J9uXWKFavgTAtvLYIxwlZkCI815Qtr/iIev4Pvai14pJ+9hTH0bqR63yDpZ9oHJTrsZlv
ATiV8vQMaptR4jdqB+nFNNnKLyV9iTPnQg2rlkE2zHORLMR8O1sveuKTf6kyDaYn+JRPydYLunPv
0vyVX9/8zVX1536YlC9H901qAd42nIqndP5S+ukjUhDm05lrz05NTsJd8bNr0595THmK7vcuPXDw
W1kaNvL5nz2IFFOQbeylhVeXbX4r8cHa3/T8c1v3fLqM4tsDPaxunjlKL5lrE29OTrqlLwak5y5+
JfCdY7N8H0v/sWMPPEfrMdC0vJp9veAz7DqqtA4t/vQjSqq0YQxpsumvycnJX197jlLxYTU8axda
WLUMGnsff+7gbHZyP0z6Uf5ta+/+c6tKL/m6tNqyFPR5VLsfVkEYWmEjFuthWkJCgpO/hqqcqcbL
Tss5Z53pM5ABaYL+2a1MeZ8IbsDH1I/r7+4XotIQOwCxfvwAckzFrexkgqXMzDjUQxaE8fJ+mO/6
NYUMTOhVEMyRfgbGu0GAT8NFNX1BPmEoA+sza9Ba8HQE/SQ+Lf4d6yZfVbYy7InDL1P+95u89bBq
GazDsVlY9Ut1DP2GMn9OPnOpVbu+v8K3+Uu1Oui2Hha4/tPeGC3GIWhmZ6qlmdN8zlkaPi6fZEGp
SIsqxUXoqJy9W0pfVHxD8KYmaRyyyDEVCfUD6aHTowu04FjplRG3XWaXhp+yGoTleyNzbulvQDQK
d8FZ+cLSv0tx1U3XSZmLBZ/hPdWhxb/tkslXlc1woC98BODDc+YcGmFZGQQhNQxpn4h20zTI5WH7
9/5vQik/qbY4Cr2njbkawFQIlBN7D2lnqoH1nDPaAVJCCV1yYQeWGnuuASFy8AC/n2fvBPvBNEND
qmnQtJXL/6Hvz4CDHwuwXk7x97FCb//D32GNPt7U2/MNt/TZMPMEDCjUYL0hc4U6hANcJ1fgpe6S
VrNa/PvMk3FVNhvUUqOT8snPxJFDowzeGT15Ou7PqPbv++dy+Kz9vZ9UC14eG4Wem0zTxyPwC6Uz
kLspBeLX1i9Cv959AXwv0ZSOByB5NihrEvOZz63MppsYLUdAX9yJGuc5IbQy+Rw8AiTxxfaRCmwj
SP5QuaRnbqOpuCCu1B87vySg1BZzzacvpqaWk5/3mI4R3ylbRld/iraclki+Mniy7xuv9/tkt3S2
c7eqO1r+7X71gy/4STWIzl9+jY5UcW0MkiTVu047K812zlmAkim4lE1u1Gm/aeE2BPtm2HyBg+v0
xU1klhsCtPQyS4H68ks+ekOMTbLdmKBVaYL+GdRPy6vX6vgAH+0Pej2fddBy2p4hW2s5c0wZ6jHl
xlkG98tzNb8+JC+lm3aremOrdr1q//RxH5bITVQLxaLR56GBPvy0MkvseIMWlDw2qWeqxUGynnPW
QPsugW+PDggQvretS144gRSB0WkmVeC+KkVj7F3BLggisSwQ7m3vpOUl8NPRnErNJsDOvRuiVdD+
BrgucgSh81Z4UDkTj5NXweiNLsaLNA9d3tR9GkuNbwUHnZ3wV2xp7UtsP7uaG8tqPv2hlkGdPFfz
r33Mpzv/XO0GlNW75vfnfXkXZaLalfNJ7uuJl4HE71EevP5Tr/wSHh3Zp52pFo7vs55z9n0IQ6Ru
IXmnBJGnFm88O0V1zfog8B1s+WnmRy/uTlJ5FKuVO4Zjm6LxqYXuC4sQCXQsvyZULpXgwi0Xptx8
5rqTyUQvTCVOJs+yNvdSIrnUTWdMbXUzcDDiNUtGfBNmZdkHmfMxC4fi1nARpQwWz7cMnp/3seyl
xzqv0twf6ZwmPr303dRuEWkvt+gpYEtqGl9i1wTynZPXfmWl1Kjlnylf+VAe0c50+9cuN7cxK7qy
7Clc6OEvYCusCXCwkVP7jAizeWIG6zZ8PfnrpZPvH5jwcwDAPZCImh2B/T3KEO3VEAikGgKBVEMg
EEg1BAKphkAg1RAIhD9UI6a/VpdHEHucIiQSlxOZSswGArHTRzXRjUCbiY5A7HCq2Y9UM5+upn59
XfcwHcVGtN/6B9r1r/0bEu1xNRGgijUCgO4DPhx/hUBUFK7bgJ1HqlmOWyMANg/9KBFRO0dLzCXR
Eddy8IlVnO5TG0eVIGqHasSbbmc+mMbZ/kXLCa9up72K1qvo8BVRo0TsbKqJuhpXmH3E45zMjWsF
lUGyqTkfArFdFEjwcC60WPqKRsEj6p0BcHxD7MxlkfwDG8k/sNnGMddDMYkpBnGTThw+OLAhdt6o
5nakmuksLOayHIll+qWdEmnzJKbjf7VDadVzvMzHeeknu5kD1NwhwYidiJLs1QosBnpcK3SSEoHw
ET7bqxX9zQ9ScOaE3EEgykA1sQwhLOGQmIiaAG43RiCQaggEUg2BQCDVEIjqg2lZRNuMbw2gLckX
tXxh3kGsRbdJMHYYu6ZqvKdTX8gZQdQdzY78uMVx3ReGQGwt1fLtnt9kg3VQDyzJOjyNnfxWCwDt
jqc4oL4gR64hqlWBJCajMdU4zWa6ZviCu1GbVRZRjdwMizfFtK04IovF8xuBqMZRzTY8mE3MbKZr
YLUgc9qf2WSJFjM09r98y6k05iGUpn/aFdM8cbSdZEg5RHVSrcBAYr5ns03zPPKIbsOP6F0F1bes
5CZmAY0YgagCqqlDhfctvsTV6fxNSlf0irHZ0XZEY+0iqpxqYuFlklw8cFiaid4ZQkqYkbnHQZIh
to0CmW/J0DqAiPahieQdtYyZnsO7FIKIeYZJVB4RVU41wzDNsqie00INrEZtFlNQSySTxRuTS5SX
Xy5vydSQ8tKJNTN5VjlyxUHGIaoC2+98tWKpg1RDuAPPVyuosyLTENsQ23APpFjB0AgEUg2BQKoh
EAikGgKBVEMgkGoIBAKphkAg1RAIBFINgUCqIRBINQQCgVRDIJBqCAQCqYZAINUQCKQaAoFAqiEQ
SDUEAqmGRYBA+E+1SIxdRsIc15hVbiV45V4spv1xwXBYd8Zi5ouBtjAWNgKppiAb7lEct6y93Xyk
RXEf7/cg5fTRgkFuOIqFjUCqKbhVc6TSe96EjEK/jC2CtMFzTRIdtURekCAR5oLhFEdHMYBTPN8k
hxD5MBsRFT8YjnCckFCCyHHlEa8lwre0hPiUFgaB2PGoFwz3zDv/EyZV92N7Lq0yKv7Ty8q9/fKF
/nl4YG72d/88vR8u8YfTL/43qS79u7P01xA0B+aem5Bkj9ChtwM0pOK3+nRv4kuJv1SC9D/y3EE5
yGXp5j2Xwoc+/aoaBusB4T/2T27ZqLbUaky+ksDmVu1/+DumWZg8/zoMEylIU8fUBNwPqQunmmCN
eadhoknxGAeejY2K3zrsffFZZeA6BN0TsEIdk0GAuRl4whwfgdjRcP9mf/vgwNi87Ej+0Lg5xHTA
4YHbgdIHIAqxDXjp9PlGOMa+Ersh31lTPFh41e/RLw48+UfKd1KHB1S/KP1H2dY/ZIqPQNTMXM2Y
jy3WnWFMg6M3xABi1gjPDg3JE7isBAE4Ce++aUST4LhyYVD9vvD+r872LatxNT8NlvgIRE1RjaqJ
z8AuQXENDQ2x4cwABweyMVm5bO2E78p6Yyf9EwcJQtA5BqP0R0cX0yM1v/DtL8ikHKFBOBjrpOEs
YGEQiNoc1b7cf30s1yu0qQsHI4kFOWbyXC/MxztknTEy8lGYvJA8eUH2aLidZ+sckS7mt/DJY3vP
7YJHR/bRuN9OvrpglqbGRyB2PEo9iSYGOMFCbG/4fBJNQ4nxRrCmEAg/qJbBokMg/KAaArG9ML/V
GcCd/QgEUg2BQKohEAikGgKBVEMgahTmFUi2Jdj6SpuI8v+FQJRorpcthZEHzWV/GkcIH7Kt5KFi
6RUQn8NbvyGClyrPU7SyCHOyxJkPPQGitDh2IVvfXnyjmlLWov2Op7pVOem4bC3T9DxoLlIohA/Z
JlDR9AqIz+Ft3CCiJ6blKVprssQa3MiDuYGJCtdqh2rWHksuc7V49Btaz6eWreidj1sLrdpzV6cI
Pj2LmgexyP6sdPFu3hV7rPylaw+qNS+xIr2ZFQHHnR8WyKcPVNP7KdF5Q/3f0VFtD4hVmIcy603i
pkugtEotgttirqlHRQvB+Qr797dwDyQp0NvqN0TipXqqSyEo2ILUNu/flIGInmfDm3jgompB1ltI
cUUgeuSJ61Oq3fU27LXLMFcrF0eUSquCBZEiukJW3aK/tV7ZtIquheLZn1+7yS/IN629audqRT+6
W4FubfmJ5VGLtnSYLYd4sYR4Ze0hiTF61zjqiphY5vR1K0ayzdo18TvbvjBty2tBFEXIzTRSlW3F
x1HNoX1bb6hKiXGTKOqaesN62dp61lZOtSzmCeF3tq2F5rd469MSU0DFLXovWrckDF9rdiyE24JC
31KUaIWN6gCihLaRv9lUtlE5VyA/W/VW2KRmJrIIP/vhna5GlkA1pBmixPYhbnG7+msYH38l858e
2k4KJAKxzdCezWY/kB2tc/B7r3EzQb8/44NUQ+x8ZNuzmQ/t1OMy7+7xMxOmxX6pkecGIwntp/oh
SNO5aMMRsHlGBUg0ctypLGRjMqCFexTgoWE1/AlusDEhhw1FsboNhOXvsUc4Ti7rlhOcMFxe8fIh
eW1hnvtTWiuNHL8huaWfPcVxtG7kOt9Qzg1qHJTrsZlvAThV4GwgNazchiM8F2GuRu1cvZgmW2nk
gzHreX2msGqbkZRLzi+PbpZmLSFuafI9O9Ng5tJMqCHSnPCt2k0n0exdmr/y65u/qR0Ls185gebo
Pv28jrcNp+Ipnb+UfvqIFIT5dObas1OTk3BX/Oza9GceY2Gmu9+79MDBb2Vp2Mjnf/YgUkyt+sZe
Wnh/v5qcPv+fs2L3q6Thv2fLqScFeqj49fUmqUnKiIcff7bviwGX9MWA9NzFrwS+c2yW75uXP0b9
2LEHnqP1GGhaXs2+XiANGvbHGyxW49HHnzs4m4XpR3q0A4uGNNlKZ7yH3n96/e3Hu+e0p9TDqm3m
sT3n36KXyf1Q9pNhpFt+uF5/eSnZqvYd9qvwwfxfN3G7rtT7PKrdD6sgDK2wEYv1MC0hy7lovOzM
Rjhe74Y702cgA9IE/bNbmdU+EdyAj/GK7+5+ISoNsa/1148fQI6puJW1wVQmyAMddkakYGa5nOKv
Z1+LXknPXKG1sgLHJuDTbulnYLwbBOp3cVz50KAgnxKUgfWZNWjlC6RBw44rH4tfh2OztNnAHesm
b1U2G/9YKNN5fWAKq7aZdeAqMjeLhhsCn3pvdq4VQP4HOa4fZi4u1Udasn5SrQ66rbrM+k97Yxn5
k/3Ng2cih5rTzPlCZqn3STVAGj4Od4Mkn0KzCikuMkf7zLul9EXFNwT6yRfjkEWOadqX9iX1MVp2
mYDARaRyir/tstYP0goNyJVz1i39DYhG4S7qRy8b8o27FFfddJ2UuVggDRaWIQipYZl0t10yeauy
ZRwO67nRRw49LGszWXpJ8uUtA2h/KXLzWxOXZoC2SC//Zt+bXAqGW+b8otriKPSejph016kQKCf2
6ueiASzXNTXBE2oA2gFSQgldcmUFlhp7rgEhcvAAv59nh/v2g2mGhlTTsBRUZ7Kfhl4Y6P9BY8/V
5RR/n1robUk6sASh68fu6bNjl5+AAYUarDdkrlCHcIDr5FrypjGux3pn9OTp+KqRKphky00+rFJI
O6/PnEOlzfwZQHwkXN4yAPj99Ylio6zftP4xv6gWvDw2Cj03GTeiR+AXSkHpvRiIX1u/CP169wXw
vURTOh6A5NmgrInMZz63MptuYrSUz57RJLkY5tU4ho8PvPYFuY8fh0ocmtp2ZeABAu/clvzjuKt/
XKk/9j34gFJbzDWfvpiaWk5+Pq9wI9bVfd94vV90ly13zGoLkM/rc45brM08Asn0kYkyl8HMQuqd
xmv2tal6YsF/7Xs6fnvmhcUZv6gG0fnLr9GRKq6NQZKkepvORUvCO4YmL+snwaVscqNO+w3Q1RDs
m2HzBQ6u06enSC374sgt8Doxt8oya6lX4MxxWqP3pZc3gu71LiXon0G5Zhlp6rU6PsBH+4NP5F9L
02OtynO1jFO22nJ6TrLj+Yzz+pyoWB8cXEyu/fzA3jY2VwNlXuZ2hT+45rc/XFmYrfgiuYlqoVg0
+jw00IefbmM3Ot6gWqPpXDT5FLU6uG5Mj9FAW4nAt0cHBAjf29bFzuVNERidZlIF7qtSlB3FBrsg
iOyyoPWupVl64WHsX+wnzpUDhwNT8rpEmMv+YsB1kSMInbfCg7RKac1y8ioYvdHFJglpHroKqPss
LItVJ8/V7HXLQWcn/JXpeD7jvD4D9IfaZgR+Wmk65ccxklq7tumjv8d+aDMx07X9LzpW1l9YnPXl
XZSJalfOJ7mvJ14GEr9HKbz6T73yS/O5aOH4PgiPLnxWj/F9qoBH6haSd0oQeWrxxrNTVC+qDwLf
wZafZn704u4klcc6PzwbwIr0+K3yi6TFCycHz1ZgNh7qu0MW/7/rw99+zVWlmOtOJhO9MJU4mVTS
fymRXOqmalxb3QwcjAh5pbOwLNbPz7cMnrcPWLOy7IOmG9p5fTZdNqy0mcb6jqULUxUr6Zn55Xjj
/j3tDhX7D9r+5cPvL/j3FntTu0Wkvdyip4AtqWl8iV0TyHfuXvuVlVKjlkNlb8tk19VerS3I/+QT
0W21MSu64u2dUOjhL2ArrAlwsJFT+4wIs/m00rqNip8k1p5NZzdCDbOK1oZ7IBEIf0Zgf6mGHxJH
IJBqCARSDYFAINUQCKQaAoFUQyAQ/lCNmP5aXR5B7HGKkEhcTmQqMRsIxE4f1UQ3Am0mOgKxw6lG
CFG/SMtcZie9KGc+aR4EzL/ACM/YQxwS7XE1EaCKNQKA7qPfQCC2K9yPMmQfgRZNx0paTgM1n66m
H7mmHuOiHa4g5pLoiGs5+MQqTvchIn5QGbGTqEa86XYiyaf0iZYTXt1OexWtV9HhK6JGidjZVNMP
L/GwkEE8zsncuFZQGSSbmvMhENtFgTQfO+NtDaOo8cft/PcCAXB8Q+zMZZH8AxvJP7DZxjHXk/GI
KQZxk04cPjiwIXbeqKaddyUvZBhTKv0sLOvpauYIYJzAbPPUJYJxaqx6jpf5OC/FbQtQKwdwIXY0
SrJXK7AY6HGt0ElKBMJHxKr8fLXCp6shdxCIMlBNLEMISzgkJqImgNuNEQikGgKBVEMgEEg1BKL6
YFoW0TbjWwNoS/JFLV+YdxBr0W0SjB3Grqka7+k0l2lLMnGJYYsDonoD10MRVUe1fLvnN9lgSZ4m
L7qIN3by6y5i9ssfR9vMabYmQCCqUIEkJqMx1TjNZrpm+IK7UZtVFlGN3AyLN8W0zSORxeKJXUo0
BMKnUc02PJgHBZvpmm0Mcdqf2WSJFjM09r98y6k0uuuFoqE1gkMxdYtj2zSGnENUJ9UKjCfmezbb
NM8jieh9FHLVPfUtK2Iu8UaHgEBULdXUocL7Fl/i6nT+JiXMA103SpZX4UQgtohqYuFlklxt22Fp
JnrnAMkXhrhnJm8cHNQQ1a9AEo+r5CIR7a2a5G3wTsWOePm8QS7ai/kYhkxDVDfVDMM0y6J6Tgs1
sBq1WUxBLZFMFm/KQoeyiO/ylkwNKS+dEMeHTcRcrLfFIfhiDVFF2H7nqxVLHaQawh14vlpBnRWZ
htiG2IZ7IMUKhkYgkGoIBFINgUAg1RAIpBoCgVRDIBBINQQCqYZAIJBqCARSDYFAqiEQCKQaAoFU
QyAQSDUEAqmGQCDVEAgEUg2BQKohEEg1LAIEAqmGqFWQTfh6DfZDH9IgSDUEAkc1BAKphkAgSkQA
P96G2HZztW0Eg18NWKuI6m6ibkT0NkAUCEb8SAMVSAQC52oIBFINgUCUCFwWQSB8AS6LIKoTpoP1
TEsPxt2850dbguU8iVb0lnyBXDrDqed12nyQaojqZJpxUCxxu0vynR9t9hTzscRL8vmR89RohwSc
qyG2Aek8NfHiRq78RNqE+FyCcVRDVDk2t5qQUxEszyKFi3gR52qImhjunA2/xINjyy0eFUgEDom+
iEeqIXbyoFZF4pFqiJ3MNFI94vEVNqJKqWRMhBzv1egNkld/MyLneT+Wj03Eo3roKt79vRpSDYHw
BahAIhBINQQCqYZAIJBqCIQBqUpk47IIouoQk/8MlUuakILYUIUSKyDbAtyYhag+DJVTWO9Q5RLr
LSIyKpCIasWwEAyJEEpANgTZSDCSVYYg+i8mhiDKc3RMYeNSC89TVyLMCQl2oy3E81HtfkyO8DjP
yTeaT2h+Dij3T2Sh/QRIYT4sGYk1h2CY40JtJctGqiGqG5+SsuFl4Bbh5zy0/jjLtZr8LsNSOCOp
s5/16fkWgMOhTOgw+730s/T87dr9IXnYum+6cYneqH9K97NDuR//CKyOwm/x6dCThlf9ZRhszJCl
HLL/7+nGZH7ZSDVE1U7WYvKIkhJA6ocz/wc8H4SVbphYMQJMRCGYTaXUO1NRoR8gNA4TIfZ75RgI
4/p9JYQ0QC/jUd3Pnphy/0wGskHomYDx540ANFbw9ONqYk7Zk1GpP5dspBqiyudqQ/IcSGreoNT5
xB/AY7MwEIVowAhA1bR/Wm/Zk9V/UfTTIOvMlW2JCMZ9kysq+z0kuCWm3P/EKhybhQ0qadiS2PwD
X9wzrcp+KI/siIBzNcT2w0cDrb+gTbiphU7E4hJIG+yutr5+ZHk6/Mfm4HIQpTk3r7+4mEto83r3
Yu770WDLsCIpYEksmHxfuCdv/ELpItUQ1Yv1fx0/Ti//tZsOGCtvQCcd4kaGpQ7VV0hFA39nDh78
F+hUlLz/OPcJ07xuxPLyy+rnuB/sngH4rgBdQQAuqif2J8PR6bMly0aqIaobkXt2y83zp8MTAKsn
uMwcwMLgnnrN97PB5II5OLmVTytGLb279pja9R/uNoey+jnufxinQ2hvK7dClcpEcreW2N/fwjcv
lCxbAb7CRiB8AY5qCARSDYFAqiEQCKQaAoFUQyCQaggEAqmGQCDVEAgEUg2BQKohELWE/x8AGeLQ
8IMliQAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-06-16 12:03:24 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.3 Tumour response.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvEAAAIgCAMAAAA7hMZZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-06-17 15:44:11 +0200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.4 Clinical cardiotoxicity.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvAAAAFACAMAAADtWrigAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-07-10 13:12:12 +0200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.05" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.5 Overall survival Wilms' tumour long-term follow-up (Parmar's method was used to obtain the necessary data for the analyses).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3sAAAEgCAMAAAA6xZrMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-07-10 13:12:32 +0200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.06" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.6 Event-free survival Wilms' tumour long-term follow-up (Parmar's method was used to obtain the necessary data for the analyses). </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3sAAAEgCAMAAAA6xZrMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-08-23 14:08:46 +0200" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2014-09-04 12:11:34 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-09-04 12:11:34 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-09-04 12:11:34 +0200" MODIFIED_BY="[Empty name]">Search strategy for the Cochrane Central Register of Controlled Trials (CENTRAL)</TITLE>
<APPENDIX_BODY MODIFIED="2010-10-13 13:51:12 +0200" MODIFIED_BY="[Empty name]">
<P>(1) For <B>anthracyclines</B> the following text words have been used:</P>
<P>Anthracyclines OR anthracycline antibiotics OR doxorubicin OR adriamycin OR epirubicin OR idarubicin OR daunorubicin OR rubidomycin OR daunoxome OR myocet OR caelyx OR doxil</P>
<P>(2) For <B>children</B> the following text words have been used:</P>
<P>infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy</P>
<P>(3) For <B>survival</B> the following text words have been used:</P>
<P>survival OR survival rate OR survival rates OR cumulative survival rate OR cumulative survival rates OR survivorship OR mean survival time OR mean survival times OR survival time OR surviv* OR median survival time OR median survival times OR overall survival OR survival analysis OR survival analyses OR disease-free survival OR disease free survival OR event-free survival OR event-free survivals OR event free survival OR progression-free survival OR progression free survival OR progression-free survivals OR event-free OR event free OR progression free OR progression-free OR time to progression OR treatment outcome OR treatment effectiveness OR treatment efficacy OR neoplasm recurrence OR neoplasm recurrences OR disease-free survivals OR disease free survivals OR event free survivals OR progression free survivals OR treatment failure</P>
<P>
<B>Final search: 1 AND 2 AND 3</B>
</P>
<P>The search was performed in All Text.</P>
<P>[*=1 or more characters]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-17 15:50:37 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-10-13 13:51:52 +0200" MODIFIED_BY="[Empty name]">Search strategy for MEDLINE</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-17 15:50:37 +0200" MODIFIED_BY="[Empty name]">
<P>(1) For <B>anthracyclines</B> the following MeSH headings and text words have been used:<BR/>anthracyclines OR anthracyclin* OR anthracycline antibiotics OR antibiotics, anthracycline OR 4-demethoxydaunorubicin OR 4 demethoxydaunorubicin OR 4-desmethoxydaunorubicin OR 4 desmethoxydaunorubicin OR IMI 30 OR IMI30 OR IMI-30 OR idarubicin hydrochloride OR hydrochloride, idarubicin OR NSC 256439 OR NSC-256439 OR NSC256439 OR idarubicin OR idarubic* OR 4'-epiadriamycin OR 4' epiadriamycin OR 4'-epidoxorubicin OR 4' epidoxorubicin OR 4'-epi-doxorubicin OR 4' epi doxorubicin 4'-epi-adriamycin OR 4' epi adriamycin OR 4'-epi-DXR OR 4' epi DXR OR epirubicin hydrochloride OR hydrochloride, epirubicin OR farmorubicin OR IMI-28 OR IMI 28 OR IMI28 OR NSC 256942 OR NSC-256942 OR NSC256942 OR epirubicin OR epirubic* OR adriablastine OR adriblastin OR adriablastin OR adriamycin OR DOX-SL OR DOX SL OR doxorubicin hydrochloride OR hydrochloride doxorubicin OR doxorubic* OR adriamyc* OR dauno-rubidomycine OR dauno rubidomycin OR rubidomycin OR rubomycin OR daunomycin OR cerubidine OR daunoblastin OR daunoblastine OR daunorubicin hydrochloride OR hydrochloride, daunorubicin OR daunorubic* OR rubidomyc* OR NSC-82151 OR NSC 82151 OR NSC82151 OR daunoxome OR daunosom* OR doxil OR caelyx OR liposomal doxorubicin OR doxorubicin, liposomal OR myocet OR doxorubicin OR daunorubicin</P>
<P>(2) For <B>children</B> the following MeSH headings and text words have been used:<BR/>infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery OR infant, newborn</P>
<P>(3) For <B>survival</B> the following MeSH headings and text words have been used:<BR/>survival OR survival rate OR rate, survival OR rates, survival OR survival rates OR cumulative survival rate OR cumulative survival rates OR rate, cumulative survival OR rates, cumulative survival OR survival rate, cumulative OR survival rates, cumulative OR survivorship OR mean survival time OR mean survival times OR survival time, mean OR survival times, mean OR time, mean survival OR times, mean survival OR survival time OR surviv* OR median survival time OR median survival times OR survival time, median OR survival times, median OR time, median survival OR times, median survival OR overall survival OR analysis, survival OR analyses, survival OR survival analysis OR survival analyses OR disease-free survival OR disease free survival OR survival, disease-free OR disease-free survivals OR survival, disease free OR survivals, disease-free OR event-free survival OR event-free survivals OR event free survival OR survival, event-free OR survivals, event-free OR progression-free survival OR progression free survival OR progression-free survivals OR survival, progression-free OR survivals, progression-free OR event-free OR event free OR progression free OR progression-free OR time to progression OR treatment outcome OR treatment effectiveness OR treatment efficacy OR neoplasm recurrence OR neoplasm recurrences</P>
<P>(4) For <B>randomized controlled trials</B> the following MeSH headings and text words have been used:</P>
<P>
<I>In the original version of the review</I>: randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:NoExp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans [mh]) (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<P>
<I>For the updates of the review</I>: randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) AND humans[mh] (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>
<B>Final search: 1 AND 2 AND 3 AND 4</B>
</P>
<P>[*=1 or more characters; tiab= title or abstract; pt=publication type; sh=subheading; mh= mesh heading; mh:NoExp=mesh heading without explosion; tw= text word]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-06-17 15:50:45 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-10-13 13:51:35 +0200" MODIFIED_BY="[Empty name]">Search strategy for EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-17 15:50:45 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f3&quot;&gt;&lt;span coll_flag=&quot;f3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Title&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s0&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Review information&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s51&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van Dalen, Elvira&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s53&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rapha&amp;#235;l, Martine&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s55&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Caron, Huib N&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s57&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kremer, Leontien&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contact person&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s6&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dates&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s10&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;What's new&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s60&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;New citation: conclusions changed, 30 August 2010&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s59&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Updated, 30 August 2010&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s11&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;History&lt;/h2&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s49&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abstract&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f210&quot;&gt;&lt;span coll_flag=&quot;f210&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f212&quot;&gt;&lt;span coll_flag=&quot;f212&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f214&quot;&gt;&lt;span coll_flag=&quot;f214&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f216&quot;&gt;&lt;span coll_flag=&quot;f216&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection criteria&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f218&quot;&gt;&lt;span coll_flag=&quot;f218&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f220&quot;&gt;&lt;span coll_flag=&quot;f220&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f222&quot;&gt;&lt;span coll_flag=&quot;f222&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s48&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language summary&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f205&quot;&gt;&lt;span coll_flag=&quot;f205&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language title&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f207&quot;&gt;&lt;span coll_flag=&quot;f207&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary text&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f235&quot;&gt;&lt;span coll_flag=&quot;f235&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f245&quot;&gt;&lt;span coll_flag=&quot;f245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f247&quot;&gt;&lt;span coll_flag=&quot;f247&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Methods&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f249&quot;&gt;&lt;span coll_flag=&quot;f249&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Criteria for considering studies for this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f251&quot;&gt;&lt;span coll_flag=&quot;f251&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f253&quot;&gt;&lt;span coll_flag=&quot;f253&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of participants&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f255&quot;&gt;&lt;span coll_flag=&quot;f255&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of interventions&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f257&quot;&gt;&lt;span coll_flag=&quot;f257&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of outcome measures&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f259&quot;&gt;&lt;span coll_flag=&quot;f259&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Primary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f261&quot;&gt;&lt;span coll_flag=&quot;f261&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Secondary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f263&quot;&gt;&lt;span coll_flag=&quot;f263&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods for identification of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f269&quot;&gt;&lt;span coll_flag=&quot;f269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f271&quot;&gt;&lt;span coll_flag=&quot;f271&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f273&quot;&gt;&lt;span coll_flag=&quot;f273&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data extraction and management&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f275&quot;&gt;&lt;span coll_flag=&quot;f275&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Assessment of risk of bias in included studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f287&quot;&gt;&lt;span coll_flag=&quot;f287&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data synthesis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f293&quot;&gt;&lt;span coll_flag=&quot;f293&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f295&quot;&gt;&lt;span coll_flag=&quot;f295&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f303&quot;&gt;&lt;span coll_flag=&quot;f303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias in included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f315&quot;&gt;&lt;span coll_flag=&quot;f315&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Effects of interventions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f317&quot;&gt;&lt;span coll_flag=&quot;f317&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Discussion&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f329&quot;&gt;&lt;span coll_flag=&quot;f329&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f331&quot;&gt;&lt;span coll_flag=&quot;f331&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for practice&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f333&quot;&gt;&lt;span coll_flag=&quot;f333&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for research&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f224&quot;&gt;&lt;span coll_flag=&quot;f224&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Acknowledgements&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f228&quot;&gt;&lt;span coll_flag=&quot;f228&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contributions of authors&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f226&quot;&gt;&lt;span coll_flag=&quot;f226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Declarations of interest&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f230&quot;&gt;&lt;span coll_flag=&quot;f230&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Differences between protocol and review&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f232&quot;&gt;&lt;span coll_flag=&quot;f232&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Published notes&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s19&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s20&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1078&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8346&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8346&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8348&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8348&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8350&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8350&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8352&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8352&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8354&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8354&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s68&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1079&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 1981 II-III FH UH&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8357&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8357&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8359&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8359&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8361&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8361&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8363&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8363&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8365&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8365&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s76&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1080&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 81 II-III FH&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8368&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8368&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8370&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8370&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8372&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8372&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8374&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8374&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8376&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8376&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s82&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1081&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 81 II-III UH&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8379&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8379&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8381&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8381&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8383&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8383&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8385&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8385&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8387&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8387&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s88&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1082&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 81 IV&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8390&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8390&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8392&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8392&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8394&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8394&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8396&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8396&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8398&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8398&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s96&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1083&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Eden 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8401&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8401&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8403&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8403&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8405&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8405&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8407&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8407&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8409&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8409&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s102&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1084&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8412&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8412&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8414&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8414&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8416&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8416&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8418&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8418&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8420&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8420&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s108&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1085&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer 1988 Group 3&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8423&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8423&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8425&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8425&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8427&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8427&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8429&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8429&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8431&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8431&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s114&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1086&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer 1988 Group 4&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8434&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8434&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8436&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8436&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8438&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8438&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8440&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8440&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8442&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8442&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s120&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1087&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nesbit 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8445&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8445&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8447&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8447&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8449&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8449&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8451&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8451&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8453&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8453&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s126&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1088&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Perilongo 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8456&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8456&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8458&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8458&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8460&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8460&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8462&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8462&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8464&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8464&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s132&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1089&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sposto 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8467&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8467&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8469&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8469&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8471&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8471&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8473&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8473&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8475&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8475&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s138&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1090&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Van der Does 1975&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8478&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8478&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8480&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8480&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8482&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8482&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8484&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8484&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8486&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8486&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s144&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1091&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Van der Does 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8489&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8489&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8491&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8491&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8493&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8493&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8495&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8495&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8497&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8497&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s150&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s21&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Characteristics of excluded studies&lt;/h2&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s22&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1262&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FRALLE 2000-A&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f9010&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9010&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f9012&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9012&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f9014&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9014&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9016&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9016&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9018&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9018&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s23&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1263&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;COG AHEP0531&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f9021&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9021&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f9023&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9023&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f9025&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9025&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f9027&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9027&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9029&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9029&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f9031&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9031&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f9033&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9033&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9035&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9035&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1264&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISRCTN94206677&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f9038&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9038&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f9040&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9040&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f9042&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9042&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f9044&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9044&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9046&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9046&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f9048&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9048&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f9050&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9050&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9052&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9052&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1265&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;NCT00186966&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f9055&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9055&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f9057&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9057&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f9059&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9059&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f9061&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9061&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9063&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9063&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f9065&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9065&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f9067&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9067&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9069&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9069&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1266&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;NCT00379457&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f9072&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9072&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f9074&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9074&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f9076&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9076&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f9078&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9078&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9080&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9080&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f9082&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9082&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f9084&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9084&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9086&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9086&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1267&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SIOP2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f9089&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9089&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f9091&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9091&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f9093&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9093&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f9095&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9095&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9097&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9097&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f9099&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9099&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f9101&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9101&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f9103&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f9103&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s31&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of findings tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s32&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1268&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Criteria list for the assessment of risk of bias in included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Risk of bias in included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s34&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;References to studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s35&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s63&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s66&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302-11.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s69&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 1981 II-III FH UH&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s72&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302-11.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s74&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green DM. The treatment of stages I-IV favorable histology Wilms' tumor. Journal of Clinical Oncology 2004;22:1366-72.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s77&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 81 II-III FH&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s80&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302-11.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s83&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 81 II-III UH&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s86&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302-11.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s89&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 81 IV&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s92&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302-11.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s94&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green DM. The treatment of stages I-IV favorable histology Wilms' tumor. Journal of Clinical Oncology 2004;22:1366-72.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s97&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Eden 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s100&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Eden OB, Lilleyman JS, Richards S, Shaw MP, Peto J. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology 1991;78:187-96.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s103&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s106&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s109&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer 1988 Group 3&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s112&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s115&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer 1988 Group 4&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s118&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s121&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nesbit 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s124&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. Journal of Clinical Oncology 1990;8:1664-74.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s127&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Perilongo 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s130&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. New England Journal of Medicine 2009;361:1662-70.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s133&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sposto 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s136&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sposto R, Meadows AT, Chilcote RR, Steinherz PG, Kjeldsberg C, Kadin ME, et al. Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology 2001;37:432-41.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s139&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Van der Does 1975&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s142&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Van der Does-van den Berg A, de Koning J, Reerink H, de Vries JA, van Zanen GE. Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972-1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972-1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde 1975;119:1445-51.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s145&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Van der Does 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s148&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Van der Does-van den Berg A, van Wering ER, Suciu S, Solbu G, van 't Veer MB, Rammeloo JA, et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology 1989;11:125-33.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s36&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s151&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alvegard 1989a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s154&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. Journal of Clinical Oncology 1989;7:1504-13.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s156&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alvegard 1989b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s159&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alvegard TA, Berg NO, Ranstam J, Rydholm A, Rooser B. Prognosis in high-grade soft tissue sarcomas. The Scandinavian Sarcoma Group experience in a randomized adjuvant chemotherapy trial. Acta Orthopaedica Scandinavica 1989;60:517-21.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s161&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alvegard 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s164&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alvegard TA, Berg NO, Baldetorp B, Ferno M, Killander D, Ranstam J, et al. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. Journal of Clinical Oncology 1990;8:538-47.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s166&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antillon 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s169&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antillon F, Castellanos M, Valverde P, Luna-Fineman S, Garrido C, Serrato T, et al. Treating pediatric soft tissue sarcomas in a country with limited resources: The experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatric Blood and Cancer 2008;51:760-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s171&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman 1984a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s174&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman KH, Amato D, Lerner H, Suit H, Corson J, Wood W, et al. Pooled results of two randomized trials of adjuvant doxorubicin for sarcomas: Eastern Cooperative Oncology Group and Dana-Farber Cancer Institute/Massachusetts General Hospital Study. In: Jones S, Salmon S, editor(s). Adjuvant Therapy of Cancer IV. Orlando: Grune and Stratton, 1984:611-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s176&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman 1984b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s179&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. Journal of Clinical Oncology 1984;2:601-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s181&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s184&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman KH, Amato D, Lerner H, Suit HD, Corson J, Wood WC, et al. Adjuvant doxorubicin for sarcoma: data from the ECOG and DFCI/MGH studies. Cancer Treatment Symposia 1985;3:109-15.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s186&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s189&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman K, Amato D, Pilepich M, Lerner H, Balcerzak S, Borden E, et al. A preliminary analysis of a randomized intergroup (SWOG, ECOG, CALGB, NCOG) trial of adjuvant doxorubicin for soft tissue sarcomas. In: Salmon S, editor(s). Adjuvant Therapy of Cancer V. Orlando: Grune and Stratton, 1987:725-34.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s191&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s194&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman K, Ryan I, Borden E, Wood WC, Lerner HL, Corson JM, et al. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10-year results and review of the literature. In: Salmon S, editor(s). Adjuvant Therapy of Cancer VI. Philadelphia: WB Saunders, 1990:529-44.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s196&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Aur 1972&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s199&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Aur RJ, Verzosa MS, Hustu HO, Simone JV. Response to combination therapy after relapse in childhood acute lymphocytic leukemia. Cancer 1972;30:334-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s201&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bacci 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s204&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bacci G, Pignatti G, Dallari D, Mercuri M, Bertoni F, Bacchini P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for telangiectatic osteogenic sarcoma of the extremities. Journal of Chemotherapy 1989;1:190-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s206&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barr 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s209&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barr RD, DeVeber LL, Pai KM, Andrew M, Halton J, Cairney AE, et al. Management of children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols. An update of the Ontario experience. American Journal of Pediatric Hematology/Oncology 1992;14:136-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s211&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bellani 1978&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s214&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bellani FF, Gasparini M, Gennari L, Fontanillas L, Bonadonna G. Adjuvant treatment with adriamycin in primary operable osteosarcoma. Cancer Treatment Reports 1978;62:279-81.&lt;/h4&gt;&lt;p&gt;.&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s216&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Berman 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s219&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, et al. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Seminars of Oncology 1989;16:30-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s221&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bessho 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s224&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bessho F, Kinumaki H, Yokota S, Hayashi Y, Kobayashi M, Kamoshita S. Liver function studies in children with acute lymphocytic leukemia after cessation of therapy. Medical and Pediatric Oncology 1994;23:111-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Biondi 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s229&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Biondi A, Rizzari C, Valsecchi MG, De Lorenzo P, Arico M, Basso G, et al. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Haematologica 2006;91:534-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s231&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Birch 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s234&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. Journal of Clinical Oncology 1986;4:400-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s236&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blakely 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s239&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blakely ML, Shamberger RC, Norkool P, Beckwith JB, Green DM, Ritchey ML. Outcome of children with cystic partially differentiated nephroblastoma treated with or without chemotherapy. Journal of Pediatric Surgery 2003;38:897-900.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s241&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bradford 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s244&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bradford WB, Jose BO, Butler D, Lindberg RD, Paris K, Spanos WJ, et al. Rhabdomyosarcoma in children--a ten year review. The Journal of the Kentucky Medical Association 1998;96:399-402.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s246&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Breslow 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s249&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Breslow NE, Ou SS, Beckwith JB, Haase GM, Kalapurakal JA, Ritchey ML, et al. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. Cancer 2004;101:1072-80.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s251&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brouwer 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s254&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brouwer CA, Gietema JA, van den Berg MP, Bink-Boelkens MT, Elzenga NJ, Haaksma J, et al. Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment. Journal of Cancer Survivorship 2007;1:255-60.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s256&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burnett 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s259&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK. Long-term result of the MRC AML10 trial. Clinical Advances in Hematology and Oncology 2006;4:445-51.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s261&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Caceres 1978&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s264&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Caceres E, Zaharia M, Moran M, Tejada F. Adjuvant whole-lung radiation with or without adriamycin treatment in osteogenic sarcoma. Cancer Treatment Reports 1978;62:297-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s266&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Canter 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Canter RJ, Qin L-X, Downey RJ, Brennan MF, Singer S, Maki RG. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity: a retrospective analysis. Cancer 2007;110:2050-60.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s271&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Carlsen 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s274&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Carlsen NL, Schroeder H, Bro PV, Hesselbjerg U, Jensen KB, Nielsen OH, et al. Response to multimodal treatment in advanced neuroblastomas. Factors associated with complete remission induction, and factors associated with prolonged survival. Anticancer Research 1989;9:837-44.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s276&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Castellino 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s279&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Castellino SM, Alonzo TA, Buxton A, Gold S, Lange BJ, Woods WG. Outcomes in childhood AML in the absence of transplantation in first remission - Children's Cancer Group (CCG) studies 2891 and CCG 213. Pediatric Blood and Cancer 2008;50:9-16.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s281&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chau 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s284&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? British Journal of Cancer 2003;89:36-42.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s286&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chessells 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s289&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chessells JM, Bailey CC, Richards S. MRC UKALL X. The UK protocol for childhood ALL: 1985-1990. Leukemia 1992;6:157-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s291&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chessells 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s294&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chessells JM, Harrison G, Richards SM, Gibson BE, Bailey CC, Hill FG, et al. Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. British Journal of Haematology 2002;118:445-55.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s296&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Craft 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s299&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Craft AW, Burgers JM. The European Osteosarcoma Intergroup (E.O.I.) studies 1980-1991. Cancer Treatment and Research 1993;62:279-86.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s301&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Creutzig 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s304&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030-42.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s306&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Creutzig 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s309&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Journal of Clinical Oncology 2006;24:4499-4506.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s311&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crist 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s314&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. Journal of Clinical Oncology 1995;13:610-30.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s316&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Culbert 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s319&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Culbert SJ, Shuster JJ, Land VJ, Wharam MD, Thomas PR, Nitschke R, et al. Remission induction and continuation therapy in children with their first relapse of acute lymphoid leukemia. A Pediatric Oncology Group study. Cancer 1991;67:37-42.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s321&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s324&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, DeLorimier A, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1989;64:349-60.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s326&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Bernardi 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s329&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di ML, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. Journal of Clinical Oncology 2003;21:1592-1601.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s331&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Bernardi 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s334&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Cataldo AD, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. Journal of Clinical Oncology 2009;27:1034-40.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s336&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dluzniewska 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s339&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dluzniewska A, Balwierz W, Balcerska A, Chybicka A, Dobaczewski G, Kowalczyk J, et al. Efficacy of idarubicin in the treatment of childhood acute non-lymphoblastic leukemia: report of Polish Pediatric Leukemia/Lymphoma Study Group. Przeglad Lekarski 2003;60 Suppl 5:17-21.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s341&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dobashi 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s344&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dobashi N, Yamaguchi Y, Asai O, Yano S, Osawa H, Yahagi Y, et al. Intensifying daunorubicin in induction for patients with core binding factor leukemia. International Journal of Hematology 2006;84:463-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s346&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dunst 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s349&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dunst J. Therapy results of the British ET-1 study for Ewing's sarcoma. Strahlentherapie und Onkologie 1998;174:289-90.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s351&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Eilber 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s354&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Eilber FR, Giuliano AE, Huth JF, Morton DL. A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma. American Journal of Clinical Oncology 1988;11:39-45.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s356&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Einhorn 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s359&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular cancer. New England Journal of Medicine 1981;305:727-31.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s361&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Elomaa 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s364&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Elomaa I. An update of Scandinavian studies of osteosarcoma. Cancer Treatment and Research 1993;62:293-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s366&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Etcubanas 1984&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s369&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Etcubanas E, Hustu O, Sklar M, Pratt C. Influence of different treatment modalities on the curability of childhood rhabdomyosarcoma of the head or neck. European Paediatric Haematology &amp;amp; Oncology 1;1984:239-44.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s371&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evans 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s374&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evans R, Nesbit M, Askin F, Burgert O, Cangir A, Foulkes M, et al. Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones. International Journal of Radiation Oncology, Biology, Physics 1985;11:129-36.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s376&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evans 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s379&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evans AE, Norkool P, Evans I, Breslow N, D'Angio GJ. Late effects of treatment for Wilms' tumor. A report from the National Wilms' Tumor Study Group. Cancer 1991;67:331-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s381&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fink 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s384&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fink FM, Gadner H, Grumayer ER, Kardos G, Revesz T, Urban C, et al. Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian-Hungarian study AML-IGCI-84. Haematology and Blood Transfusion 1990;33:233-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s386&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Frappaz 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s389&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Frappaz D, Perol D, Michon J, Berger C, Coze C, Bernard JL, et al. The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis. British Journal of Cancer 2002;87:1197-1203.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s391&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fukuoka 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s394&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fukuoka M, Masuda N, Takada M, Kodama N, Kawahara M, Furuse K. Dose-intensive chemotherapy in extensive-stage small cell lung cancer. Seminars in Oncology 1994;21:43-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s396&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gallegos-Castorena 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s399&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gallegos-Castorena S, Medina-Sanson A, Gonzalez-Ramella O, Sanchez-Zubieta F, Martinez-Avalos A. Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol. Leukemia and Lymphoma 2009;50:1132-37.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s401&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Garbes 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s404&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Garbes ID, Gomez GA, Han T, Henderson ES. Salvage chemotherapy for advanced Hodgkin's disease. Medical and Pediatric Oncology 1987;15:45-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s406&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gaynon 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s409&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. Journal of Clinical Oncology 1993;11:2234-42.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s411&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Glanzmann 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s414&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiotherapy &amp;amp; Oncology 1998;46:51-62.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s416&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s419&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green DM, Breslow NE, Beckwith JB, Moksness J, Finklestein JZ, D'Angio GJ. Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. Journal of Clinical Oncology 1994;12:2132-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s421&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s424&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green DM, Breslow NE, Evans I, Moksness J, D'Angio GJ. Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. Medical and Pediatric Oncology 1996;26:147-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s426&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s429&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green DM, Hyland A, Chung CS, Zevon MA, Hall BC. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. Journal of Clinical Oncology 1999;17:3207-15.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s431&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Grier 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s434&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Grier HE, Gelber RD, Clavell LA, Camitta BM, Link MP, Garcea MJ, et al. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematology and Blood Transfusion 1990;33:193-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s436&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gururangan 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s439&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gururangan S, Sposto R, Cairo MS, Meadows AT, Finlay JL. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. Journal of Clinical Oncology 2000;18:2017-25.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s441&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hainsworth 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s444&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hainsworth JD, Williams SD, Einhorn LH, Birch R, Greco FA. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. Journal of Clinical Oncology 1985;3:666-71.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s446&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Halazun 1974&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s449&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Halazun JF, Wagner HR, Gaeta JF, Sinks LF. Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia. Cancer 1974;33:545-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s451&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Harms 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s454&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Harms D, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000;14:2234-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s456&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hayashi 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s459&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hayashi K, Tsuchiya H, Yamamoto N, Takeuchi A, Tomita K. Functional outcome in patients with osteosarcoma around the knee joint treated by minimised surgery. International Orthopaedics 2008;32:63-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s461&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hays 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s464&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hays DM, Shimada H, Raney RB Jr, Tefft M, Newton W, Crist WM, et al. Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents. Cancer 1988;61:1893-1903.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s466&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Henze 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s469&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Henze G, Fengler R, Hartmann R, Dopfer R, Gobel U, Graf N, et al. Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia. Cancer Chemotherapy &amp;amp; Pharmacology 1989;24:S16-S19.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s471&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hitchcock-Bryan 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s474&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hitchcock-Bryan S, Gelber R, Cassady JR, Sallan SE. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology 1986;14:211-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s476&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hodgson 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s479&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hodgson DC, Tsang RW, Pintilie M, Sun A, Wells W, Crump M, et al. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy. International Journal of Radiation Oncology, Biology, Physics 2003;57:1374-81.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s481&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Holland 1971&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s484&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Holland JF. E Pluribus Unum: Presidential address. Cancer Research 1971;31:1319-29.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s486&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Humphrey 1975&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s489&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Humphrey GB, Fernbach DJ, Razek AA, Stuckey WJ, Komp D, George S. Evaluation of daunorubicin (NSC-82151) and methotrexate (NSC-740) in combination as a remission maintenance regimen in the treatment of acute leukemia. Cancer Chemotherapy Reports 1975;59:395-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s491&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Iarussi 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s494&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Iarussi D, Indolfi P, Pisacane C, Casale F, Martino V, Fusco A, et al. Comparison of left ventricular function by echocardiogram in patients with Wilms' tumor treated with anthracyclines versus those not so treated. The American Journal Of Cardiology 2003;92:359-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s496&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ihde 1977&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s499&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treatment Report 1977;61:1385-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s501&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Isu 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s504&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Isu K, Yamawaki S, Usui M. A group study of neoadjuvant chemotherapy for osteosarcoma - Results and problems of T-12 protocol. Journal of the Japanese Orthopaedic Association 1992;66:S9-S10.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s506&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Iwenofu 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s509&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Modern Pathology 2008;21:231-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s511&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jaffe 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s514&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jaffe N, Link MP, Cohen D, Traggis D, Frei E III, Watts H, et al. High-dose methotrexate in osteogenic sarcoma. National Cancer Institute Monograph 1981:201-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s516&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Janka-Schaub 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s519&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Janka-Schaub GE, Winkler K, Gobel U, Graubner U, Schwenger M, Haas RJ, et al. First results of the CO ALL-85 cooperative study for high-risk patients with acute lymphatic leukemia. Klinische Padiatrie 1988;200:171-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s521&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kalapurakal 2010&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s524&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kalapurakal JA, Li SM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, et al. Intraoperative spillage of favorable histology wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group. International Journal of Radiation Oncology, Biology, Physics 2010;76:201-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s526&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Karachunskii 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s529&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Karachunskii AI, Miakova NV, Rumiantseva I, Timakov AM, Makhortykh TZ, Fechina LG, et al. The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity. Terapevticheskii Arkhiv 2007;79:19-26.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s531&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Karachunskiy 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s534&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Karachunskiy A, Herold R, von Stackelberg A, Miakova N, Timakow A, Mahortih T, et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22:1144-53.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s536&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kazanowska 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s539&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kazanowska B, Reich A, Wrobel G, Balcerska A, Balwierz W, Bodalski J, et al. Metastatic soft tissue sarcomas in children - A remaining challenge for paediatric oncology. A retrospective multicenter study from the Polish Pediatric Solid Tumors' Group. Nowotwory 2006;56:517-62.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s541&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Khattab 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s544&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Khattab TM, Atra AA, Elimam NA, Kassar A, Zayed A, Baothman A. Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols. Saudi Medical Journal 2008;29:776-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s546&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kinsella 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s549&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kinsella TJ, Miser JS, Waller B, Venzon D, Glatstein E, Weaver-McClure L, et al. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. International Journal Of Radiation Oncology, Biology, Physics 1991;20:389-95.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s551&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kobe 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s554&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008;112:3989-94.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s556&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Komp 1976&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s559&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Komp DM, George SL, Falletta J, Land VJ, Starling KA, Humphrey GB, et al. Cyclophosphamide-asparaginase-vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia. Cancer 1976;37:1243-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s561&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Konopka 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s564&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Konopka L, Pawelski S. Results of three polychemotherapy programs in non-Hodgkin's lymphomas. Journal of Chemotherapy 1989;1:1259-62.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s566&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuleva 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s569&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuleva SA, Anishkin MI, Kolygin BA. A comparison of two risk-adapted regimens of therapy for Hodgkin's disease in children and adolescents. Voprosy onkologii 2008;54:53-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s571&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kurrle 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s574&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kurrle E, Ehninger G, Freund M, Heil G, Hoelzer D, Link H, et al. A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia. Blut 1988;56:233-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s576&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lager 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s579&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Journal of Clinical Oncology 2006;24:3415-22.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s581&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Li 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s584&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Li CK, Chik KW, Ha SY, Lee ACW, Yuen HL, Ling SC, et al. Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL 97 study. Hong Kong Medical Journal 2006;12:33-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s586&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lilleyman 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s589&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lilleyman JS, Gibson BE, Stevens RF, Will AM, Hann IM, Richards SM, et al. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia. British Journal of Haematology 1997;97:603-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s591&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lindberg 1977&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s594&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lindberg RD, Murphy WK, Benjamin RS, Sinkovics JG, Martin RG, Romsdahl MM, et al. Adjuvant chemotherapy in the treatment of primary soft tissue sarcomas: a preliminary report. In: Management of Bone and Soft Tissue Tumors. Chicago: Book Medical Publishers, 1977:343-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s596&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Link 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s599&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Link MP, Goorin AM, Miser AW. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. New England Journal of Medicine 1986;314:1600-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s601&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Madej 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s604&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Madej G, Siedlecki P, Meyza J. Preliminary evaluation of the effectiveness of a modified treatment program in patients with malignant testicular neoplasms. Polski Tygodnik Lekarski 1987;42:836-40.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s606&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Madon 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s609&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Madon E, Pastore G, Cordero Di ML, Brach del PA, Lanino E. Italian multicenter experience in the treatment of neuroblastoma and soft tissue sarcoma. Minerva Pediatrica 1985;37:603-10.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s611&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahajan 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s614&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahajan A, Woo SY, Kornguth DG, Hughes D, Huh W, Chang EL, et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatric Blood and Cancer 2008;50:976-82.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s616&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahmoud 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s619&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. New England Journal of Medicine 1993;329:314-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s621&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maiakova 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s624&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maiakova SA, Makhonova LA. Consolidating chemotherapy in the treatment program of acute lymphoblastic leukemia in children. Vestnik Akademii Meditsinskikh Nauk SSSR 1986:15-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s626&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Malpas 1974&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s629&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Malpas J, Mathe G, Hayat M. Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia. Bulletin du Cancer 1974;61:411-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s631&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Marcus 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s634&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Marcus RE, Catovsky D, Prentice HG, Newland AC, Chessells JM, Stevens RF, et al. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985. Haematology and Blood Transfusion 1987;30:346-51.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s636&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Matsuzaki 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s639&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Matsuzaki A, Ishii E, Nagatoshi Y, Eguchi H, Koga H, Yanai F, et al. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group. International Journal of Hematology 2001;73:369-77.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s641&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s644&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maurer HM. The Intergroup Rhabdomyosarcoma Study: update, november 1978. National Cancer Institute Monograph 1981;56:61-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s646&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Meisel 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s649&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Meisel JA, Guthrie KA, Breslow NE, Donaldson SS, Green DM. Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group. International Journal of Radiation Oncology, Biology, Physics 1999;44:579-85.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s651&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Meza 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s654&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. Journal of Clinical Oncology 2006;24:3844-51.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s656&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Miser 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s659&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Miser JS, Pritchard DJ, Rock MG, Shives TC, Gilchrist GS, Smithson WA, et al. Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies. Cancer Treatment and Research 1993;62:333-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s661&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Moricke 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s664&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;M&amp;#246;ricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, D&amp;#246;rdelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-89.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s666&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Muus 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s669&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E, et al. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Seminars of Oncology 1993;20:47-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s671&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nachman 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s674&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nachman J, Sather HN, Buckley JD, Gaynon PS, Steinherz PG, Tubergen DG, et al. Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols: Results of treatment. Cancer 1993;71:3377-85.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s676&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nishimura 1983&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s679&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nishimura H, Yamada T, Hagio Y, Inoue T, Tsunawaki A, Yakushiji M, et al. Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or cddp in combination with adriamycin (ADM). Gan To Kagaku Ryoho 1983;10:938-43.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s681&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;No authors list 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s684&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;No authors listed. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Lancet 1987;2:353-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s686&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ochiai 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s689&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ochiai K. Strategy for the ovarian cancer treatment. Japanese Journal of Cancer and Chemotherapy 1993;20:2454-60.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s691&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oh 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s694&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, et al. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Annals of Hematology 2006;85:781-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s696&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okamura 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s699&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okamura J, Ikuno Y, Yamada S, Tasaka H, Nibu K, Ikeda N, et al. Results of treatment in children with diffuse large cell lymphoma. Rinsho Ketsueki 1987;28:1365-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s701&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Omura 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s704&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 1985;3:1240-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s706&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ortega 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s709&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ortega JA, Wharam M, Gehan EA, Ragab AH, Crist W, Webber B, et al. Clinical features and results of therapy for children with paraspinal soft tissue sarcoma: A report of the intergroup Rhabdomyosarcoma study. Journal of Clinical Oncology 1991;9:796-801.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s711&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Paulino 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s714&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Paulino AC, Wilimas J, Marina N, Jones D, Kumar M, Greenwald C, et al. Local control in synchronous bilateral Wilms tumor. International Journal of Radiation Oncology, Biology, Physics 1996;36:541-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s716&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Paulino 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s719&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Paulino AC, Bauman N, Simon JH, Nguyen TX, Ritchie JM, Tannous R. Local control of parameningeal rhabdomyosarcoma: outcomes in non-complete responders to chemoradiation. Medical and Pediatric Oncology 2003;41:118-22.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s721&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pavlovsky 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s724&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pavlovsky S. Argentinian Group for the Treatment of Acute Leukemia: our experience in the treatment of acute lymphoblastic leukemias. Sangre 1981;26:845-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s726&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pawson 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s729&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. British Journal of Haematology 2001;115:622-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s731&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peeters 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s734&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peeters J, Meitert J, Paulides M, Beck JD, Langer T. Late effects surveillance system after childhood cancer in Germany, Austria and parts of Switzerland-update 2009. Strahlentherapie und Onkologie 2009;185(Suppl 2):5-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s736&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Perez 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s739&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Perez CA, Tefft M, Nesbit ME Jr, Burgert EO Jr, Vietti TJ, Kissane J, et al. Radiation therapy in the multimodal management of Ewing's sarcoma of bone: report of the Intergroup Ewing's Sarcoma Study. National Cancer Institute Monograph 1981:263-71.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s741&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pfreundschuh 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s744&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pfreundschuh M, Zwick C, Zeynalova S, Duhrsen U, Pfluger KH, Vrieling T, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology 2008;19:545-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s746&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Picci 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s749&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Picci P, Bacci G, Ferrari S, Mercuri M. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Annals of Oncology 1997;8:1107-15.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s751&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pontz 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s754&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pontz BF, Gutjahr P. Aggressive cytostatic treatment of osteogenic sarcoma in childhood. Deutsche Medizinische Wochenschrift 1981;106:200-7.&lt;/h4&gt;&lt;p&gt;. (1981) [Aggressive cytostatic treatment of osteogenic sarcoma in childhood (author's transl)]. Dtsch.Med.Wochenschr. 106, 200-207.&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s756&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pratt 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s759&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pratt CB, Hustu HO, Kumar AP, Johnson WW, Ransom JL, Howarth CB, et al. Treatment of childhood rhabdomyosarcoma at St. Jude Children's Research Hospital, 1962--78. National Cancer Institute Monograph 1981:93-101.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s761&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pratt 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s764&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pratt CB, Meyer WH, Rao BN, Parham DM, Fleming ID. Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990. Cancer Treatment and Research 1993;62:323-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s766&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Quattrin 1975&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s769&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Quattrin N, Montuori R, Di Girolamo R, Cimino R. Our recent therapeutic experiences in acute leukemia. Minerva Medica 1975;66:2538-45.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s771&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rai 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s774&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981;58:1203-12.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s776&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rammeloo 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s779&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rammeloo LA, Postma A, Sobotka-Plojhar MA, Bink-Boelkens MT, Berg A, Veerman AJ, et al. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Medical and Pediatric Oncology 2000;35:13-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s781&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raney 1983&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s784&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raney RB Jr, Lawrence W Jr, Maurer HM, Lindberg RD, Newton WA Jr, Ragab AH, et al. Rhabdomyosarcoma of the ear in childhood. A report from the Intergroup Rhabdomyosarcoma Study-I. Cancer 1983;51:2356-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s786&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raney 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s789&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raney B, Schnaufer L, Ziegler M, Chatten J, Littman P, Jarrett P. Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958-1984. Cancer 1987;59:1-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s791&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raney 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s794&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raney RB Jr, Tefft M, Maurer HM, Ragab AH, Hays DM, Soule EH, et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer 1988;62:1257-66.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s796&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raney 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s799&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raney RB Jr, Crist W, Hays D, Newton W, Ruymann F, Tefft M, et al. Soft tissue sarcoma of the perineal region in childhood. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1972 through 1984. Cancer 1990;65:2787-92.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s801&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raza 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s804&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raza S, Ullah K, Ahmed P, Khan B. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia. Journal of the College of Physicians and Surgeons-Pakistan 2008;18:546-50.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s806&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rees 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s809&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rees JK, Gray RG. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study. Haematology and Blood Transfusion 1990;33:243-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s811&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ritchey 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s814&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ritchey ML, Pringle KC, Breslow NE, Takashima J, Moksness J, Zuppan CW, et al. Management and outcome of inoperable Wilms tumor. A report of National Wilms Tumor Study-3. Annals of Surgery 1994;220:683-90.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s816&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ritter 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s819&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ritter J, Creutzig U, Schellong G. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83. Haematology and Blood Transfusion 1990;33:185-92.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s821&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roy 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s824&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. British Journal of Haematology 2005;129:35-44.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s826&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sakic 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s829&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sakic M, Berbic-Fazlagic J. Results of treatment with protocols BFM 90 and BFM 95. Medicinski Arhiv 2006;60:369-72.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s831&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sallan 1977&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s834&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sallan SE, Camitta BM, Frei E III, Furman L, Leavitt P, Bishop Y, et al. Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): addition of an anthracycline to vincristine and prednisone. Medical and Pediatric Oncology 1977;3:281-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s836&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schaison 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s839&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schaison G, Sommelet D, Bancillon A, Perel Y, Leblanc T, Bergeron C, et al. Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87. Leukemia 1992;6 Suppl 2:148-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s841&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scherrer 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s844&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scherrer R, Bettelheim P, Geissler K, Jager U, Knobl P, Kyrle PA, et al. High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL)-a single-institution study. Annals of Hematology 1994;69:181-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s846&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schmits 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s849&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schmits R, Glass B, Trumper L, Pfreundschuh M. Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL. Annals of Hematology 2001;80 Suppl 3:B77-B83.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s851&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Seibel 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s854&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the children's oncology group. Blood 2008;111:2548-55.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s856&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Silverman 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s859&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000;14:2247-56.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s861&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Skoczen 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s864&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Skoczen S, Balwierz W, Moryl-Bujakowska A, Pawinska K, Luszczynska A, Balcerska A, et al. Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group. Przeglad Lekarski 2006;63:11-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s866&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Smithson 1982&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s869&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Smithson WA, Telander RL, Carney JA. Mesenchymoma of the liver in childhood: five-year survival after combined-modality treatment. Journal of Pediatric Surgery 1982;17:70-2.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s871&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sotnikov 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s874&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sotnikov VM, Polianskaia AM, Pan'shin GA, Ingberman I, Kaplanskaia IB. Chemoradiation treatment of patients with aggressive non-Hodgkin's lymphomas in stages I to II of the disease. Terapevticheskii Arkhiv 1989;61:20-3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s876&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spears 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s879&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spears WT, Morphis II JG, Lester SG, Williams SD, Einhorn LH. Brain metastases and testicular tumors: long-term survival. International Journal of Radiation Oncology, Biology, Physics 1992;22:17-22.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s881&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spreafico 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s884&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D'Angelo P, et al. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Pediatric Blood and Cancer 2008;51:23-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s886&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stary 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s889&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stary J, Gajdos P, Blazek B, Ptoszkova H, Mihal V, Pospisilova D, et al. Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic. Casopis Lekary Ceskych 2003;142:404-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s891&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steinherz 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s894&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer 1993;72:3120-30.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s896&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steinherz 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s899&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: report from the Childrens Cancer Group. Journal of Clinical Oncology 1996;14:389-98.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s901&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steinherz 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s904&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998;82:600-12.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s906&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tarella 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s909&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tarella C, Cuttica A, Caracciolo D, Zallio F, Ricca I, Bergui L, et al. High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments. Annals of Hematology 2001;80 Suppl 3:B123-B126.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s911&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Taylor 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s914&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia and Lymphoma 2006;47:2321-30.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s916&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tefft 1978&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s919&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tefft M, Razek A, Perez C, Burgert EO, Gehan EA, Griffin P, et al. Local control and survival related to radiation dose and volume and to chemotherapy in non-metastatic Ewing's sarcoma of pelvic bones. International Journal of Radiation Oncology, Biology, Physics 1978;4:367-72.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s921&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thirugnanam 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s924&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biology of Blood and Marrow Transplantation 2009;15:1479-84.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s926&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thomas 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s929&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thomas PR, Tefft M, D'Angio GJ, Norkool P. Acute toxicities associated with radiation in the second National Wilms' Tumor Study. Journal of Clinical Oncology 1988;6:1694-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s931&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tournade 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s934&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tournade MF, Com-Nougue C, Voute PA, Lemerle J, De Kraker J, Delemarre JFM, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' tumor trial and study: A risk-adapted therapeutic approach in Wilms' tumor. Journal of Clinical Oncology 1993;11:1014-23.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s936&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tsuchiya 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s939&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Research 1998;18:657-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s941&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van der Does 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s944&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van der Does-van den Berg A, van Wering ER, Suciu S, Solbu G, Rammeloo JA, de Koning J, et al. Results of treatment of children with acute lymphatic leukemia (ALL) according to the ALL V protocol of the Netherlands Working Group on Leukemia in Children. Tijdschrift voor Kindergeneeskunde 1988;56:61-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s946&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vinogradova 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s949&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vinogradova I, Lutsenko IN, Kaplanskaia IB, Vorob'ev IA, Samoilova RS, Gorgidze LA, et al. Efficacy of therapy of different variants of anaplastic large T-cell lymphomas. Terapevticheskii Arkhiv 2008;80:33-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s951&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Virchis 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s954&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. British Journal of Haematology 2004;124:26-32.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s956&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vose 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s959&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger D, Chan WC, et al. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group. Seminars in Hematology 1994;31:4-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s961&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Watts 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s964&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Watts RG, Hilliard LM, Berkow RL. Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation. Journal of Pediatric Hematology/Oncology 2002;24:622-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s966&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Weinstein 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s969&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Weinstein H, Ravindranath Y, Krischer J, Steuber P, Civin C, Gresik M, et al. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML). Leukemia 1992;6 Suppl 2:52-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s971&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wilimas 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s974&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wilimas JA, Douglass EC, Lewis S, Fairclough D, Fullen G, Parham D, et al. Reduced therapy for Wilms' tumor: analysis of treatment results from a single institution. Journal of Clinical Oncology 1988;6:1630-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s976&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Willemze 1982&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s979&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Willemze R, Haanen C, Dekker A, Sizoo W, Abels J, Tricot G, et al. Results of a multicentre study of the treatment of acute lymphoblastic leukaemia in adolescents and adults (1978-1981). The Netherlands Journal of Medicine 1982;25:303-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s981&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Willnow 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s984&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Willnow U, Lindner H, Rothe K, Kamprad F. The results of a prospective study for treatment of rhabdomyosarcoma in children. Kinderarztliche Praxis 1986;54:661-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s986&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zaharia 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s989&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zaharia M, Caceres E, Valdivia S, Moran M, Tejada F. Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma. International Journal of Radiation Oncology, Biology, Physics 1986;12:907-10.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s991&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zintl 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s994&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zintl F, Plenert W, Malke H. Results of acute lymphoblastic leukemia therapy in childhood with a modified BFM protocol in a multicenter study in the German Democratic Republic. Haematology and Blood Transfusion 1987;30:471-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s996&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zittoun 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s999&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, et al. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group. Leukemia 1992;6 Suppl 2:76-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s37&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1001&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FRALLE 2000-A&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1004&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Baruchel A, Auvrignon A, Auclere M-F, Perel Y, Mechinaud F, Landman-Parker J, et al. Childhood standard-risk B-cell precursor acute lymphoblastic leukemia (SR-BCP-ALL): toxicity and efficacy interim results of the FRALLE 2000-A protocol (O.093). In: Pediatric Blood and Cancer. Vol. 47. 2006:380.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1006&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cayuela J-M, Beldjord K, Preudhomme C, Cave H, Eliahou J-F, Auclerc M-F, et al. Minimal residual disease (MRD) in childhood standard-risk B-cell precursor acute lymphoblastic leukemia (SR-BCP-ALL) at the end of induction (EOI) after a three or four drug induction (O.094). Pediatric Blood and Cancer 2006;47:380-1.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s38&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1008&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;COG AHEP0531&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1011&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Not mentioned. COG AHEP0531. Not mentioned.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1013&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISRCTN94206677&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1016&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TRIAL relapsed AML 2001/01. www.controlled-trials.com.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1018&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;NCT00186966&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1021&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Treatment of children and adolescents with refractory or relapsed acute myeloid leukemia. www.controlled-trials.com.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1023&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;NCT00379457&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1026&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;A protocol for nonmetastatic rhabdomyosarcoma [RMS-2005]. www.controlled-trials.com.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1028&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SIOP2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1031&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nephroblastoma clinical trial and study. www.controlled-trials.com.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s39&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other references&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s40&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional references&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1033&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Billingham 1978&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1035&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Biondi 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1037&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gratias 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1039&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1041&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Green 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1043&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Higgins 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1045&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Higgins 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1047&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kremer 2002a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1049&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kremer 2002b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1051&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lachin 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1053&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lee 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1055&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lefrak 1973&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1057&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lipshultz 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1059&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mertens 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1061&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Messinger 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1063&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Parmar 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1065&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pieters 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1067&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Reulen 2010&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1069&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Van Dalen 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1071&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Von Hoff 1979&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1073&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wouters 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s41&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other published versions of this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1075&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Van Dalen 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s42&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Classification pending references&lt;/h2&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s46&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data and analyses&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1270&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 No anthracyclines versus anthracyclines&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1271&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1 Overall survival&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1272&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.1 ALL&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1276&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.2 Wilms' tumour&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1280&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.3 Rhabdomyosarcoma/undifferentiated sarcoma&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1283&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.4 Hepatoblastoma&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1285&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2 Event-free survival&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1286&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.1 ALL&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1289&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.2 Wilms' tumour&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1293&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.3 Non-Hodgkin lymphoma&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1295&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.4 Hepatoblastoma&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1297&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3 Tumour response&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1298&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3.1 ALL&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1301&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3.2 Rhabdomyosarcoma / undifferentiated sarcoma&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3.3 Hepatoblastoma&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1305&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4 Clinical cardiotoxicity&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1306&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4.1 Cardiac death&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1309&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4.2 Congestive heart failure&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1311&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.5 Overall survival Wilms' tumour long-term follow-up&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1312&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.5.1 Stage II-III FH and UH&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1314&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.5.2 Stage IV&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1316&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.6 Event-free survival Wilms' tumour long-term follow-up&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1317&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.6.1 Stage II-III FH and UH&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1319&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.6.2 Stage IV&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s43&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figures&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1321&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 1 (Analysis 1.1)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1322&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 2 (Analysis 1.2)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1323&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 3 (Analysis 1.3)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1324&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 4 (Analysis 1.4)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1325&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 5 (Analysis 1.5)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1326&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 6 (Analysis 1.6)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s12&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sources of support&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s13&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Internal sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s14&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;External sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s61&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Foundation of Paediatric Cancer Research (SKK), Netherlands&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s62&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stichting Kinderen Kankervrij (KiKa), Netherlands&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s44&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feedback&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s17&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendices&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1327&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Search strategy for PubMed&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f9348&quot;&gt;&lt;span coll_flag=&quot;f9348&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f9350&quot;&gt;&lt;span coll_flag=&quot;f9350&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1328&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Search strategy for Embase (OVID)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f9353&quot;&gt;&lt;span coll_flag=&quot;f9353&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f9355&quot;&gt;&lt;span coll_flag=&quot;f9355&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1329&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3 Search strategy for Cochrane Central Register of Controlled Trials (CENTRAL)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f9358&quot;&gt;&lt;span coll_flag=&quot;f9358&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f9360&quot;&gt;&lt;span coll_flag=&quot;f9360&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-06-17 15:50:45 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>(1) For <B>anthracyclines</B> the following Emtree terms and text words have been used:</P>
<P>1. exp ANTHRACYCLINE ANTIBIOTIC AGENT/ or exp ANTHRACYCLINE/ or exp ANTHRACYCLINE DERIVATIVE/<BR/>2. (anthracycline or anthracyclines).mp.<BR/>3. anthracyclin$.mp.<BR/>4. doxorubicin.mp. or exp DOXORUBICIN DERIVATIVE/ or exp DOXORUBICIN/<BR/>5. adriamycin.mp.<BR/>6. exp DAUNORUBICIN DERIVATIVE/ or daunorubicin.mp. or exp DAUNORUBICIN/<BR/>7. rubidomycin.mp.<BR/>8. epirubicin.mp. or exp EPIRUBICIN/<BR/>9. exp IDARUBICIN DERIVATIVE/ or exp IDARUBICIN/ or idarubicin.mp.<BR/>10. (doxorubic$ or adriamyc$ or daunorubic$ or rubidomyc$ or epirubic$ or idarubic$).mp.<BR/>11. (daunoxome or doxil or caelyx or myocet).mp.<BR/>12. or/1-10</P>
<P>(2) For <B>children</B> the following Emtree terms and text words have been used:</P>
<P>1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/<BR/>2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/<BR/>3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/<BR/>4. or/1-3<BR/>5. (infant$ or newborn$ or (new adj born$) or baby or baby$ or babies or neonate$ or perinat$ or postnat$).mp.<BR/>6. (child$ or (school adj child$) or schoolchild$ or (school adj age$) or schoolage$ or (pre adj school$) or preschool$).mp.<BR/>7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp.<BR/>8. (minors$ or (under adj ag$) or underage$ or juvenil$ or youth$).mp.<BR/>9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.<BR/>10. (pediatric$ or paediatric$ or peadiatric$).mp.<BR/>11. (school or schools or (high adj school$) or highschool$ or (primary adj school$) or (nursery adj school$) or (elementary adj school) or (secondary adj school$) or kindergar$).mp.<BR/>12. or/5-11<BR/>13. 4 or 12</P>
<P>(3) For <B>survival</B> the following Emtree terms and text words have been used:</P>
<P>1. (survival or survival rate or survival rates).mp.<BR/>2. (cumulative survival rate or cumulative survival rates).mp.<BR/>3. survivorship.mp.<BR/>4. (mean survival time or mean survival times).mp.<BR/>5. (survival time or surviv$).mp.<BR/>6. (median survival time or median survival times).mp.<BR/>7. overall survival.mp.<BR/>8. (survival analysis or survival analyses).mp.<BR/>9. (disease-free survival or disease free survival).mp.<BR/>10. (disease-free survivals or disease free survivals).mp.<BR/>11. (event-free survival or event-free survivals or event free survival or event free survivals).mp.<BR/>12. (progression-free survival or progression free survival or progression-free survivals or progression free survivals).mp.<BR/>13. (survival period or survival probability).mp.<BR/>14. (event-free or event free or progression free or progression-free).mp.<BR/>15. (time to progression or treatment outcome or treatment effectiveness or treatment efficacy).mp.<BR/>16. (neoplasm recurrence or neoplasm recurrences).mp.<BR/>17. (cancer recurrence or cancer recurrences or cancer recidive or cancer remission).mp.<BR/>18. (therapy outcome or therapeutic efficacy).mp.<BR/>19. or/1-18<BR/>20. SURVIVAL RATE/ or SURVIVAL/ or SURVIVAL TIME/<BR/>21. Treatment Outcome/<BR/>22. Cancer survival/ or Cancer Recurrence/<BR/>23. or/19-22<BR/>24. 19 or 23</P>
<P>(4) For <B>randomized controlled trials</B> the following Emtree terms and text words have been used:</P>
<P>
<I>In the original version of the review (based on </I>
<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>)<I>:</I>
</P>
<P>1. Clinical Trial/<BR/>2. Controlled Study/<BR/>3. Randomized Controlled Trial/<BR/>4. Double Blind Procedure/<BR/>5. Single Blind Procedure/<BR/>6. Comparative Study/<BR/>7. RANDOMIZATION/<BR/>8. Prospective Study/<BR/>9. PLACEBO/<BR/>10. Phase 2 Clinical Trial/<BR/>11. phase 3 clinical study.mp.<BR/>12. phase 4 clinical study.mp.<BR/>13. Phase 3 Clinical Trial/<BR/>14. Phase 4 Clinical Trial/<BR/>15. or/1-14<BR/>16. allocat$.mp.<BR/>17. blind$.mp.<BR/>18. control$.mp.<BR/>19. placebo$.mp.<BR/>20. prospectiv$.mp.<BR/>21. random$.mp.<BR/>22. ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp.<BR/>23. (versus or vs).mp.<BR/>24. (randomized controlled trial$ or randomised controlled trial$).mp.<BR/>25. controlled clinical trial$.mp.<BR/>26. clinical trial$.mp.<BR/>27. or/16-26<BR/>28. Human/<BR/>29. Nonhuman/<BR/>30. ANIMAL/<BR/>31. Animal Experiment/<BR/>32. or/29-31<BR/>33. 32 not 28<BR/>34. (15 or 27) not 33</P>
<P>
<I>For the updates of the review (based on </I>
<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>)<I>:</I>
</P>
<P>1. Randomized Controlled Trial/<BR/>2. Controlled Clinical Trial/<BR/>3. randomized.ti,ab.<BR/>4. placebo.ti,ab.<BR/>5. randomly.ti,ab.<BR/>6. trial.ti,ab.<BR/>7. groups.ti,ab.<BR/>8. drug therapy.sh.<BR/>9. or/1-8</P>
<P>
<B>Final search: 1 AND 2 AND 3 AND 4</B>
</P>
<P>[mp= title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name; $=1 or more characters; ti,ab=title or abstract; sh=subheading; /=Emtree term]</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-08-23 14:08:46 +0200" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>